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Abstract  
 
Platelets are one of the most abundant cell type in the blood, and they play a crucial role in 
the process of homeostasis. Platelet traits, such as platelet count (PLT) and mean platelet 
volume (MPV) are highly heritable and stable within individuals, but the molecular 
mechanisms controlling these traits are poorly understood. Genome-wide association 
studies (GWAS) have identified BRD3 as a regulator of platelet traits. BRD3, along with BRD2, 
BRD4 and BRDT, is classified within the bromodomain and extra terminal (BET) family, 
specialised in recognising and binding to acetylated lysine residues.  
In this project, I studied the functions of BRD3 during megakaryopoiesis, the process that 
leads to platelet formation. Because platelets do not have nucleus, megakaryocytes are the 
best model to study chromatin interactors associated with platelet traits. I used CRISPR/Cas9 
to generate a BRD3 KO iPSc model. These cells were capable to differentiate into MKs, using 
a forward programming protocol, demonstrating that BRD3 is not essential for MK 
differentiation. I found that a subset of genes was differentially expressed in the absence of 
BRD3, despite genome-wide chromatin accessibility and H3K27ac signatures remaining 
unaltered. In order to investigate whether there was a compensatory effect among BET 
proteins, I designed BRD2 and BRD4 KO iPSCs, as well as combinations of BET KOs. BRD2 KO 
generated MK progenitors, indicating that the protein is also dispensable in MK generation. 
Interestingly, using an inhibitor that recognises all BET proteins, MK progenitor 
differentiation was impaired, but not late megakaryopoiesis, suggesting that some BET 
proteins might play a critical role in early MK differentiation. 
Overall, these results indicate that BRD2 and BRD3 are dispensable in megakaryocytes  
differentiation, and probably, that BRD4 might be essential due to its role in mesoderm 
differentiation. Together, this work starts to unveil the requirement of BET during  
megakaryopoiesis. 
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1.1 Haematopoiesis 
 
 
The human body produces over 100 billion blood cells every day. This process is known as 
haematopoiesis. Blood cells are highly specialised cells that have three main functions. (1) Transport 
of gases, nutrients, hormones and waste products. (2) Protection against pathogens. (3) Regulation 
of fluids and pH levels. The haematopoietic system is highly controlled, and the dysregulation of its 
functions can result in catastrophic outcomes for the body. Hence, understanding the complex 
molecular mechanisms that control the blood differentiation and function is imperative for the 
improvement of health care of patients suffering from blood diseases.  
1.1.1. Embryonic haematopoiesis 
Haematology studies on animal models, such as mouse and zebrafish, generated a great amount of 
knowledge on the events that characterise haematopoietic development (Jagannathan-Bogdan and 
Zon 2013). It is accepted that vertebrate haematology is developmentally conserved with differences 
mainly in the temporal sequence of differentiation, probably due to differences in individual 
gestation periods (Tavian and Peault 2005). Until the 1970s, it was assumed that the yolk sac was the 
main blood-forming tissue during embryogenesis, and blood precursor cells would migrate to the 
fetal liver and bone marrow (M. A. S. Moore and Metcalf 1970). Currently, it is known that the 
differentiation process from a pluripotent cell stage to progenitor blood cells happens in several 
different tissues in the embryo (figure 1.1.1). There are two main waves of embryonic 
haematopoietic differentiation; the primitive wave of haematopoiesis happens exclusively extra-
embryonically in the yolk sac (Lux et al. 2008), whilst the definitive haematopoiesis takes place in the 
yolk sac and intra-embryonically.  
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Figure 1.1.1 Sequential waves of embryonic haematopoiesis. Schematic representation of 
haematopoietic development during mouse embryogenesis with the embryonic day of emergence 
(middle), type of progenitors generated (top) and the location of each wave of haematopoiesis 
(bottom). Mouse haematopoiesis mimics the human haematopoiesis process during embryogenesis. 
Schematics adapted from (Lacaud and Kouskoff 2017; Dzierzak and Speck 2008). 
 
In the primitive haematopoiesis, shortly after gastrulation, mesoderm cells migrate away from the 
primitive streak and form several populations with distinct developmental fates including blood cells 
(Huber et al. 2004). In the yolk sac, mesoderm cells expressing the receptor for vascular endothelium 
growth factor (VEGFR+ or CD309), in the posterior primitive streak, differentiate into blood precursor 
cells, denominated blood islands (Garcia-Martinez and Schoenwolf 1993; Lugus et al. 2009; 
Ferkowicz and Yoder 2005). These blood precursors have a limited self-renewal and differentiation 
potential, and their primary function is to facilitate oxygenation of the rapidly dividing embryo. 
Primitive macrophages, megakaryocytes, and erythroid cell types have been reported at this early 
embryonic stage (Tober et al. 2007; Palis et al. 1999). 
The second wave of early haematopoiesis is characterised by the development of immature myeloid 
and lymphoid cells, as well as the appearance of the first haematopoietic stem cells (HSCs). The 
erythro/myeloid progenitors identified at the embryonic stage are still immunophenotypically 
immature as the surface markers, transcription factors and lineage potential are present in unique 
proportions when compared with their adult counterparts (McGrath et al. 2015). The first lymphoid 
cell precursors (B and T cells) have been observed at this stage where haemogenic endothelial cells 
(CD144+/CD41-) differentiated into T-cell precursors, and successfully generated mature T-cells upon 
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transplantation, confirming T-cell progeny from haemogenic endothelium (Yoshimoto et al. 2012). 
The generation of the first B cells has been identified in the yolk sac and in the para aortic 
splanchnopleura (P-Sp) (Yoshimoto et al. 2011). The P-Sp region is the first intra-embryonic region 
where blood cells emerge, and it develops into the aorta–gonad–mesonephros (AGM) from which 
the haemogenic endothelium is known to derive (A Medvinsky and Dzierzak 1996).  
Time-lapse imaging techniques and cell-tracking methods have contributed to tracing HSC progeny 
to haemogenic endothelium. A temporally restricted genetic tracing strategy, using an inducible VE-
cadherin (CD144+) Cre-line, has shown that first HSCs arise exclusively from endothelium (Zovein et 
al. 2008) located in both the yolk sac and the AGM (A Medvinsky and Dzierzak 1996; Godin, Dieterlen-
Lièvre, and Cumano 1995). High-resolution imaging of live zebrafish embryos confirmed the 
migration of endothelial cells from the AGM to the sub-aortic space, and their transdifferentiation 
into multipotent haematopoietic stem/progenitor cells (HSPCs). This is a process regulated by 
transcription factors Runx1 (Kissa and Herbomel 2010) and GATA-2 (Tsai et al. 1994; Ling et al. 2004). 
The onset of circulation is a determinant factor that allows the distribution of HSCs throughout the 
organism (North et al. 2009; Hirsch et al. 1996; Potocnik, Brakebusch, and Fässler 2000) . The first 
HSCs and the endothelial precursors share a similar surface expression signature, differing in the 
presence or absence of CD45 expression (Dzierzak and Speck 2008; Taoudi et al. 2008). It is believed 
that CD45+ HSCs migrate and colonise the fetal liver where they undergo expansion (Alexander 
Medvinsky, Rybtsov, and Taoudi 2011). HSCs are then established in the spleen and thymus, and just 
before birth, the bone marrow.  Osawa et al. first demonstrated that the transplant of single HSCs 
harbours the potential to generate the entire repertoire of differentiated blood cells (multilineage 
potential) for long periods of time (Osawa et al. 1996).  
1.1.2. Adult haematopoiesis, an evolving model 
HSCs are rare cells with the ability for self-renewal, and differentiation into all the blood progenitors 
and lineage restricted blood cells. Due to the high demand of differentiated blood cell s; the self-
renewal, maintenance, and lineage determination of HSC is a controlled process that meets the 
constant supply of progenitors throughout life. HSC are found mainly in the stem cell niche in the 
bone marrow, but can also be found in fetal liver, cord blood and peripheral blood (Bluteau et al. 
2013). The distinct properties of HSC, such as cell -surface markers, differentiation potential and cell-
cycle status change remarkably throughout life, depending on the niche and development-stage. 
Thus, actively dividing HSCs are found in the fetal liver and quiescent HSCs in the bone marrow (Stuart 
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H. Orkin and Zon 2008); and older HSCs are biased toward myeloid lineages (Sudo et al. 2000; W. W. 
Pang et al. 2011). HSCs self-renewal ability has also been categorised into short term (ST-HSC) and 
long-term (LT-HSC) depending on the cells lifespan (C. E. Muller-Sieburg et al. 2004a; Weissman, 
Anderson, and Gage 2001; Reya et al. 2001). The recent discoveries on HSCs intrinsic properties led 
to a greater understanding of the mechanisms regulating differentiation of blood cells.  
The model describing the differentiation of blood cells is commonly known as the haematopoietic 
tree. The evidence used to build this classical model was based on antibodies staining and 
fluorescence-assisted cell sorting (FACS) which allows the isolation of cells expressing combinations 
of surface markers (Morrison and Weissman 1994). Functional and molecular characterisation of 
these populations was achieved mainly by in vitro colony assays and transplantation experiments (F. 
Notta et al. 2011). The classical hierarchical model describes how HSCs give rise to all blood cell types 
in a stepwise manner, where a given cell has a more restricted lineage than its precursor (figure 
1.1.2). In this model, HSCs either self-renew or differentiate into multipotent progenitors (MPP) 
(Osawa et al. 1996; Kent et al. 2009; Weksberg et al. 2008). MPPs lose self-renewal capability, but 
directly commit to two separate branches; the common myeloid progenitors (CMPs) and the 
multipotent lymphoid progenitors (MLPs) (Koichi Akashi et al. 2000; Kondo, Weissman, and Akashi 
1997). On the myeloid branch, CMPs give rise to granulocyte-monocyte progenitors (GMP) and 
megakaryocyte-erythrocyte progenitors (MEPs). GMPs differentiate into granulocytes (neutrophils, 
eosinophils and basophils) and monocytes, cells involved in fighting infections. MEPs are the 
precursor cells of erythrocytes and megakaryocytes, and consequently platelets. The lymphoid 
branch generates lymphoid cells (such as B and T lymphocytes) and innate lymphoid cells (such as 
natural killer cells), but also has the potential to differentiate into the granulocytes (GMP) lineage. 
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Figure 1.1.2 Diagram of canonical haematopoietic tree. An illustration of the ontological 
differentiation events derived from a haematopoietic stem cell (HSC). The common myeloid 
progenitor (CMP) and multipotent lymphoid progenitor (MLP) are derived from a direct bifurcation 
from the HSC and multiple pluripotent progenitor (MPP). CMP further differentiates into the myeloid 
lineage cells (megakaryocytes, MK and erythroblasts, EB) and into the granulocyte -monocyte 
progenitor (GMP). The MLP matures into the lymphoid lineage (common-lymphoid progenitor, CLP, 
and lymphoid cells) and can give rise to the granulocyte-monocyte lineage. The haematopoietic 
differentiation process happens in the bone marrow where haematopoietic (HSC) and all the 
progenitor cells develop. The differentiated cells are then released in the bloodstream and tissues. 
Those include erythrocytes (Ery), megakaryocytes and platelets (MK/Pla), neutrophils (Neutr), 
basophils (Baso), eosinophils (Eos), master cells (MC), monocytes/macrophages (M/M), dendritic 
cells (DC), B cells (B), T cells (T) and natural killer cells (NK). Figure from (Antoniani, Romano, and 
Miccio 2017). 
 
The haematopoietic tree was devised based on population studies of cell transplant experiments in 
immunocompromised mice, which have been crucial in studying HSCs biology (Osawa et al. 1996). 
However, differences in mature cell outputs from single HSCs transplants remained unexplained until 
recently. Methods based on population level characterisation disregard important details, such as 
differences in transcriptional states within the same cell population; or whether the detected 
changes happen only on a few cells or a subpopulation. These issues be come critical when analysing 
rare cells, such as HSCs. The canonical haematopoietic model explains the relationship between 
progenitors and mature cells, as a hierarchical progression, based on the following assumptions; (1) 
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cells are phenotypically classified into distinct compartments with shared homogeneous surface 
marker signatures; (2) all cells in a compartment retain the differentiation potential of that category; 
and (3) when a cell differentiates, the progeny cannot regain the previous compartment potential. 
Currently, it is recognised that seemingly homogeneous populations of blood cells, based on cell 
surface markers, can contain an array of intermediate cell types with different transcriptomic profiles 
and capability to differentiate into divergent cell outcomes (Moignard et al. 2013). 
The advent of modern technologies, based on single cell profiling, shone light on the heterogeneity 
of HSC populations. Currently, it is recognised that individual HSCs exhibit promiscuous multilineage-
primed states prior to lineage commitment (M. Hu et al. 1997; K. Akashi et al. 2003; Miyamoto et al. 
2002). These primed differentiation programmes are thought to be epigenetically fixed and 
transmitted to the next generation through self-renewal (Christa E Muller-Sieburg et al. 2012; W. W. 
Pang, Schrier, and Weissman 2017; Müller-Sieburg et al. 2002; C. E. Muller-Sieburg et al. 2004b; 
Sieburg et al. 2006). Müller-Sieburg et al. classified the HSC populations in myeloid-biased (My-bi) 
HSCs, lymphoid-biased (Ly-bi) HSCs or balanced HSCs that generate lymphoid and myeloid lineages 
in the same ratio. It has also been shown that My-bi HSCs generate defected lymphoid cells (C. E. 
Muller-Sieburg et al. 2004b) and, accordingly, Ly-bi HSCs have impaired ability to differentiate into 
myeloid lineage. More recently, the hypothesis that lineage-primed HSCs gradually acquire lineage 
status has gained strength with the CLOUD-HSPCs concept (Velten et al. 2017). Continuum of Low 
primed UnDifferentiated haematopoietic stem-and progenitor-cells (CLOUD-HSPCs) are HSC-like 
cells (Lin-CD34+), characterised by the expression of stemness signature in combination with 
phenotypic blood multi-progenitor transcriptomic signatures. Verten et al. demonstrated, by 
multiplexed index sorting and single-cell RNA-sequencing that distinct lineages emerge from CLOUD-
HSPCs without passing through stable progenitor stages. Interestingly, this study also showed that 
the earliest priming events express myeloid/lymphoid or megakaryocyte/erythrocyte signatures, 
which suggests that these might be the first priming events on adult haematopoiesis.  
 
The identification of lineage-primed HSCs and multi-lineage precursor cells calls for an updated 
haematopoietic model that capture the inherent flexible and pluralistic nature of the blood cells 
differentiation. The attempts to re-design the haematopoiesis model have been few and shy, 
probably reflecting the recognition that our understanding of the transcription networks regulating 
blood differentiation is only starting to unveil. 
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1.2 Megakaryopoiesis 
 
 
1.2.1. Megakaryopoiesis development 
1.2.1.1. Early MK lineage commitment 
HSCs undergo lineage commitment steps, to differentiate into megakaryocytes, in a process 
denominated megakaryopoiesis. Recently, the model stating bifurcation of lymphoid versus myeloid 
lineages has been challenged, as new data suggests that MK fate determination is triggered at earlier 
differentiation stage. Single-cell profiling studies revealed that the HSC priming happens at earlier 
stages than previously thought, and primitive HSC subsets express myeloid transcriptional profiles. 
Multiplexed qPCR revealed that populations of progenitor cells, sorted based on cell surface markers 
and considered homogeneous populations, are actually heterogeneous sub-populations with diverse 
differentiation potential revealing an early myeloid/lymphoid separation (Guo et al. 2013). In this 
study, single cell gene clustering showed that the megakaryocyte-erythroid lineage is closer to HSCs 
than the lympho/myeloid lineages, suggesting a staggered lineage commitment. Primed HSC subsets 
are thought to be developmentally regulated as lymphoid-biased HSCs are found mainly early in life, 
and myeloid-biased HSCs predominantly populate the HSC niche later in life (W. W. Pang et al. 2011; 
Christa E Muller-Sieburg et al. 2012). Interestingly, studies based on single cell transcriptome data, 
identified MK and platelet transcriptomes as the most common in aged HSCs, demonstrating an age-
related biased differentiation towards myeloid commitment (Grover et al. 2016). Sanjuan-Pla et al. 
reinforced the concept of platelet-primed HSCs by demonstrating that Von Willebrand factor 
expressing HSCs (VWF+ HSCs) generate mainly platelets and myeloid cells upon transplantation in 
mice (Sanjuan-Pla et al. 2013). Studies based on surface markers demonstrated that a subset of adult 
HSC expresses integrin CD41, previously thought to be present only on embryonic HSCs (Gekas, Graf, 
and Pampori 2013). It was also shown that CD41+ HSCs possess long-term repopulation capacity in 
transplantation experiments, yielding a myeloid-biased progeny which aligns with the hypothesis of 
age-related myeloid-biased HSCs. 
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Megakaryocytes directly and independently branch from a multipotent cell, such as HSC or MPP, 
rather than an oligopotent progenitor.  Rising from the hypothesis that myeloid lineage commitment 
is not gradual and might not progress through CMP stage; Notta et al. devised a sorting strategy to 
examine cellular heterogeneity within the CD34+ compartment (HSC), and map the origins of myeloid 
cells at different stages of development (fetal liver, neonatal cord and bone marrow) (Faiyaz Notta 
et al. 2016). In this study, based on 11 cell markers, progenitors expressing myeloid-erythroid-MK 
signatures were prominently found in the fetal liver, as opposed to the bone marrow. The study also 
showed that, in bone marrow, MK lineage commitment happens exclusively within the multipotent 
cell compartment (figure 1.2.1). This data challenges the classical progeny of MKs in adult 
haematopoiesis, by suggesting that MK lineage commitment happens earlier than CMP progenitor 
stage.  
 
 
 
 
 
Figure 1.2.1 Redefined model of human blood lineage formation. Graphical representation of a 
redefined haematopoiesis model including lineage potential of progenitor subsets. This model 
hypothesises a developmental shift in the progenitor potential from a three-tier at embryonic stage 
(multipotent, oligopotent and unipotent cells) to a two-tier hierarchy by adulthood where MKs 
derive directly from HSCs. Figure from (Faiyaz Notta et al. 2016). 
 
Common myeloid progenitor (CMP) population is not, as previously thought, a population of cells 
that directly derives from a naïve HSC, but instead a flexible and complex population expressing 
dynamic transcriptional states. A study combining massively parallel single-cell RNA-seq (MARS-seq) 
with indexed FACS sorting identified 19 transcriptionally distinct subpopulations within the CMP 
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population (Lin-c-Kit+Sca1-) (Paul et al. 2015). This study demonstrated that myeloid progenitors are 
cells primed towards individual fates (MKs, erythrocytes, monocytes, neutrophils, eosinophils, 
basophils or dendritic cells), defining an early transcriptional commitment in the cell development. 
In the same study, the authors also index-sorted 8 subpopulations within the 
megakaryocyte/erythroblast progenitors (MEP). One of these subpopulations presented a MK 
signature and the other 7 subpopulations showed clear erythrocyte characteristics varying from early 
progenitor to mature erythrocytes signatures, suggesting a developmental progression within the 
MEP population. Importantly, a subpopulation was identified, within the CMP population, 
remarkably expressing MK-related genes which is a strong indication that MKs might diverge from 
erythrocytes prior to MEP stage. This observation falls in line with the identification of myeloid-
primed HSCs, suggesting that MK lineage commitment derives directly from HSCs and not from a 
CMP progenitor. 
1.2.1.2. MK maturation and proplatelet formation  
Megakaryocytes (MKs) are large (50-100 µm) and rare cells which represent only 1% of the myeloid 
lineage. MKs major function is the production and release of platelets, a process d enominated 
thrombopoiesis. Every day, an average of 1011 platelets are released into the bloodstream, making 
platelets one of the most common cells in the body. Until recently, it was thought that 
thrombopoiesis happened exclusively in the bone marrow, but there is evidence that MKs also 
reside, and produce platelets, in the lungs (Slater, Trowbridge, and Martin 1983; Lefrançais et al. 
2017). The assembly and release of platelets is a stepwise maturation process that involves MK 
polyploidisation by endomitosis, MK maturation and proplatelet formation.  
 
MK maturation starts with endomitosis, a process primarily thrombopoietin-driven by which MKs 
become polyploid (Deutsch and Tomer 2013; Kenneth Kaushansky 2005). Similarly to other cells, MKs 
undergo a normal 2N DNA replication. Although, cytokinesis (cell division) is absent, and MKs begin 
accumulation of DNA content (up to 128N) in a single polylobulated nucleus. The lack of cell division 
happens due to a defect in late cytokinesis which results in a defective cleavage furrow, necessary 
for physical cell separation (Geddis et al. 2007; L. Lordier et al. 2008). Endomitosis is accompanied 
by a cell size increase to accommodate the new nucleic genomic DNA load. This increase in DNA 
cargo is related to the capacity to generate platelets (Mattia et al. 2002). 
 
During MK maturation, the cells increase the cytoplasmic protein and lipid content that lead to the 
formation of secretory granules. These granules include dense granules, lysosomes and α -granules. 
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The granule production is followed by the development of the invaginated membrane system (IMS). 
The IMS is a complex system of tubules present in the cytoplasm and continuous with the plasma 
membrane. This structure requires a significant reorganisation of the mature MKs, and it is thought 
to function as a reservoir for proplatelet formation (Schulze et al. 2006).  
 
Mature MKs form cytoplasmic protrusions that progressively elongate to form beaded structures, 
the proplatelets (Machlus, Thon, and Italiano 2014). Proplatelets are long branching protrusions 
extended and released by fragmentation of mature MKs into the sinusoidal blood vessels (Junt et al. 
2007). These structures are loaded with platelet-specific granules, RNAs and proteins required for 
the posterior platelet maturation (Thon et al. 2010). The factors that trigger proplatelets release are 
still unclear, although a few mechanistic theories have been proposed, such as the positioning of the 
MKs on the vascular interface and their exposure to gradients of blood components; the presence of 
podosomes in the process of proplatelets extension (Schachtner et al. 2013); and the shear forces of 
blood flow (Junt et al. 2007). Proplatelets in the blood stream undergo a final maturation step, driven 
by microtubule-based forces, to become fully functional platelets (Thon et al. 2012).   
 
1.2.2. Megakaryopoiesis regulation 
1.2.2.1. Transcriptional regulation 
During megakaryopoiesis, the MK-primed HSC gradually acquire lineage maturity through a 
coordinated network of transcriptional factors, cytokine signals, and epigenetic cues. Single -cell 
transcriptome studies revealed that the MEP population comprises distinct populations differentially 
primed to MK or erythroid lineage (Psaila et al. 2016). However, despite the distinct lineage priming 
at MEP stage, MKs and erythrocytes share considerable gene expression signatures (L. Chen et al. 
2014). MK and erythroid lineages share many critical TFs, and although both differentiation 
processes are accurately regulated, it is acceptable to speculate that could be a functional overlap in 
TF function (Doré and Crispino 2011). The main regulators controlling megakaryopoiesis intrinsic 
gene expression programmes include GATA-1 (S H Orkin et al. 1998), FOG-1(Pope and Bresnick 2010), 
TAL1 (H. Chagraoui et al. 2011), FLI1 (Kawada et al. 2001), and RUNX (Growney et al. 2005).  
1.2.2.1.1. GATA-1 
GATA-1 (GATA-binding factor 1) is a zinc-finger transcription factor (TF), that promotes 
transcriptional activation by recruiting coregulators to chromatin via its N- and C-domains, as well as 
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2 zinc fingers DNA domains (Kaneko et al. 2012). GATA-1 has been associated with regulation of both 
early and late megakaryopoiesis, and it is considered a master regulator due to its interactions with 
multiple MK-specific TF and cofactors. In mice, GATA-1 is required for MK-erythroid lineage 
commitment (Iwasaki et al. 2003), and the ablation of GATA-1 results in impaired early maturation 
of megakaryocyte-erythroid progenitors (Stachura, Chou, and Weiss 2006). Abnormal MK 
proliferation was observed in GATA-1-null MKs, indicating that GATA-1 controls MK cell cycle (S H 
Orkin et al. 1998) and therefore, a major player in MK growth, as well as lineage commitment. At 
later stages of megakaryopoiesis, downregulation of GATA-1 results in polyploidisation disruption, 
reduced number of circulating platelets, and defective haemostasis activation responses in mice 
(Muntean et al. 2007; Meinders et al. 2016; Vyas et al. 1999). GATA-1 interacts with FOG-1 (Friend 
of GATA-1), a zinc finger TF directly associated with regulation of MK-specific gene activity (Pope and 
Bresnick 2010). The GATA-1/FOG-1 complex is maintained from embryonic stage throughout the 
megakaryocyte/erythrocyte maturation (Tsang et al. 1997; Chang et al. 2002). In humans, a genetic 
defect in GATA-1 N-terminal zinc-finger (amino acid change from methionine to valine) inhibits its 
interaction with FOG-1, leading to MK maturation defects and thrombocytopenia (Nichols et al. 
2000). A SNP in the same GATA-1 domain has also been reported to cause an abnormal size and 
number of dysmorphic platelets that present a weak functional profile in aggregation studies (Freson 
et al. 2001). Mutations in GATA-1 exon 2 (N-terminal transactivation domain), leading to premature 
stop codons, are commonly found in children with transient myeloproliferative disorder (TMD) and 
acute megakaryblastic leukemia (AMKL) (Greene et al. 2003). 
1.2.2.1.2 TAL-1 
TAL-1 (T-cell acute lymphocytic leukemia protein 1) belongs to a basic helix-loop-helix (bHLH) protein 
family which is incapable of intrinsically binding to DNA. Therefore, proteins containing the bHLH 
domain rely on interaction with other TFs to regulate gene transcription (Hsu et al. 1994).  TAL-1 is a 
haematopoietic TF with important regulatory functions at both embryonic and adult 
haematopoiesis. Studies in mice demonstrated that TAL-1 regulates establishment of haemogenic 
endothelium, as well as haematopoietic commitment (Shivdasani, Mayer, and Orkin 1995; Lancrin et 
al. 2009; D’Souza, Elefanty, and Keller 2005). TAL-1 role in regulation of early lineage commitment of 
MK/erythroid cells was further demonstrated by chromatin immunoprecipitation (ChIP) experiments 
showing that TAL-1 is required prior to GATA-1 binding (Kassouf et al. 2010; Palii et al. 2011).  TAL-1 
function at late haematopoiesis has also been demonstrated as TAL-1-null mice fails to differentiate 
both erythrocytes and MKs (Schlaeger et al. 2005), and TAL-1 knockdown affects MK polyploidisation 
and platelet count (Hedia Chagraoui et al. 2011). In line with these results, overexpression of TAL-1 
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in human embryonic stem cells (hESC) increases differentiation of MK-erythroid progenitors (Yung 
et al. 2011). 
1.2.2.1.3.  FLI-1 
FLI-1 (Friend leukemia integration 1) belongs to the ETS transcription factors family (Karim et al. 
1990). FLI-1 role in early haematopoiesis has been reported (F. Liu et al. 2008), although FLI-1 
regulation is mainly associated with late lineage development. This TF was first identified as a 
regulator in megakaryopoiesis for its role on regulation of glycoprotein IX promoter, a sub-unit of 
von Willebrand receptor (Bastian et al. 1999). Mice lacking FLI-1 present defective megakaryopoiesis 
development (Kawada et al. 2001). Despite binding to both early and late megakaryopoiesis-specific 
genes, ablation of FLI-1 only affects late megakaryopoiesis (L. Pang et al. 2006); and inducible 
deletion of FLI-1 presents a thrombocytopenia phenotype (Starck et al. 2010). In humans, FLI-1 
hemizygous deletion leads to Paris-Trousseau syndrome (PTS), an abnormally leading to 
dysmegakaryopoiesis and thrombocytopenia (Stevenson et al. 2015; Di Paola 2015). It has been 
shown that overexpression of FLI-1 in CD34+ cells from PTS patients, restores normal 
megakaryopoiesis (Raslova et al. 2004). Lastly, FLI-1 has been shown to interact with GATA-1 to 
synergistically activate MK-specific promoters at terminal differentiation of MKs (Eisbacher et al. 
2003).  
1.2.2.1.4.  RUNX1 
RUNX1 (Runt-related transcription factor 1) is a member of the RANT TF family, and together with 
its heterodimeric partner, CBFβ, regulates a broad spectrum of myeloid and lymphoid genes. Mouse 
model of RUNX1 KO is embryonically lethal, and a conditional KO results in MK reduced 
polyploidisation and platelets abnormal cytoplasmic development (Growney et al. 2005). This 
phenotype has been explained due to RUNX1 role in the switch from mitosis to endomitosis, required 
for MK polyploidisation and platelets cytoskeleton rearrangements (Larissa Lordier et al. 2012). 
Interestingly, a similar phenotype in observed in GATA-1 KO mice (Vyas et al. 1999).  The 
transcriptional regulation of MKs by both GATA-1 and RUNX1 is a result of their direct physical 
association (Xu et al. 2006), required for polyploidisation regulation by switching MK mitosis to 
endomitosis (Larissa Lordier et al. 2012). Both TFs, RUNX1 and GATA-1, are co-expressed during 
activation of MK-specific promoters (Elagib et al. 2003), highly expressed during megakaryocytic 
differentiation and equally switched off during early erythroid maturation (Lorsbach et al. 2004). In 
humans, RUNX1 mutations lead to acute myeloid leukemia with characteristic thrombocytopenia 
and impaired platelet function (Heller et al. 2005). 
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1.2.2.2. Microenvironment and signalling regulation  
Megakaryocytes development happens in highly specialised microenvironment, where gradients of 
growth factors and cytokines are tightly regulated. Microenvironmental signals drive transcriptional 
differences that influence MKs size, ploidy level and function. The direct influence of the 
microenvironment in MK maturity was studied by Slayton et al. where neonatal liver haematopoietic 
stem cells, that generally produce small MKs with low DNA content, produced adult-size and ploidy 
MKs when transplanted into an adult microenvironment (Slayton et al. 2005). In vitro models of 
megakaryopoiesis have explored the influence of cytokines signalling in MK differentiation. Despite 
significant differences in methodology, the successful models generally replicate MK generation by 
exogenous supplementation of thrombopoietin (TPO) and human stem cell factor (SCF) (Q. Feng et 
al. 2014; Moreau et al. 2016). 
1.2.2.2.1. Thrombopoietin  
Thrombopoietin (TPO), produced in hepatocytes, is the main cytokine regulating MK differentiation. 
TPO belongs to the four-helix bundle family of proteins, which includes erythropoietin (EPO) and 
leukemia inhibitory factor, amongst others. TPO binds to receptor cMpl (CD110) (Bartley et al. 1994). 
cMpl does not have intrinsic kinase activity, instead it associates with the cytoplasmic tyrosine kinase 
Janus kinase 2 (Jak2). This association triggers the cMpl internalization and dimerization 
(deactivation), as well as the phosphorylation (activation) of Jak2 (Drachman, Griffin, and Kaushansky 
1995). Multiple signalling pathways are activated following cMpl-Jak2 association; including signal 
transducer and activator of transcription (STAT), mitogen-activated protein kinase (MAPK) and 
phosphoinositol-3 kinase (PI3K) pathways, as reviewed by Geddis et al. (Geddis, Linden, and 
Kaushansky 2002). 
 
TPO regulates late megakaryopoiesis and platelet production via a feedback-loop mechanism in 
which TPO levels are gauged by platelet numbers in circulation (Kuter and Rosenberg 1995). cMpl, 
TPO receptor on the surface of platelets, binds to TPO in circulation, which is degraded following 
binding. The decrease in TPO concentrations results in the reduction of platelet production. 
Consequently, the decrease of circulating platelets increases TPO concentrations, thus, driving MKs 
to release more platelets into the bloodstream.  TPO feedback-loop is the main mechanism 
controlling platelet release in normal health conditions, although TPO concentration can also be 
influenced by other factors in disturbed conditions such as inflammation. For example, 
thrombocytosis induced by inflammatory mediator IL-6 results in increased levels of TPO in plasma 
(Kaser et al. 2001). TPO circulating concentration can also be regulated by ageing platelets. These 
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become desialylated and bind to the hepatic Ashwell -Morell receptor (AMR) which induces TPO 
transcription, and consequent production of platelets (Grozovsky et al. 2015). 
 
TPO signalling regulates early and late megakaryopoiesis. Mice lacking either TPO or its receptor 
show deficiencies in early haematopoietic progenitor cells as well as late-stage MK differentiation 
(Kimura et al. 1998). It has been shown that ablation of TPO avoids MK maturation in murine bone 
marrow cells (K Kaushansky et al. 1995) and causes severe thrombocytopenia (F J de Sauvage et al. 
1996). Similarly, mice deficient in TPO receptor, cMpl, show low ploidy MKs and severe 
thrombocytopenia (Alexander et al. 1996). Soon after the identification of TPO, the study of 
megakaryopoiesis improved significantly due to the development of in vitro models based on TPO 
supplementation(Bartley et al. 1994; Frederic J. de Sauvage et al. 1994; Lok et al. 1994). Despite being 
important for MK differentiation, it has previously been shown that TPO on its own does not sustain 
MK cell maintenance (Ryu et al. 2001). 
1.2.2.2.1. Stem Cell Factor 
Stem cell factor (SCF, known as kit-ligand or steel-factor) is a cytokine that binds to c-Kit, a tyrosine 
kinase receptor (CD117). SCF was first discovered when mutations on the gene locus resulted in 
phenotypes affecting haematopoiesis (Zsebo et al. 1990). In that study, mice with mutated SCF locus 
presented anaemia as well as deficiencies in master cell phenotypes, and haematopoiesis could not 
be restored. Another study showed that mutations in the SCF receptor, c-Kit, cause a similar 
phenotype (Reith et al. 1990). 
 
SCF regulates almost every step of megakaryopoiesis. At early stage, SCF promotes HSC self-renewal 
potential (Bowie et al. 2007). SCF also regulates MK growth, especially at late maturation stage. A 
study testing the effect of megakaryopoiesis-specific cytokines on TPO-induced apoptosis has found 
that only SCF reduced apoptosis in MK cells (Kie et al. 2002). The study also showed that SCF 
enhances MK maturation ex vivo when used in conjunction with TPO by increasing MK 
polyploidisation levels.  
1.2.3. Platelets    
In normal conditions, the bloodstream has 150-400 x 109 circulating platelets per litre of blood 
(Sylman et al. 2018; Smock and Perkins 2014). Platelets are anucleated cells, containing secretory 
vesicles and the translational machinery necessary for protein synthesis. The secretory vesicles in 
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platelet cells include α-granules, dense granules, lysosomes and t-granules (Machlus, Thon, and 
Italiano 2014). The most abundant granules in platelets, α-granules, contain proteins important in 
haemostasis, such as P-selectin, fibrinogen and vWF. Dense granules contain membrane transporters 
and high concentration of calcium; lysosomes are loaded with enzymes involved in protein, 
carbohydrates and lipid degradation; and t-granules store disulphide isomerase, a protein required 
for thrombus formation (Kim et al. 2013). Although, granules formation has not yet been fully 
characterised, it is clear that their contents are directly inherited from MKs. Similarly, the platelet 
transcriptome is mainly derived from MKs, and therefore, it provides an insight into the 
transcriptional profile of MKs. However, extrapolation of transcriptional data from MKs to platelets 
should be performed with caution. Firstly, MKs package mRNA in a selective manner, and disparity 
in mRNA and protein expression has been found between MKs and platelets (Cecchetti et al. 2011). 
Secondly, platelets might be able to receive RNA transcripts from other cells, as an intracellular RNA 
transfer mechanism has been reported (Risitano et al. 2012). Lastly, it is acceptable to speculate that 
the microenvironmental impact could trigger alternative pathways, inducing differences in 
translation or protein function. 
Platelets have been reported to be involved in immunity processes (Semple, Italiano, and Freedman 
2011; Thomas and Storey 2015) and angiogenesis (W. Feng et al. 2011) , but their most well studied 
role is in the haemostasis process and thrombus formation.  Due to their small size, platelets circulate 
close to the luminal surface of the endothelium, which facilitates their response to changes in 
endothelial integrity. The sub-endothelium vWF forms a bridge between collagen, exposed at the 
compromised endothelium site, and the platelet membrane receptors GP Ib-IX-V, GP Ia/IIa and GPVI 
(López 1994; Nieswandt and Watson 2003). Platelet activation leads to a cytoskeleton 
rearrangement transforming the discoid platelet into a spiny spherical  cell (Shin et al. 2017). The 
platelet shape change is followed by the release of chemical activation factors, such as adenosine 
diphosphate (ADP) and thromboxane A2, which escalate platelet adhesion response. Following the 
initial activation, platelets release thrombin which escalates the formation of the thrombus. 
Thrombin converts fibrinogen to fibrin, resulting in the formation of a network of fibrin fibres  
(Heemskerk, Bevers, and Lindhout 2002). This structure helps to stabilise the platelet mass which 
results in a strengthened barrier to blood loss. Following a haemostasis episode, platelet count 
rapidly increases due to increased cell demand.  
Platelet traits, such as platelet count (PLT) and mean platelet volume (MPV), are highly heritable 
(Qayyum et al. 2012). During steady state thrombopoiesis, platelet mass is tightly controlled with 
PLT and PMV being inversely correlated (Bessman 1984). Interestingly, these traits also directly 
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correlate with MK ploidy level, as a decrease in PLT, and corresponding increase in PMV, leads to 
higher MK ploidy (Stenberg et al. 1991; Mazur et al. 1988). Platelet size is directly related to function; 
therefore, it is critical that normal platelet differentiation is maintained. Dysregulation of 
thrombopoiesis can lead to 1) the production of low platelet numbers leading to bleeding disorders, 
such as thrombocytopenia, or 2) over reactive platelets leading to acute coronary syndrome (ACS). 
ACS identifies various diseases, caused by pathological platelet thrombosis, leading to the formation 
of intracoronary occlusion. ACS includes conditions such as partial coronary occlusion (unstable 
angina) and total coronary occlusion (myocardial infarction) (Smith et al. 2015). Myocardial infarction 
has been correlated with platelet traits such as MPV and platelet distribution width (PDW), which 
refers to the size variability in platelet population (Chu et al. 2010; KLOVAITE et al. 2011a). Hence, it 
is important to understand the transcriptional mechanisms controlling these traits. One way of 
identifying possible genomic variants regulating these traits is by performing genome-wide 
association studies (GWAS), which identifies the association between genome variants and disease 
phenotypes.  
1.2.4. Genome-wide association studies (GWAS) 
Genome-wide association studies (GWAS) have transformed our understanding of genetic variation 
as the studies are based on unbiased scanning of the genome in a population, revealing previously 
unknown patterns of inheritance. Previously to GWAS, the identification of genome loci causative of 
disease was based on linkage analysis (Botstein and Risch 2003). Despite this method being 
successful at mapping variants affecting Mendelian diseases (Koenig et al. 1987; Kerem et al. 1989), 
its use was limited on mapping loci underlying complex diseases (Lander and Schork 1994). In 
contrast, GWAS determine the association between hundreds of thousands of variants within a 
population and a trait, series of traits or disease status; thereby identifying variants associated with 
specific trait or disease susceptibility (MacArthur et al. 2017; M. J. Li et al. 2016). The major drawback 
of GWAS is that the association between a genetic variant and a trait does not directly relate to 
causation, and therefore is not informative of the mechanism whereby the variant regulates the 
phenotypic differences. Hence, the identified variants can have a direct effect on the trait, i.e. a 
change in an amino acid affecting the protein function or stability (Butler et al. 2017); or the variant 
can indirectly affect a trait by being in linkage disequilibrium (LD) with a functional variant. Linkage 
disequilibrium (LD) refers to the correlation among DNA variants as a result of evolutionary forces 
(Hill & Robertson 1968).  
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The statistical power of GWAS is proportional to the population sample size. In order to increase 
statistical power, larger studies including GWAS from various cohorts can be integrated into meta-
analysis. Although, the main challenge of meta-analysis lye on the normalisation of the methodology 
and analysis criteria used to generate individual databases. In order to overcome this drawback, 
GWAS of larger cohorts have been performed, using a single analysis platform, and it has been shown 
that this strategy leads to a gain of statistical power over meta-analysis (Astle et al. 2016). GWAS of 
large cohorts improve the detection of rare variants (minor allele frequency <1%), which map 
predominantly in or near coding regions, and have larger phenotypic effect sizes. Although, 70-90% 
of the identified variants map to non-coding regions of the genome (Astle et al. 2016; Wood et al. 
2014a; Maurano et al. 2018). This fact could be due to co-inheritance of variants in strong linkage 
disequilibrium (LD) with the sentinel (the most significant) variant; or due to variants being located 
in cis-regulatory elements (Gallagher and Chen-Plotkin 2018). In conclusion, GWAS have the ability 
to determine association between traits and variants, and also estimate variance explained by sets 
of single nucleotide polymorphisms (SNPs) (He et al. 2015); look for potential causal SNPs within a 
locus, (fine-mapping, Mendelian randomization)(Spain and Barrett 2015; Wood et al. 2014b; 
Robinson et al. 2016); identify SNPs related to multiple traits (pleiotropy) (Willer et al. 2013); and 
carry out pathway analysis (Willer et al. 2013).  
 
Mechanisms controlling platelet traits are poorly understood, and GWAS have been a critical tool in 
the study of such mechanisms. GWAS studies have been performed to study variants associated with 
platelet traits (Astle et al. 2016; Oh et al. 2014; Schick et al. 2016), and platelet function (Qayyum et 
al. 2015) in different populations. In the quest to learn about how genome variants influence PMV 
and PLT, a meta-analysis of GWAS was performed on 67,000 individuals (Gieger et al. 2011). This 
study identified 68 genomic loci associated with PLT and MPV, of which 11 loci had not previously 
been associated with haematopoiesis. One of these association is the BRD3 gene, which encodes for 
one of the Bromodomain and Extra Terminal (BET) proteins. Following the GWAS identification of 
these genes, a reverse genetic screen was performed in zebrafish, where BRD3 protein expression 
was knocked down by morpholino to investigate the phenotypic result of BRD3 ablation (Bielczyk-
Maczyńska et al. 2014b). The association between BRD3 and platelets was confirmed when the BRD3 
morpholino-knockdown resulted in reduced number of thrombocytes and erythrocytes, but normal 
cell generation of all other cell lineages assessed. The reduced thrombocyte number was partially 
restored with in vitro transcription of RNA-encoding human BRD3. This study also shown that JQ1 
inhibition (a BET inhibitor) resulted in ablation of thrombocyte formation when administered at early 
stages of embryo formation, but not at later stages. The authors hypothesised that BRD3 is required 
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for thrombocyte differentiation from HSCs, but not thrombocyte maintenance. Although, it is 
important to note that JQ1 inhibits other proteins of the same family, and not only BRD3.  
  
Astle et al. performed a GWAS in a large study of 174K healthy participants included in two large 
cohorts - UK Biobank (Sudlow et al. 2015) and INTERVAL (C. Moore et al. 2014) - and identified 29.5 
million genetic variants associated with 36 blood cell traits (Astle et al. 2016). In this study, common 
variants in the BRD3 coding sequence (rs2157770 (A/G); rs459571 (C/T)) were associated with MPV 
and PDW, respectively. Figures 1.2.2 and 1.2.3 show BRD3 locus zoom plots for MPV and PDW 
generated in that study. Each plot represents the association between single nucleotide variants 
(SNVs) and the platelet trait (MPV and PDW, respectively). The association is measured as a p-value 
of association. It is interesting to note that the pattern of association for MPV and PDW is rather 
distinct, which suggests that the mechanism by which the variations affect these platelet traits may 
be different. 
 
 
 
Figure 1.2.2 BRD3 locus zoom plot with SNP association for volume of platelets. This plot represents 
the telomere of the long arm of chromosome 9 with the genes indicated in the lower box (BRD3 
coding region). The dots represent single nucleotide variants (SNVs) and the x-axis (left) is the p-value 
(minus log10) of association between mean platelet volume (MPV) and the individual SNVs. The 
height of each dot represents the strength of evidence for the association (rather than effect size). 
Dots are coloured according to the LD (linkage disequilibrium between the causal variant and the 
lead variant (labelled). 
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Figure 1.2.3. BRD3 locus zoom plot with SNP association for distribution width of the volume of 
platelets. This plot represents the telomere of the long arm of chromosome 9 with the genes 
indicated in the lower box (BRD3 coding region). The dots represent single nucleotide variants (SNVs) 
and the vertical axis (left) is the P-value of association between platelet distribution width of volume 
(PDW) and the individual SNVs. The height of each dot represents the strength of evidence for the 
association (rather than effect size). Dots are coloured according to the LD (linkage disequilibrium) 
between the causal variant and the lead variant (labelled). 
 
The aforementioned GWAS identified variants associated with platelet traits. Although, the 
validation of such associations is a critical step to understand the role of such variants in 
transcriptional regulation of MKs and platelets, and its consequence on cellular traits. Therefore, the 
main aim of this thesis is to explore the role of BRD3 during megakaryopoiesis regulation. 
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1.3 Bromodomains 
 
1.3.1. Bromodomain modules  
Bromodomain modules (BDs) are evolutionary conserved modules that selectively recognise and 
bind to acetylated lysines. These protein-interaction modules were named after the Drosophila gene 
brahma, where the BD sequence was first identified (Haynes et al. 1992). BD structure is formed by 
four α-helices (αZ, αA, αB and αC) bound by flexible loop regions (AB, BC and ZA loops) (figure 1.3.1). 
Several conserved residues are characteristic of BDs; in particular an asparagine (Asn) residue at the 
BC loop that forms a hydrogen bond with Kac, promoting the binding of acetylated peptide to the 
hydrophobic pocket within the four helices (Owen et al. 2000). Interactions with acetylated peptides 
are initiated and stabilised by the surrounding charged surface, where extensive hydrogen bonds are 
established. 
 
 
Figure 1.3.1. Structure of bromodomain modules. The structure of the first bromodomain (123 
amino acids) of BRD3 (BRD3(1)). Bromodomains contain four α -helices (αZ, αA, αB and αC) bound by 
flexible loop regions (AB, BC and ZA loops). A conserved Asn residue in the BC loop region is 
responsible for docking BD modules to acetylated Lys (Kac) peptides. Image generated on RCSB PDB 
(Research Collaboratory for Structural Bioinformatics, Protein Database) website.  
 
In humans, the bromodomain modules are shared by 46 known proteins containing a total of 61 BD 
modules. Bromodomain proteins (BRDs) have been classified in eight distinct families, based on 
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structure based alignments (Filippakopoulos et al. 2012b). In this thesis, I focus on the Bromodomain 
and Extra Terminal (BET) family of proteins described below. 
1.3.1.1. Bromodomain and Extra Terminal family 
There are four members of the Bromodomain and Extra Terminal (BET) family: BRD2, BRD3, BRD4 
and BRDT. These are ubiquitously expressed in the human body, with the exception of BRDT, which 
is expressed only in testis cells. BET proteins have a highly conserved and homologous structure 
containing: 2 N-terminal bromodomain modules (BDs) displaying high levels of sequence 
conservation, an extra terminal recruitment domain (ET), and other conserved motifs (A, and B). 
Proteins BRD4 and BRDT also contain a C-Terminal Motif (CTM) (figure 1.3.2).   
 
 
Figure 1.3.2 BET protein structure homology. BET proteins share a very similar and highly conserved 
structure. Proteins are constituted by two bromodomains (BD1 and BD2) with lysine acetylation 
recognition functions. Motifs A, B and ET are required for localisation, dimerization and protein 
interactions, respectively. BRD4 and BRDT contain a C-terminal domain (CTD) with protein-protein 
interaction functions. Adapted from (Pablo Garcia-Gutierrez and Garcia-Dominguez 2015). 
 
BD1 and BD2 modules are both acetyl-lysine recognition sites. Interestingly, the similarity among the 
first bromodomain (BD1) sequences in all BET proteins is higher than between BD1 and BD2 within the 
same protein (Filippakopoulos et al. 2012a). This fact could explain the functional overlap observed 
among some BET proteins (Stonestrom et al. 2015). Motif A, located between both BD modules, 
contains a region of 12 amino acids that acts as a nuclear localisation signal. It has been shown that in 
vitro deletion of the A motif causes mislocalisation of the proteins (Fukazawa and Masumi 2012). Motif 
B is required for homo and hetero dimerization (P. Garcia-Gutierrez, Mundi, and Garcia-Dominguez 
2012); and the ET domain is important for interaction with other proteins (Rahman et al. 2011). BRD4 
and BRDT are longer proteins which also contain a C-terminal motif (CTM). This motif is important for 
protein-protein interaction as it has been shown to interact with P-TEFb, facilitating effective 
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transcription (Schröder et al. 2012). Bromodomain proteins form complexes with diverse protein 
partners due to the ability to initiate interactions by the ET or CTM domains (Rahman et al. 2011). 
These large protein assemblies have important roles in transcriptional programmes.   
1.3.2. Bromodomain proteins (BRDs) in transcription  
Bromodomains integrate protein complexes with functions in chromatin remodelling, highlighting 
the critical roles of BRDs in transcription regulation. BRDs are subunits of histone acetyltransferases 
(HATs) and anchor the HAT complex to acetylated chromatin, where other HAT subunits remodel the 
surrounding chromatin (Nagy and Tora 2007). As acetylation readers, BRD elements also recruit 
remodelling complexes to acetylated chromatin regions. These complexes alter the contact between 
DNA and histones, allowing the movement of nucleosomes. An example is SWI/SNF remodelling 
complex which is found at promoters of actively transcribed genes (Khavari et al. 1993; W. Wang et 
al. 1996). These functions are not exclusive and some BRD-containing complexes can perform several 
functions where the BRD-element plays critical roles. One example is the BRD-containing p300/CBP 
complex which has HAT activity (Arany et al. 1994), acetylates transcription factors such as GATA1 
(Boyes et al. 1998) and can bind to acetylated p53 (Mujtaba et al. 2004).   
 
Many transcription proteins contain several BD modules or a combination of BD with other effector 
domains. This feature allows targeted recognition of histone PTMs combinations, alluring to the 
precision of the transcription process. An example of a double bromodomain protein is TAF1, a 
subunit of TFIID with important functions in transcription initiation (Cianfrocco et al. 2013). TAF1 
contains two tandem copies of bromodomains, and in this configuration, it binds with greater affinity 
to double acetylated lysines that are appropriately spaced (Jacobson et al. 2000). BD domains are 
also found in combination with other effector domains with transcription regulatory functions. The 
subunit of the NURF chromatin remodelling complex, BPTF, is one example where bromodomain and 
PHD finger domains co-exist. PHD finger domains recognise methylated lysines, and it has been 
shown that NURF binds to both H4K16ac and H3K4me3 in the same nucleosome (Ruthenburg et al. 
2011). The interpretation of histone patterns by specialised multi-domain proteins is an important 
regulatory mechanism that is just starting to be understood.    
 
25 
 
1.3.3. BET proteins in transcription regulation and cell 
cycle progression 
BET proteins, a bromodomain family, directly regulate transcription initiation and elongation by 
interacting with RNA polymerase II. BRD4 has a direct effect at all stages of transcription. This protein 
has been reported to phosphorylate RNA polymerase II, promoting transcription initiation (Devaiah 
et al. 2012). Transcription elongation is also regulated by BRD4 by recruitment of the transcription 
elongation factor, P-TEFb, to gene promoters (Jang et al. 2005). Additionally, BRD4 assists Pol II 
physical progression through hyperacetylated nucleosomes by interacting with acetylated histones 
(Kanno et al. 2014). BRD2 also associates directly with RNA polymerase II (Crowley et al. 2002); and 
both BRD2 and BRD3 have been shown to facilitate transcription of RNA Pol II though nucleosomes 
(LeRoy, Rickards, and Flint 2008a). Similarly to other BET proteins, BRD2 recognises acetylated 
histones and recruits transcriptional cofactors (Kanno et al. 2004), as well as transcription factors 
and other chromatin remodelling complexes  (Denis et al. 2006) with impact on transcription and cell 
development. 
  
BET proteins are essential in cell cycle control. Both BRD2 and BRD4 remain bound to chromatin 
during mitosis which suggests these proteins might have a role in maintaining epigenetic memory 
(Dey et al. 2003; Kanno et al. 2014). This is thought to be a transcription priming mechanism for a set 
of genes essential upon cell division (Maruyama et al. 2002). BRD2 and BRD4 have also been reported 
to control cell cycle progression. Mochizuki et al. have shown that BRD4 regulates G1-S phase 
progression (Mochizuki et al. 2008). In this study, BRD4 KD cells arrested at G1 phase as opposed to 
normal cell cycle progression observed in control cells. Arrest in G1 phase coincided with 
dysregulation of G1 gene signatures which were re-established following overexpression of BRD4 in 
KD cells. Furthermore, chromatin immunoprecipitation in control cells revealed recruitment of BRD4 
to promoters of the G1 genes dysregulated in BRD4 KD. Together this shows that BRD4 regulates G1 
gene expression, and progression to S phase, by binding to promoters of G1-characteristic genes.   
BRD2 has been shown to control S phase progression through regulation of cyclin A expression 
(Maruyama et al. 2002). Immunoprecipitation of BRD2 has revealed that the protein is present at 
cyclin A promoter during S-phase; and overexpression of BRD2 accelerates cell cycle through 
increased expression of cyclin A and transcriptional activation marks (H4 acetylation) at cyclin A 
promoter. BET proteins regulate cell progression at both gene promoters and bodies (LeRoy et al. 
2008b), but also influence cell identity by regulation of non-coding regulatory regions. 
 
26 
 
BET proteins regulate transcription at enhancers. Recent studies, investigating the role of BET 
proteins in regulation of oncogenes, found that BRD4 co-localises with Mediator at enhancer regions 
(Lovén et al. 2013a). In this study, BET inhibition resulted in loss of BRD4 preferentially at enhancers, 
with consequent transcription elongation defects on genes regulated by those enhancers. In a 
different study, on adipose and muscle cells, it has been demonstrated that BRD4 co-localises with 
lineage-specific TFs at active enhancers (J.-E. Lee et al. 2017). In line with the previous study, BRD4 
deletion prevented enrichment of Mediator and RNA polymerase II at enhancers; consequently 
preventing cell-specific gene signatures and differentiation (Bhagwat et al. 2016a). BRD2 has also 
been found to play a role on enhancer-driven transcription. In a study on differentiation of mouse T 
cells, BRD2 associated with the CTCF-cohesin complex that supports loop formation during cis-
regulatory enhancer assembly (Cheung et al. 2017). BRD3 association with active enhancers has not 
been reported, in fact this is the less investigated of all the BET proteins.  
1.3.4. BET inhibition  
The hydrophobic nature of the acetyl-lysine recognition site in BET proteins presents an opportunity 
for the development of antagonist compounds. BET inhibitors are highly potent and selective 
molecules, capable of displacing BETs from chromatin with disruptive consequences on the 
transcriptional programs (Anand et al. 2013; Chapuy et al. 2013). However, despite the high 
selectivity over non-BET bromodomain proteins, the current BET inhibitors bind indiscriminatingly to 
the BET family due to the similarity among protein sequences (Filippakopoulos et al. 2010; Picaud et 
al. 2013). The first compounds developed to target BET proteins were I-BET and JQ1. I-BET is a 
benzodiazepine derivative capable of downregulating expression of inflammatory genes (Nicodeme 
et al. 2010). JQ1 is a triazolothienodiazepine compound first reported to halt cell cycle progression 
and  induce apoptosis in human tumour cell lines (Filippakopoulos et al. 2010). Currently, there are 
several BET inhibitors used in research, and some are being tested in clinical trials for oncological 
diseases (Doroshow, Eder, and LoRusso 2017). The efficacy of these drugs is due to the general 
transcription repression of oncogenes and cell cycle arrest; in particular, c-Myc, a gene associated 
with cell growth, cell cycle progression and apoptosis that is frequently dysregulated in oncogenesis. 
BET inhibition often results in downregulation of c-Myc (Delmore et al. 2011b), probably due to the 
eviction of BRD4 from the c-Myc locus and consequent absence of PTEFb recruitment (Jang et al. 
2005). It has been suggested that BET inhibition is particularly efficient at targeting tumour cells due 
to the eviction of BRD4 from oncogenic driver super-enhancers (Lovén et al. 2013b). Invariably 
unwanted effects have been observed during clinical trials for BET inhibitors with the most 
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commonly reported being thrombocytopenia (low platelet count), highlighting the role of BET 
proteins in platelet development (Berthon et al. 2016; Amorim et al. 2016). The pharmacological 
inhibition of BET proteins has shown therapeutic activity in a variety of pathologies  (Prinjha, 
Witherington, and Lee 2012), and it represents an invaluable tool in the study of functional 
interactions between BET proteins and other regulatory factors. 
1.3.5. BRD3-GATA-1 interaction 
BRD3 directly binds to GATA-1 during erythroid-MK differentiation. Acetylation of the TF GATA-1 is 
essential for chromatin-binding at GATA1-activated and repressed genes (Boyes et al. 1998; J. M. 
Lamonica, Vakoc, and Blobel 2006). The first bromodomain of BRD3 recognises and binds to the 
acetylated lysines on the C-terminal of GATA1 (K312 and K315), adjacent to the zinc finger domains 
(Gamsjaeger et al. 2011). Lamonica et al. showed that acetylation of GATA-1 is essential for BRD3 
association with chromatin (Janine M Lamonica et al. 2011). Additionally, the study showed that BET 
inhibition disrupted both BRD3 and GATA-1 chromatin occupancy, and therefore it was suggested 
that BRD3 promotes GATA-1 stable association with chromatin. However, this study has described 
the interaction between BRD3 and GATA1 in a simplistic and isolated way, which could lead to 
misinterpretation. Firstly, the inhibition experiments assume a targeted effect on BRD3, rather than 
the nonspecific targeting of all BET proteins characteristic of BET inhibitors. Secondly, the study 
assumes that both BRD3 and GATA1 are the only factors involved in thi s interaction. Therefore, the 
effects of other BET proteins or the possibility of a multiprotein complex containing BRD3, has been 
overlooked.  
 
A different study investigated the effects of BET proteins on GATA-1 regulated genes during 
erythropoiesis, and concluded that BRD3 is dispensable for GATA-1 gene activation during 
erythropoiesis (Stonestrom et al. 2015). Stronestrom et al. showed that, despite high level of co-
occupancy between BRD3 and GATA-1, displacement of BRD3 does not affect GATA1-mediated 
erythroid transcription. Interestingly, the depletion of BRD2 and BRD4 blunted several of the 
erythroid GATA1-regulated genes. These results show that BRD3 is not essential for erythroid GATA1-
mediated gene transcription, and suggest that BRD3 might be recruited differently from BRD2 and 
BRD4. In addition, it was also reported that BRD3 and BRD2 could functionally overlap during 
erythropoiesis, as the overexpression of BRD3 on BRD2 KOs partially restored normal phenotype. 
This was the first time that a BET functional overlap was reported, and it highlights  the complex 
system of transcription mechanisms. 
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1.4 Model systems to study megakaryopoiesis 
 
 
The rarity of megakaryocytes, and the difficult accessibility to the bone marrow are the main 
obstacles in the study of megakaryopoiesis. Current megakaryopoiesis models include: animal 
models; immortalised cell lines with MK dysfunctional phenotypes, and stem cell derivation models. 
Each of these options presents a reliable research tool, but require careful consideration depending 
on the end application, as each model has its own drawbacks. Here, I briefly summarise advantages 
and disadvantages of each of these models, with particular focus on stem cell models as this has 
been my chosen model in this project.  
1.4.1. Animal models 
Animal models present the possibility to study megakaryopoiesis as part of a whole organism. 
Considering that the haematopoietic system is evolutionarily well conserved in mammals, animal 
models present a reliable resource to study physiological aspects of MK and platelet formation. 
Animals, such as mice and zebrafish, have been the basis of some important advances in the study 
of haematopoiesis as reviewed by (Schmitt, Lizama, and Zovein 2014). Some of the advantages 
offered by animal models rely on the ability to generate transgenic animals to mimic human disease 
phenotypes, and on the relatively short life span allowing transgenerational studies.  However, the 
major limitation of animal models is that some human disease phenotypes are poorly replicated in 
animals (Seok et al. 2013). 
1.4.2. Immortalised cell lines 
Immortalised cell lines with dysfunctional phenotypes are an alternative model to study 
megakaryopoiesis. These are patient-derived cancerous cells that are adapted for in vitro culturing. 
Examples of this model are the CHRF-288-11 cell line derived from a solid tumor expressing MK and 
platelet characteristic markers (Fugman et al. 1990); the Dami cell established from peripheral blood 
of patients with megakaryoblastic leukemia (Greenberg et al. 1988); or IST-IU derived from narrow 
of a patient with leukemia (Sledge et al. 1986). These models hold a faithful genetic background for 
the disease, but they are cancerous and also omit the effects of environmental cues. Patients with 
rare bleeding disorders are ultimately the reason why it is important to study MKs and platelet 
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formation. These patients present an invaluable source of scientific information as the genome and 
epigenome of the cells contain the details that we, as scientists, are trying to unveil. However, often 
it is not ethically feasible to collect tissue samples from patients with bleeding disorders  (blood or 
skin biopsies) for cell line generation.  
1.4.3. Stem cell models 
A stem cell is an unspecialised cell, capable of replicating into an identical daughter cell through cell 
division (self-renewal), and capable of differentiating into multiple cell types upon environmental 
stimuli (pluripotency). There are different classifications of stem cells based on the level of potency 
retained. 1) Totipotent cells are capable of generating all cells and tissues in the body. 2) Pluripotent 
cells retain the capability to differentiate into all embryonic tissues. 3) Multipotent and oligopotent 
cells are able to generate all or a limited number of lineages, respectively. 4) Unipotent ( also called 
progenitor) are cells capable of differentiating into one lineage only. 
 
Induced pluripotent stem cells (IPSCs) are an irreplaceable tool in the modern study of biology. In 
1981, Martin G.R. and Martin Evans published two independent studies demonstrating isolation, in 
vitro culturing and pluripotency of embryonic stem cel ls (ESC) from mouse blastocysts (Martin 1981; 
Evans and Kaufman 1981). These experiments paved the way to the development of stem cell-based 
models. Despite the inherent potential of embryonic stem cells, the use of these cells remained 
surrounded by ethical controversy, fuelling the development of iPSC technology (Volarevic et al. 
2018). In 2006, Yamanaka reported the induction of pluripotency from somatic cells (mouse 
fibroblasts) (Takahashi and Yamanaka 2006). The reprogramming of fully differentiated (somatic) 
cells into iPSCs was achieved through overexpression of four TFs: Oct3/4, c-Myc, Sox2 and Klf4. 
Currently, iPSCs are extensively used in scientific research due to their numerous advantages. 1) The 
potential to derive iPSCs from somatic patient lines, which not only allows the study of individual 
mutations, but also could present an autologous cell therapy alternative preventing immune 
rejection potential. 2) Morphological and growth similarities to ESCs. 3) Differentiation potential into 
somatic cells. This is due to the iPSC pluripotency levels, meaning that all  3 germ layers can be derived 
from iPSCs. The differentiation potential can be tested based on expression levels of pluripotency 
genes; or by cell differentiation towards the 3 germ layers (either by spontaneous or directed 
differentiation) (Buta et al. 2013). Although, in iPSC- based therapies, pluripotency of iPSCs is verified 
by the formation of teratomas following iPSC injection into immunocompromised mice, the hallmark 
for functional pluripotency (W. Zhang 2014). 
30 
 
 
When iPSCs were first generated, the process was extremely laborious and inefficient, and the 
tumorigenic potential associated with overexpression of c-Myc was a concern (Nakagawa et al. 
2008). In the past decade, several methods have been developed to counteract these pitfalls, and 
alterations included: parental somatic cell type, reprogramming factors used, delivery methods and 
culture conditions. Several methods have been developed for the generation of iPSCs as review by 
(González, Boué, and Belmonte 2011). Currently, iPSCs could present a practical alternative to the in 
vitro differentiation of megakaryocytes and various protocols have been developed as described in 
the next section.    
1.4.4. in vitro models of megakaryopoiesis 
The development of in vitro models of megakaryopoiesis enables the molecular study of MKs 
differentiation and presents an attractive potential source of platelets for transfusion. The 
generation of MKs in the laboratory is a recent achievement as the first report on the differentiation 
of hES-derived MKs was published just over a decade ago. In that first protocol, Gaur et al. reported 
a method, based on TPO supplementation, which enabled the differentiation of hESC into high ploidy 
(2N-32N), CD41a+/CD42b+ MKs (GAUR et al. 2006). This protocol was simple, but the efficiency of 
differentiation was low (0.1-0.4 MKs per input hESC).  
 
An alternative protocol was presented by Takayama et al. where supplementation with vascular 
endothelial growth factor (VEGF) promoted the formation of embryonic stem cell-derived sacs (ES-
sacs) (Takayama et al. 2008). Haematopoietic progenitors in the ES-sacs were induced to MKs upon 
TPO supplementation. This protocol enable the production of 2-5 MKs per ESC which still presents a 
low yield, and was considerably laborious. 
 
 The first study, showing functional hESC-derived platelets contributing to in vivo thrombus 
formation following laser injury in a mouse model, was published in 2011 (Lu et al. 2011). The 
production of haemangioblasts, as a result of cytokines supplementation, was followed by 
exogenous administration of TPO, SCF and IL-11 to obtain platelet-producing MKs. This protocol 
presented two important advantages in comparison with previous ones: the cells were differentiated 
in feeder and serum-free conditions, and the MK yield was considerably higher (100 MK per hESC). 
A similar protocol on directed differentiation was reported in 2014 where iPSCs were differentiated 
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into MKs, and produced HLA-ABC-negative platelets as a potential source of universal platelets for 
transfusion (Q. Feng et al. 2014).  
 
Another interesting protocol was published by Nakamura et al. where pluripotent stem cell-derived 
progenitors generated stable immortalised MK progenitor cell lines (imMKCLs). This was achieved 
through the overexpression of BMI1 and BCL-XL, to suppress senescence and apoptosis, respectively; 
and the controlled expression of c-Myc to promote proliferation (Nakamura et al. 2014). Despite 
allowing long-term cultures, this protocol has a demanding upfront cell requirement (4 platelets 
produced per imMKC).  
 
Lastly, a forward programming protocol has recently been reported based on the overexpression of 
three key haematopoietic TFs (GATA1, TAL1 and FLI1) (Moreau et al. 2016). The cells are initially 
cultured in a 3D format to generate mesodermal embryoid bodies upon supplementation of BMP4. 
This step is followed by culturing embryoid bodies in suspension with TPO and SCF supplementation 
until cells present a MK-specific phenotype. This protocol enables the production of 2E+5 MKs per 
input hiPSC in a xeno-free manner and allows culturing of MKs for up to 120 days. A new version of 
this protocol has been developed where the initial 3D culturing system was replaced by a 2D cell 
monolayer. The advantages of the new system are the lower cost, justified by the removal of 
expensive 3D culturing plates; and the maintenance of the 2D conditions in which iPSCs are normally 
cultured. This version is explained in detail in the results session as this was the model I used to 
perform the experiments reported in this thesis. 
 
Despite the advances made in the field of ex vivo MK differentiation strategies, the current protocols 
present the following disadvantages. 1) The MKs generated are not yet able to achieve high 
polyploidisation, resulting in low pro-platelet release when compared with human adult MKs. 2) The 
pro-platelets generated present inappropriate and premature activation confirming cell immaturity. 
An important advantage of all aforementioned in vitro models is the possibility to genetically 
engineer cell lines with variants to mimic MK-related disease phenotypes. The ability to genetically 
engineer cells has recently been improved with the adaptation of the Clustered Regularly Interspaced 
Palindromic Repeats (CRISPR) and CRISPR-related proteins (Cas) or CRISPR/Cas system.  
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1.4.3. Genetic manipulation system- CRISPR/Cas9 
CRISPR/Cas is a bacterial adaptive immunity system that has recently been adapted to allow cellular 
genetic manipulation. In bacteria, CRISPR/Cas9 is used as a defence mechanism against invading 
viruses and plasmids (Barrangou et al. 2007). Upon phage infection, short DNA fragments from the 
invader’s genome (protospacers) are incorporated into the bacteria’s CRISPR loci. Following a second 
encounter with the phage invader, the CRISPR loci are transcribed, and the CRISPR RNA generated 
(crRNA) integrates the protospacers. The crRNAs hybridise with trans-activating RNA (tracrRNA) to 
guide the Cas9 to the specific foreign DNA, next to a protospacer adjacent motif (PAM). The foreign 
DNA is cleaved by Cas9, inactivating the bacteriophage infection. Although this process is generally 
extremely efficient; bacteriophages are known to adapt very rapidly and circumvent CRISPR/systems. 
One hypothesis to explain such resistance is the existence of anti -CRISPR genes or other genetic 
elements capable of inactivating CRISPR/Cas systems (Bondy-Denomy et al. 2013). The balance 
between CRISPR/Cas9 systems in bacteria and the phage resistance might have contributed to the 
evolution of the variety of CRISPR/Cas systems currently known. 
The adaptation of the CRISPR/Cas system as a genetic engineering tool is recent, but the precision 
and ease of use explain how it became a ubiquitous method in modern molecular biology. The 
bacterial immune system was adapted so the crRNA and tracrRNA are fused into a single guide RNA 
(sgRNA) which flags the target genomic DNA. Similarly to the original bacterial CRISPR/Cas system, 
the sgRNA-targeted loci is then cleaved by the Cas9 protein at 3-4bp upstream from the PAM 
sequence. Upon Cas9 cleavage (double strand break, DSB), the DNA is repaired by either non-
homologous-end-joining (NHEJ) or homologous directed recombination (HDR). NHEJ happens at 
higher frequency and it is error-prone, generating insertions and/or deletions (indels) in the repaired 
loci. The HDR is a high-fidelity mechanism that happens at lower frequencies. This disadvantage can 
be overcome by exogenous supplementation of repair templates, which are incorporated in the 
genome by Watson-Crick base-pairing. The technology has been used in cell lines manipulation, 
transgenic mice manipulation, and even in human gene therapy as reviewed by (Sander and Joung 
2014). 
New mutant versions of Cas9 have been developed to enable CRISPR/Cas9 system repurposing. The 
Cas9 binding and catalytic units that be separately manipulated. The catalytic activity is controlled 
by two distinct endonuclease domains: the HNH nuclease domain which cleaves the complementary 
strand to the sgRNA; and the RuvC nuclease domain cleaves the non-complementary strand. Each of 
these domains can be inactivated by single point mutations. Thus, Cas9 D10A (active RuvC) and H840 
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(active HNH) mutants are termed nickases due to their ability to nick only one DNA strand. The 
enzyme is designated dead Cas9 (dCas9) when both catalytic domains are inactivated, and the 
enzyme completely lacks endonuclease activity. This is a convenient feature for experiments aiming 
at disrupting transcription, as dCas9 can be directed to gene promoters, impeding binding of 
polymerase II (Qi et al. 2013). dCas9 can also be fused to enzymatic domains, such as repressor or 
activator domains. This variation of the system is referred to as CRISPR interference (CRISPRi), and 
depending on the domain fused to the dCas9 enzyme, it can be used with gene up-regulation or 
silencing intentions (Hilton et al. 2015; Thakore et al. 2015). Other uses of CRISPR/Cas9 include 
epigenome editing where Cas9 is used to recruit chromatin modifying enzymes to specific loci (Lei et 
al. 2017; X. S. Liu et al. 2016); live cell chromatin imaging where fluorescently labelled dCas9 is 
directed to target regions (B. Chen et al. 2013; P. Qin et al. 2017); or genetic and epigenetic screens 
where thousands of sgRNAs target a population of cells with the aim of identifying the genes 
responsible for a particular phenotype (Doench 2017). In this thesis, CRISPR has been used to 
generate KO cell clones and CRISPRi was attempted to generate knockdown clones to investigate the 
regulatory roles of BRD3 and other BETS in gene transcription during megakaryopoiesis.  
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1.5 Chromatin and gene transcription 
 
 
Every cell in the body contains the same genetic information, yet cells are abl e to differentially 
express (or repress) genes, resulting in cellular and tissue differentiation. Complex and timely 
interactions between chromatin and specialised proteins, such as transcription factors and cofactors, 
are the basis of gene transcriptional regulation networks.  Disruption of these interactions often 
result in cellular diseased states. Therefore, defining the epigenetic elements regulating 
haematopoiesis is critical to understand the onset and development of disease, such as 
haematopoietic disorders. 
1.5.1. Chromatin structure organisation 
Chromatin is a very dynamic structure, consisting of DNA and proteins, where the basic unit is the 
nucleosome. Each nucleosome is formed by ~147 base pairs of DNA folded around an octamer of 
four core histone proteins H2A, H2B, H3 and H4 (Luger et al. 1997). In the nucleosome core, the 
histones are arranged in H3-H4 tetradimer and H2A-H2B dimers. Linker histone H1 acts as a DNA 
stabiliser by condensing the DNA and the string of repeating nucleosome units (Izzo, Kamieniarz, and 
Schneider 2008). 
 
Histones are proteins containing a globular (spherical) domain and a positively charged NH2-terminus 
(“tail”) protruding from the nucleosome unit. Histone tails are subjected to reversible residues 
modifications - posttranslational modifications (PTMs) - including acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation, ribosylation and biotinylation (Cubeñas-Potts and 
Matunis 2013; Meas and Mao 2015; Rossetto, Avvakumov, and Côté 2012; Greer and Shi 2012; 
Eberharter and Becker 2002). These modifications alter the interaction between histones and the 
DNA, affecting chromatin conformation and accessibility. Chromatin can be characterised as 
euchromatin or heterochromatin. Euchromatin is characterised by a high level of histone acetylation, 
where the DNA sequence is more accessible to transcription factors and RNA polymerase II. These 
features are associated with active chromatin, displaying PTM-rich sites that are actively transcribed, 
or regulate transcription, such as enhancers (Heintzman et al. 2009; Barski et al. 2007). 
Heterochromatin presents a condensed architecture, enriched in histone trimethylation leading to 
transcriptional silencing (Kouzarides 2007).  Heterochromatin has been classified in facultative 
heterochromatin, including regions that are differentially expressed during development and then 
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become silenced, such as the X-chromosome in female cells (Jeppesen and Turner 1993); and 
constitutive heterochromatin containing regions permanently silenced and characterised by 
H3K9me2/3 signatures and low acetylation levels (Trojer and Reinberg 2007).  
 
Each histone tail modification exerts an effect on the chromatin structure, but it is the combinatorial 
effect of PTMs that dictates the overall chromatin state and functional outcome. Several models 
have been proposed to explain regulation of transcription by histone PTMS, including: the signalling 
network model (Schreiber and Bernstein 2002), charge neutralisation model (Roth and Allis 1992) 
and histone code model (Strahl and Allis 2000). The histone code model is the most widely accepted, 
and it postulates that synergistic combinations of histone PTMs drive distinct biological functions 
(Gardner, Allis, and Strahl 2011). Although the histone code provides an explanation for the current 
knowledge of chromatin regulation, it is becoming clear that this is a simplistic view of the histone 
PTMs role in transcriptional regulation. Recent studies uncovered previously unknown chromatin 
details involved in transcription regulation mechanisms, such as histone PTMs asymmetry within the 
nucleosome leading to bivalent functions (Voigt et al. 2012), or the identification of novel histone 
PTMs (Arnaudo and Garcia 2013). Overall, chromatin structure directly impacts the interactions 
between transcription regulators and DNA. Therefore, understanding the network of factors 
regulating histone PTMs will improve the knowledge of the processes regulating gene transcription.  
1.5.2. Transcriptional regulation 
Cell identity is defined by the set of genes transcribed at any given time. The expression of protein-
coding genes relies on several steps, including transcription initiation, elongation, mRNA processing 
and translation. Transcription initiation is regulated by the association between 2 types of cis -
elements: the gene promoter and distal regulatory elements, such as enhancers, silencers and 
insulators (Z. Hu and Tee 2017; Ogbourne and Antalis 1998; Fourel, Magdinier, and Gilson 2004). 
Promoters define the transcription starting site (TSS), gene directionality, and contain the docking 
sites for all the transcriptional machinery (Smale and Kadonaga 2003; Lenhard, Sandelin, and Carninci 
2012). Cis-acting regulatory elements are brought together by trans-acting DNA-binding 
transcription factors. The interactions between distal elements, particularly enhancers, and TFs are 
of most importance for transcription initiation regulation in a temporal and spatial manner (Whyte 
et al. 2013). 
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Characteristic epigenetic features are common in cis-regulatory elements and support their role in 
transcriptional regulation.  Firstly, the absence of nucleosomes results in highly accessible DNA which 
promotes binding of TFs and cofactors at these regions (Hihara et al. 2012). Secondly, nucleosomes 
surrounding these highly accessible regions are often characterised by specific histone modifications. 
As examples, enhancer chromatin signatures are often characterised by high levels of H3k4me1 and 
low levels of H3k4me3, while promoters are marked by H3K4me3 (Hon, Hawkins, and Ren 2009; 
Heintzman et al. 2007a; Barski et al. 2007). Additionally, the distinction between inactive and active 
enhancers can be based on H3k27ac marks (Creyghton et al. 2010). Lastly, regulatory elements 
presenting active signatures are generally populated by transcriptional factors, cofactors and 
activators (Heintzman et al. 2009).  
 
Enhancers are cis-elements with structural characteristics that influence precise spatiotemporal 
transcription regulation. Enhancers contain multiple TF binding sites. The combinatorial TF 
occupancy evolves during cell development resulting in precise regulation patterns (Lin et al. 2010; 
Sandmann et al. 2006; Sandmann et al. 2007). In addition to variation in TF occupancy during cell 
development, epigenetic information at enhancers changes in complexity during differentiation. 
Heintzman et al. demonstrated that enhancers are marked with cell -specific histone PTMs patterns, 
which are strongly correlated to cell-specific gene signatures (Heintzman et al. 2009). These gene 
signatures can be activated through long-range interactions between the enhancers and the gene 
promoters, independently of the distance, or orientation between the 2 elements (Clapier and Cairns 
2009; Geyer, Green, and Corces 1990). Several models have been proposed to explain the 
interactions between distal enhancers and promoters as reviewed in (Mora et al. 2016), although 
the DNA-looping model is the most widely accepted. In this model, DNA loops are formed between 
enhancers and promoters, where both elements are in closer proximity to each other than 
intervening sequences. The DNA loops are formed with intervention of TFs and other intermediate 
cofactors. For example, during transcription initiation, the Mediator complex recruits cohesin, which 
stabilises DNA loops between enhancers and promoters (Kagey et al. 2010). Additionally, CTCF has 
also been reported to stabilise DNA loops (S. S. P. Rao et al. 2014).  
 
TFs intervene in the establishment of long-range interactions between promoters and enhancer 
regions. The mechanisms by which TFs regulate such interactions have been object of various studies 
as reviewed in (Spitz and Furlong 2012). Although, these interaction mechanisms are still unclear, 
particularly as the recruitment of TFs themselves might be regulated by other cofactors (Janine M 
Lamonica et al. 2011). In this thesis, I focus on the regulatory mechanisms of BRD3 during 
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megakaryopoiesis. BRD3 is recruited by acetylated GATA-1 to chromatin during erythropoiesis 
(Janine M Lamonica et al. 2011). GATA-1 is also an important TF in megakaryopoiesis, as described 
in section 1.2.4.1.1. However, the role of BRD3 in megakaryopoiesis has never been studied.  
1.5.2.1. Histone lysine acetylation (Kac), a mark of active chromatin  
Lysine acetylation (ɛ-N-acetylation or Kac) is a reversible protein post-translational modification 
(PTM) that consists on the addition of an acetyl group to the side-chain nitrogen of lysine. Histone 
acetylation has been one of the most studied histone modifications due to its impact on chromatin 
conformation (Verdin and Ott 2015a). Lysine acetylation neutralises residue charge, reducing 
electrostatic attraction between histones and the negatively charged DNA. The change in chromatin 
configuration provides accessibility for transcriptional machinery with downstream impact on gene 
transcription (Clayton, Hazzalin, and Mahadevan 2006). This conformational plasticity is the 
consequence of enzyme-mediated reactions, controlled by chromatin modifier enzymes.  
 
Chromatin modifiers act in a spatial and temporal manner to deposit (“writers”) or remove 
(“erasers”) histone modifications. These enzymes are classified into categories, depending  on the 
PTM regulated. Histone acetyltransferases (HATs) acetylate residues on histone tails, and histone 
deacetylases (HDACs) remove the acetyl group (K. K. Lee and Workman 2007; Haberland, 
Montgomery, and Olson 2009). In addition to “writers” and “erasers”, there are proteins responsible 
for interpreting the signalling marks on histones, called “readers” (figure 1.5.1). These highly 
specialised enzymes play important roles in regulation of the transcriptional machinery, and often 
target a particular amino acid residue. Bromodomains, the family which BRD3 belongs to, are 
chromatin “readers” specialised in recognising lysine acetylation in chromatin and TFs  (Zhou et al. 
1999; Zeng and Zhou 2002). Several of these acetylation regulatory enzymes have been characterised 
as being critical in normal haematopoiesis as reviewed in  (Glozak and Seto 2007). The abnormal 
function of such proteins is often causative of malignant states which makes them amenable to be 
targeted by small molecule drugs.  
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Figure 1.5.1 Enzymatic regulation of histone acetylation. Histone tails become acetylated upon 
addition of acetyl group to the histone tail by “writer” enzymes (HATs). Acetylation changes 
chromatin into a transcriptionally active conformation (euchromatin).  “Reader” enzymes, such as 
bromodomain proteins, interpret acetylation and trigger recruitment of transcription factors and 
cofactors. “Eraser” enzymes (HDACs) are responsible to return the chromatin to its inactive state 
(heterochromatin). Adapted from (Verdin and Ott 2015b). 
 
Lysine acetylation is found widely spread across the entire proteome, highlighting its central role in 
signalling networks and transcription activation (Kori et al. 2017). As the structure of acetylated 
chromatin is altered to a more relaxed state (euchromatin), it becomes transcriptionally active and 
accessible to RNA polymerases and transcription factors (Marushige 1976; Hebbes, Thorne, and 
Crane-Robinson 1988). Functional interaction between the transcription factors, harbouring acetyl-
binding domains, and acetylated histone residues leads to transcription activation (Shogren-Knaak 
et al. 2006). Therefore, The effect of acetylation on transcription can happen in two ways: by altering 
the interactions between histone and DNA resulting in a modified chromatin structure; or by 
recruiting other proteins relevant to transcription (Josling et al. 2012).  
 
The influence of Kac on transcription is broader than chromatin structure effects.  Choudhary C. et al. 
were the first to show, by high-resolution mass-spectrometry, that lysine acetylation is associated 
with regulation of chromatin remodelling, cell cycle, splicing or nuclear transport (Choudhary et al. 
2009). DNA-protein binding interactions are also affected by lysine acetylation levels. For example, 
the highly conserved lysine-rich motifs within the zinc finger domain of GATA1 become acetylated, 
triggering cell differentiation (J. M. Lamonica, Vakoc, and Blobel 2006; Boyes et al. 1998). Protein-
protein interactions can also be mediated by acetylation. Erythroid Krüppel-like factor (EKLF), an 
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erythroid-specific transcription factor, has been shown to require Kac for interactions with other 
transcriptional regulatory proteins (X. Chen and Bieker 2004).  Other functions such as DNA repair 
(Celic et al. 2006), chromatin compaction (Shogren-Knaak et al. 2006) and protein stability have been 
associated with acetylation. 
 
Histone acetylation marks, or combinations of marks, have been associated with particular 
epigenetic states. Acetylation marks at H3k9, H3k14 and H3k27 have been found to accumulate at 
transcription starting sites of active genes  (Z. Wang et al. 2008). Enhancer chromatin signatures are 
often characterised by high levels of H3k4me1 and low levels of H3k4me3 (Heintzman et al. 2007b). 
Additionally, acetylation marks allow the distinction of enhancers in inactive and active states 
(Creyghton et al. 2010).  
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1.6 The aims of my project 
 
 
BRD3 was identified in a GWAS as one of the genes regulating platelet traits. However, the 
mechanisms by which BRD3 regulates platelet formation have remained unknown. As platelet in vitro 
models generate a low platelet yield, this project explores the role of BRD3 in megakaryocytes 
(platelet progenitors) differentiation. Therefore, the overarching goal of this project was to explore 
the role of BRD3 during megakaryopoiesis. As the project progressed, my work was divided in 4 main 
aims:   
1) The first aim of this project was to generate and validate a model system to study BRD3 during 
MK differentiation. To achieve this goal, I generated an iPSC model, using CRISPR/Cas9 technology. 
The model validation was achieved by characterisation of iPSC BRD3 KO cells and investigation of the 
BRD3 KO capability to produce in vitro MKs. 
2) The second aim of this project was to explore the role of BRD3 on regulatory elements during 
megakaryopoiesis. BET proteins occupy transcription regulatory elements in a cell -specific manner, 
and active regulation can be characterised by characteristic chromatin signatures. Active regions 
present a euchromatin (accessible) conformation and are highly acetylated. Therefore, I investigated 
how active chromatin signatures change in the absence of BRD3, and the consequences of those 
changes on gene transcription.  
3) The third aim of this project was to investigate the effects of ablating BET protein complexes 
during megakaryopoiesis. BET proteins BRD2, BRD3 and BRD4 associate in transcriptional complexes 
involved in regulation of peripheral blood cells (Dawson et al. 2011). Such complexes can be targeted 
with BET inhibitors which indiscriminately target BRD2, BRD3 and BRD4. Therefore,  I used BET 
inhibition at different stages of MK differentiation to investigate whether BET proteins (individually 
or in the complex) have an important regulatory role in Megakaryopoiesis. By comparing of BET 
inhibition and BRD3 KO results, I aimed at uncovering the differences in BET protein requirements 
during megakaryopoiesis. 
4) The last aim of my project was to understand individual requirements of BET proteins, namely 
BRD2 and BRD4, during megakaryopoiesis. These 2 proteins have been shown to play active roles in 
cell cycle development and blood cell differentiation, such as erythropoiesis. I designed iPSC BET KO 
models to study individual BRD2 and BRD4 protein requirements on MK differentiation. 
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Chapter 2 
Material and Methods 
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2.1. Cell culture 
2.1.1. iPSC 
Unless otherwise stated, all iPSC manipulation protocols were performed following Professor 
Vallier’s protocols (Vallier and Pedersen 2008). 
A1ATD1-c was derived from skin fibroblasts with the monocistronic iPS reprogramming kit (Vectalys), 
consisting of four retroviral vectors encoding: OCT4, SOX2, KLF4, v-MYC. This line was derived from a 
patient with an alpha1 anti-trypsin gene mutant, which has been corrected to match a reference 
genotype (Yusa et al. 2011).  
The iPSC line S4-SF5 was derived from human fibroblastic cells by Sendai virus infection (CytoTune, 
LifeTechnologies) with the Yamanaka’s factor (OCT4, SOX2, KLF4, MYC). The derivation was completed 
in Professor Vallier’s laboratory on mouse embryonic fibroblasts (MEF) cells and adapted to feeder-
free conditions from passage 20 (Rouhani et al. 2014). 
2.1.1.1. AE6++ medium (for iPSC culture)  
500ml Dulbecco’s modified eagle’s medium (DMEM)/F12 (cat. 11330-032, Thermo Fisher Scientific) 
3.6ml 7.5% sodium bicarbonate (cat. 25080094, Thermo Fisher Scientific) 
5ml L-ascorbic acid 2-phosphate, final concentration 320 ug/ml (cat. A8960, Sigma-Aldrich, Gillingham, 
UK) 
10ml 50x insulin transferrin selenium (cat. 41400045, Thermo Fisher Scientific) 
5μg/ml recombinant FGF2 (cat. 233-FB, R&D systems) 
10μg/ml recombinant activin A (cat. 338-AC, R&D systems) 
2.1.1.2. Cell maintenance 
iPSC were grown in cell culturing plates (various sizes, from Corning) pre -coated with  10μl/ml 
vitronectin VTN-N (cat. A14700, Thermo Fisher Scientific) in D-PBS (cat. D8537, Sigma-Aldrich). The 
VTN-N coating facilitated cell adhesion as cells were cultured in a feeder-free format. AE6++ media was 
pre-incubated at 37⁰C. Feeding was carried out 6 times a week. Antibiotics were not used. Aseptic 
technique was performed and plates were only opened inside a sterile laminar flow cabinet in a 
dedicated stem cell facility. Cells were incubated between manipulations at 37⁰C, 5% CO2 (controlled 
temperature and pH). 
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2.1.1.3. Passage (culture propagation) 
Cells required passage approximately every 5 days, usually when cells reached 80% confluence. 
Adherent cells were washed once with 2ml D-PBS. Standard passage for cell maintenance involved 
incubating cells in 1ml of 50μM ethylene-diamine-tetra-acetic acid (EDTA, CIMRCK) in D-PBS-/- 
(without Mg2+/Ca2+) (PBS-EDTA) for 2 minutes (or until cells dissociation was observed under the 
microscope). EDTA was aspirated and 1ml D-PBS-/- was added to the well to gently wash the cells 
monolayer. Care was taken to avoid dislodging the cells. Wells were replenished with 1 ml of AE6++ 
media and gently pipetted over the cells to lift small cell clumps into suspension. The cell suspension 
was split into VTN-N pre-coated plates. Splitting rations varied between 1:5 and 1:20 depending on 
the starting cell density and the requirements of upcoming experiments.  
2.1.1.4. Passage (single cells for experiment set up) 
For experiments initiation, cells were seeded as single cells using TrypLE (cat. 12563029, Thermo Fisher 
Scientific) for dissociation.  IPSC culture media was removed and cells were washed with 1ml D-PBS. 
1ml room temperature TrypLE was added and plates incubated at 37⁰C until cells were completely 
dissociated (as observed under the microscope). TryplE was aspirated and cells were collecte d in 10ml 
AE6++ media supplemented with 10uM of Y-27632 to aid cell survival. Cell suspension was centrifuged 
(200g, 3 minutes) and pellet was ressuspended in 1ml AE6++ media containing 10µM ROCK inhibitor 
(Y-27632) and seeded at the required density in vitronectin-coated tissue culture plates. 
2.1.2. HEK293T (ATCC CRL-11268) 
HEK293T manipulation was performed following ATCC recommendations. 
 2.1.2.1. Media recipe  
500ml DMEM - high glucose (cat. D6429, Sigma-Aldrich) 
55ml heat-inactivated fetal bovine serum (cat. F9665, Sigma-Aldrich) 
5.5ml 10,000U/ml penicillin-streptomycin (cat. 15140-122, Thermo Fisher Scientific) 
5.5ml minimal essential medium non-essential amino acids (cat. 11140-035, Thermo Fisher Scientific) 
0.6ml 8mg/ml tylosin solution (cat. T3397, Sigma-Aldrich) 
2.1.2.2. Cell maintenance 
Cells were maintained in uncoated 10cm2 tissue culture plates in 10ml HEK293T complete media. 
Media was warmed to 37⁰C prior to contact with cells and was changed two times per week. Cells 
were incubated between manipulations at 37⁰C, 5% CO2. 
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2.1.2.3. Cell passage 
At >50% confluent, cells were gently washed with D-PBS to remove serum (present in the media) 
before incubation with 2ml trypsin for 3-5 minutes at 37⁰C, until cells were dissociated. HEK293T 
complete media was added to the dish to neutralise the trypsin and collect the cells. Cells were 
homogenised, counted with a haemocytometer and reseeded in uncoated dishes at the required 
density. Maintenance of HEK293T was performed following the method described on ATCC website. 
2.1.3. Thawing cells 
To initiate a culture from frozen stock, frozen vials were thawed in a water bath at 37⁰C until a small 
piece of ice remained. Vials were sprayed with 70% ethanol, and contents transferred to a 15ml falcon. 
Complete media (10ml) was added drop wise, and the cell suspension was centrifuged (200g, 3 
minutes). The pellet was ressuspended gently in 1ml of complete media containing 10μM final 
concentration of Y-27632 (ROCK inhibitor, cat. Y0503, Sigma-Aldrich) and seeded in a 6 well plate. The 
contents of each well were replenished with 1.5ml of complete media. 24 hours later the medium was 
replaced with complete media without Y-27632. 
2.1.4. Cryopreservation 
Cells were dislodged using EDTA (50μM) in PBS (without Mg2+/Ca2+), and ressuspended in freezing 
media consisting of 0.1ml DMSO (cat. D8418, Sigma-Aldrich) and 0.9ml knockout serum replacement 
medium (cat. 10828028, Thermo Fisher Scientific). The cell mix was transferred to a cryovial and placed 
in a Mr Frosty freezing container containing isopropyl alcohol (cat. I9516, Sigma-Aldrich). This was 
placed in a -80⁰C freezer for 24hr before transferring into a -150⁰C freezer for longer term storage. 
These steps were undertaken quickly because DMSO is toxic to cells at room temperature.  
2.1.5. Forward programming (FoP) to generate iMK 
Moreau et al. published the protocol used in my experiments (Moreau et al. 2016). Alterations have 
been made by Dr Cedric Ghevaert’s lab to the published protocol to improve yield, chiefly the single 
cell seeding of iPSC, culture in standard tissue culture flasks rather than an Aggrewell dish, and the 
removal of Ly-294002 (PI3 kinase inhibitor) from the protocol. The protocol used in this study is as 
follows.  
2.1.5.1. Reagents 
1X TrypLE Select (cat. 12563029, Thermo Fisher Scientific) 
AE6++ media (cat A1517001, Thermo Fisher Scientific) 
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Vitronectin VTN-N (cat. A14700, Thermo Fisher Scientific) 
Nunc 6- and 12-well uncoated tissue culture plates (Thermo Fisher Scientific) 
Recombinant FGF2 (cat. 233-FB, R&D Systems)  
BMP4 (cat. 314-BP-010, R&D Systems)  
Rock inhibitor Y-27632 (cat. Y0503, Sigma-Aldrich) 
rhTPO (cat. 01417-050, CellGenix) 
rhSCF (cat. PHC2116, Thermo Fisher Scientific)  
Protamine Sulphate (cat. P4505, Sigma-Aldrich) 
D-PBS (cat. D8537, Sigma-Aldrich)  
TrypLE (cat. 12563029, Thermo Fisher Scientific)  
CellGro-SCGM (cat. 0020802-0500, CellGenix,)  
Viral Vectors (Vectalys), see figures 2.1, 2.2 and 2.3 for vector maps. 
pTRIPU3-TAL1 (batch pV.2.3.107_p16_01_1, titre 5.5x109TU/ml) 
pWPT-hFLI1 (batch pV.2.3.993_p15_11_2, titre 1.5x109TU/ml) 
pWPT-hGATA (batch pV.2.3.1073_p15_10_1, titre 2.6x109TU/ml) 
PBE flow buffer (D-PBS, 0.5% BSA and 2% PFA 
2.1.5.2. MK Forward Programming (FoP) protocol 
(Day -1) ~1x105 cells are collected using PBS+EDTA method and reseeded as small clumps onto a 
vitronectin coated well of a 12-well plate, in AE6++ media, and allowed to reattach for 24 hours. Single 
cells can also be seeded, following the same protocol as described above for iPSCs. All subsequent 
steps of this protocol must be performed in a CL2 viral laboratory.  
 (Day 0) Cells are transduced with the appropriate volume of recombinant lentivirus to get the desired 
multiplicity of infection (MOI). Conventional forward programming requires GATA1, TAL1 and FLI1 
lentiviruses, thawed on ice, all used at an MOI 20. All lentiviruses used were produced commercially 
(Vectalys). Lentivirus mix is added to 0.5ml mesoderm-inducing medium: AE6 + FGF2 20ng/ml + BMP4 
10ng/ml (R&D) + Protamine sulphate 10μg/ml. For transduction of multiple wells a master mix was 
prepared.  Cells and transduction mix are left to incubate for 24 hours.  
 (Day 1) Cells are washed 1x PBS before 0.5ml fresh mesoderm-inducing media (without protamine 
sulphate) was added and incubated for 24 hours. 
 (Day 2) Medium was changed to 0.5ml MK-1 media: CellGro SCGM (CellGenix) + Human TPO 20ng/ml 
(CellGenix) + Human SCF 25ng/ml (Life Technologies), for MK differentiation. Cells were left for 48 
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hours before fresh medium was added. The first medium addition required 0.5ml MK media with 2x 
concentration of cytokines (MK-2 media). Subsequent medium changes (50% exchange)  involved 
careful removal of half the medium by tilting the plate and collecting only medium, not cells, before 
adding half the volume fresh medium (2x cytokines).  
(Day 9/10) The supernatant of each well was collected into a 15ml falcon tube and the well rinsed 1x 
PBS (0.5ml), before being pooled with the supernatant. To collect the adherent cell fraction 300μl 
TrypLE was added to wells and incubated for 10 mins at 37oC, 5% CO2. The TrypLE-cell mix was added 
to the corresponding falcon tube and quenched with 10 ml PBS before being centrifuged 300g, 5min, 
room temperature. Cell pellet was then re-suspended in 0.2ml MK-2 media (TPO 20ng/ml, SCF 
25ng/ml). A small aliquot of cells were used for flow cytometry analysis to monitor MEP and MK 
markers. Remaining cells were re-plated onto 6 well plates in a total of 2ml MK-2 media. At this stage 
it is safe to remove cells from the CL2 viral laboratory to be subsequently handled in a standard CL2 
TC laboratory. Medium was refreshed every 48-72 hours, (50% exchange).  
(Day 20/21) Cells were collected and stained again to monitor MK maturation by flow cytometry. Cells 
can be re-plated and maintained long-term by refreshing the MK-2 media every 3 days (50% exchange) 
and checking MK purity every 7-10 days. Cell density can be adjusted once an accurate cell count has 
been obtained. Optimal cell density is 2E+5-1.5E+06 cells/ml. Cells can be split 1:5 when cell density 
exceeds 1.5E+06 cells/ml. Forward programmed MKs (FoP-MKs) can be frozen in IMDM 20% FBS 5% 
DMSO ideally at 0.5-1E+6 cells per vial. Upon thawing, these cells can be placed back in MK-2 media 
(TPO 20ng/ml, SCF 25ng/ml), refreshing every 2-3 days. In my experiments, I have stopped cultures at 
day 20, once MK markers were expressed. 
2.2. Molecular techniques 
2.2.1. DNA visualisation 
Snapgene software was used to visualise DNA manipulation including primer positions, cloning, Sanger 
sequencing alignments, restriction digestion and CRISPR Cas9 gene editing strategies. Sequences were 
obtained from Ensembl or manufacturers of plasmids and oligonucleotides.  
2.2.2. Genomic DNA extraction 
All molecular protocols described were followed according to (Sambrook et al, 2011). 
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Genomic DNA (gDNA) extraction from cell cultures was performed using the Wizard Genomic DNA 
Purification Kit (cat. A1125, Promega) following the manufacturer’s instructions.  
2.2.3. Genotyping 
All PCR were performed using the high-fidelity Phusion polymerase (NEB M0530) following the 
manufacturer’s instructions on a GeneAmp PCR System 9700 thermal cycler. Primers used for BRD2, 
BRD3 and BRD4 PCR (i.e. for confirmation of mutations in KO clones and Sanger sequencing) are listed 
in table 2.2.1. Primers were purchased as lyophilised desalted oligonucleotides (Sigma-Aldrich) and 
ressuspended to 10uM in water. PCR was carried out at standard conditions (98 0C-30 sec, 30 cycles 
of (98 0C-10 sec, 65-70 0C-30 sec, 72 0C-30 sec), 72 0C-5 min, 4 0C-∞). 
1% Agarose gels were used for visualisation of PCR products. 1g of agarose gel was dissolved by heating 
in 100ml 1x TBE buffer. When cool, 0.1μl/ml of SYBR Safe DNA gel stain (cat. SS3102, Thermo Fisher 
Scientific) was added. PCR products were mixed at 1:6 ratio with 6X Orange loading dye (cat. R0631, 
Thermo Fisher Scientific). Samples were run alongside a 1kb Generuler DNA ladder (cat. SM0311, 
Thermo Fisher Scientific). Gels were run at 90mV for 30-60 minutes and DNA was imaged with a 
Syngene Chemi Genius. Following successful PCR confirmation on gel electrophoresis,  DNA was 
purified using the Qiaquick PCR purification kit (cat. 28104, Qiagen) and quantified by 
spectrophotometry using the Labtech Nanodrop Spectrophotometer at 260nm. Products were either 
used for Sanger sequencing at Source Bioscience, Cambridge, UK or cloning purposes.   
Locus targeted Exon targeted Primer  sequence 
BRD2 Exon 4 BRD2KO.PCR8.FWR TGTGTGAGAGTCGGGGATCG 
Exon 4 BRD2KO.PCR8.REV CAGGCCCTAGGCCATTACCA 
Exon 4 BRD2KO.PCR9.FWR GCAGGGGCCTCCCTGTGGAT 
Exon 4 BRD2KO.PCR9.REV TGGCCCCCTTCTTGTGGCTGT 
BRD3 Exon 2 BRD3.E2.FWR CAGTGGTTGGAGAGTCGTTC 
Exon 2 BRD3.E2.REV CCAGTGAGGCAGAAGAAGG 
BRD4 Exon 2 BRD4 E2 Fwd1 ACTCTGCCTCCTCTGTTGGTTTGT 
Exon 2 BRD4 E2 REV AGATCTGTGGGCCTTCCTTTCTCC 
Table 2.2.1 Successful PCR primers for BRD2, BRD3 and BRD4 genotyping of KO clones.  
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2.2.4. Restriction endonuclease digestion  
Restriction digestion was performed following protocols recommended on the NEB online tool. All 
enzymes were purchased from NEB and used in optimal buffer supplied. Restriction digests were 
routinely set up on ice and performed at 37oC for 1 hour. 1% TBE gels were used to analyse DNA 
fragments SYBR safe DNA gel stain (Invitrogen) was added to visualise DNA or for DNA extraction. 6x 
Orange G loading buffer (Sigma) was added to DNA samples before loading into a gel.  
2.2.5. Gel purification of DNA from agarose gels 
Gel purification was done following the manufacturer instructions for the QIAquick gel extraction kit 
(Qiagen). Dephosphorylation of restriction digested products was performed with either Antarctic 
phosphatase (NEB), as per manufacturer instructions.  PCR products intended for cloning were purified 
using the QIAquick PCR purification kit (Qiagen), following manufacturer instructions. Ligations were 
performed with T4 DNA ligase (NEB).  
2.2.6. Transformation of high-efficiency competent E.coli 
Competent E.coli cells (NEB) were thawed on ice for 10min before aliquoting 10µl into transformation 
tubes on ice. 1-5µl containing 1pg-100pg were added to the cell mixture and the tube gently flicked 
twice. Transformation mixture was placed on ice for 30min to stabilise bacterial membrane and 
increase the interaction between the calcium cation (in the buffer) and negatively charged DNA. Heat  
shock, at 42°C for 30sec, was performed to allow incorporation of the exogenous DNA into the cells 
(as heat shock changes the fluidity of the membrane). Following heat shock, the tubes were 
immediately placed on ice for 5minutes to return membrane stabili ty to its steady state and reduce 
DNA transport. 950µl of SOC media (NEB) were added to the cell mixture and tubes incubated at 37°
C for 60min with vigorously shaking (250rpm). Selection agar plates were warmed to 37°C in the 
bacteria incubator. The cell mixture was centrifuged and 13,000rpm for 2min and 500µl of supernatant 
removed. Pellet was ressuspended in the remaining supernatant (SOC medium) and spread onto 
selection plates. Plates were incubated at 370 C overnight. 
2.2.7. Expansion and purification of plasmids 
Vectors for expansion were transformed into NEB 5α competent E.coli (cat. C2987, NEB). Plates were 
incubated overnight and clones expanded in LB media containing appropriate selection (depending on 
vector used). The Qiaprep miniprep kit (cat. 27104, Qiagen) was used to purify plasmids from <5ml 
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bacterial cultures. The Promega Pureyield Maxiprep (cat. A2393, Promega) was used to purify plasmids 
from larger bacterial cultures. All plasmids were eluted in nuclease-free water.  
2.2.8. Flow cytometry  
Single cell suspensions were obtained either by collecting supernatant of suspension cultures or by 
enzymatically treating (TryplE) monolayer cultures. Pellets were ressuspended in blocking buffer 
containing 2% BSA in PBS and incubated for 20min at 4°C. The staining was carried out at 4°C in the 
dark with a mastermix of antibodies diluted in PBS at recommended concentrations (see table 2.2.2). 
The reaction was washed and collected with PBE flow buffer and fixed with 0.2% formyl saline. An 
unstained mix was used to visualise cells and set gates. Single stained mixes were used to perform 
compensation. Flow cytometry was performed on the Beckman Coulter Gallios Cytometer and 
analysed using Kaluza Analysis v.1.5a (Beckman Coulter).  This protocol was obtained from (Moreau et 
al. 2016). 
 
Table 2.2.2. Flow cytometry antibodies used for characterisation of FoP dif ferentiating cells and 
pluripotency. 
2.2.9. Cell sorting 
Cells were dissociated using TrypLE and either stained with antibodies (for MK sorting based on surface 
markers), or unstained (if transfected with plasmids containing a fluorescent marker) . Cells were 
sorted on the BD FACSDiva 8.0.1 by the NIHR Cambridge BRC Cell Phenotyping Hub. Viable single cells 
were either collected bulk (MKs for processing) or plated in single wells of a 96 well plate with ROCK 
inhibitor for 24 hours (for KO generation experiments).  
Antibody Fluorochrome Assay 
concentration 
Catalogue 
Number 
Manufacturer 
CD41a APC 1:10 dilution  559777 BD Biosciences 
CD41a FITC 1:10 dilution 555469 BD Biosciences 
CD42b PE 1:10 dilution 555473 BD Biosciences 
CD235a FITC 1:1000 dilution  559943 BD Biosciences 
CD34 APC 1:10 dilution 345804 BD Biosciences 
CD43 PE 1:10 dilution 553271 BD Biosciences 
Tra-1-60 PE 1:100 dilution 12-8863-80 Thermo Fisher 
SSEA4 Alexa fluor 488 1:100 dilution 53-8843-41 Thermo Fisher 
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2.2.10. CRISPR/Cas9  
2.2.10.1. Single guide RNA (sgRNA) design 
CRISPR experiments were performed following (F. Ran et al. 2013) 
sgRNA sequences were designed using Wellcome Trust Sanger Institute CRIPSR tool. This tool helps 
identify guide sequences that minimize identical genomic matches to reduce the risk of cleavage away 
from target sites (off-target effects). The sgRNAs consist of a 20 nucleotide sequence (protospacer) 
upstream of an NGG sequence (protospacer adjacent motif or PAM) at the genomic recognition  site. 
The PAM sequences were not included in the sgRNAs. The identified sgRNAs were aligned to the 
human genome on BLAST (Basic Local Alignment Search Tool) and the sequences with lower possible 
off-target effects were selected. Reverse complement for each guide was calculated and BbsI 
overhangs designed to allow ligation into the BbsI restriction sites into Cas9 plasmids.  The sgRNAs 
were purchased as lyophilised desalted oligonucleotides (Sigma-Aldrich) and cloned according to 
previously described protocol (F. A. Ran, Hsu, Wright, et al. 2013). The strategy to create deletions in 
the required locus relied on the delivery of two sgRNAs (one on each strand) and a Cas9nickase to 
create one nick at each targeted site. This method minimises off-target effects as it uses 2 sgRNAs on 
the target site. The vectors used were pSpCas9n(BB)-2A-PURO (PX462), pSpCas9n(BB)-2A-GFP(PX461 
from Addgene) and pSpCas9n(BB)-2A-tomato (modified by Dr Annette Muller).Vector maps are shown 
in appendix section 6.1.1 and sgRNA sequences in table 2.2.3.  
Locus targeted sgRNA sequence 
BRD2 sgRNA.BRD2.KO.10 caccgTTAATAGTACCCATGTCCAT 
sgRNA.BRD2.KO.10.comp aaacATGGACATGGGTACTATTAAc 
sgRNA.BRD2.KO.11 caccgACTTGAAAACAATTATTATT 
sgRNA.BRD2.KO.11.comp aaacAATAATAATTGTTTTCAAGTc 
sgRNA.BRD2.KO.12 caccgAATGTAACAGTTGGTGAACA 
sgRNA.BRD2.KO.12.comp aaacTGTTCACCAACTGTTACATTc 
sgRNA.BRD2.KO.13 caccgCAACTGTTACATTTACAACA 
sgRNA.BRD2.KO.13.comp aaacTGTTGTAAATGTAACAGTTGc 
BRD3 sgRNA.BRD3.KO.2 caccgAGTCGCCCCCGCGGGG 
sgRNA.BRD3.KO.2.comp aaacCCCCGCGGGGGCGACTc 
sgRNA.BRD3.KO.3 caccgTGTGAACCCACCCCCCCCGG 
sgRNA.BRD3.KO.3.comp aaacCCGGGGGGGGTGGGTTCACAc 
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sgRNA.BRD3.KO.8 caccgCCCCGCGGGGGCGACTGTCG 
sgRNA.BRD3.KO.8.comp aaacCGACAGTCGCCCCCGCGGGGc 
BRD4 sgRNA.BRD4.KO.1 caccgGATTTCTCAATCTCGTCCCA 
sgRNA.BRD4.KO.1.comp aaacTGGGACGAGATTGAGAAATCc 
sgRNA.BRD4.KO.2 caccgTTCCCAAATGTCTACAACAC 
sgRNA.BRD4.KO.2.comp aaacGTGTTGTAGACATTTGGGAAc 
sgRNA.BRD4.KO.8 caccgTGCCCCTTCTTTTTTGACTT 
sgRNA.BRD4.KO.8.comp aaacAAGTCAAAAAAGAAGGGGCAc 
sgRNA.BRD4.KO.9 caccgCCCCGGGAGGGAGCAGAAGA 
sgRNA.BRD4.KO.9.comp aaacTCTTCTGCTCCCTCCCGGGGc 
sgRNA.BRD4.KO.10 caccgGGGGGCGAGGACTTCATCGC 
sgRNA.BRD4.KO.10.comp aaacGCGATGAAGTCCTCGCCCCCc 
sgRNA.BRD4.KO.11 caccgACCCTTCATTGCCACCCAGG 
sgRNA.BRD4.KO.11.comp aaacCCTGGGTGGCAATGAAGGGTc 
sgRNA.BRD4.KO.12 caccgCACTACCCCAGCAGCCATCA 
sgRNA.BRD4.KO.12.comp aaacTGATGGCTGCTGGGGTAGTGc 
sgRNA.BRD4.KO.13 caccgCAGGGCAGCGGCTCGGTTGC 
sgRNA.BRD4.KO.13.comp aaacGCAACCGAGCCGCTGCCCTGc 
Table 2.2.3 sgRNA oligos used for generation of BET KOs. SgRNAs (capital letters) were designed with 
overhangs (small letters) compatible with plasmid overhangs resulting from digestion with BbsI 
enzyme. 
2.2.10.2. Plasmid preparation containing sgRNAs and Cas9 
A published protocol for CRISPR/Cas9 genome editing was followed (F. A. Ran, Hsu, Wright, et al. 
2013). In brief, sgRNAs were phosphorylated, annealed, diluted at 1:200 and ligated into the 
corresponding linearised plasmid (appendix 6.1.1). Plasmids were transformed into E.coli and 
expanded, as previously described (section 2.2.6). No inserts and no plasmid controls were used, as 
well as a PUC19 control. Expansion was carried out in LB medium and maxi preps performed using 
Pure Yield Promega system (#A2392). Insertion of sgRNAs was carried out by restriction digestion (see 
plasmid maps in appendix 6.1 for details on restriction enzymes used), followed by Sanger sequencing 
with U6 forward primer GGGCAGGAAGAGGGCCTAT. 
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2.2.10.3. Cloning into pGEM-T Easy 
Cloning was required to identify all the alleles in each clone. This allows the identification of 
heterozygous and homozygous indels through Sanger sequencing. Cloning was performed into the 
pGEM-T Easy Vector System II (cat. A1380, Promega) following the manufacturer’s instructions.  
In brief, PCR amplicons were purified as described above, and A-tailed using the Phusion polymerase 
kit and dATP (cat. N8080241 and R0141 respectively, Thermo Fisher Scientific) to allow ligation. The 
amplicons were purified again and ligated into PGEMT-Easy (3:1 and 5:1 molar ratio) in ligation buffer 
according to the instructions manual. The plasmids were transformed into E.coli competent cells and 
plated on Fast-Media Amp XGal agar plates (cat. fas-am-x, Invivogen). Successful ligation of amplicons 
into the pGEM-T Easy vector interrupts the LacZ gene which alters the colour of the resulting E.coli 
colonies from blue to white, allowing selection for sequencing. Between five and ten colonies were 
picked, and plasmids were purified by miniprep and sent for Sanger sequencing using the T7F primer 
TAATACGACTCACTATAGGG.  
2.2.10.4. Nucleofection of hiPSC lines and derivation of antibiotic resistant strains 
In preparation for and up to 7 days prior to nucleofection, plates (6 well format) were coated with 
vitronectin. Proliferating iPSC cultures were pre-treated with ROCK inhibitor Y27632 (10uM) for 24h 
pre-nucleofection. Cultures were dislodged from the wells using 0.5mM EDTA in PBS (without 
Mg2+/Ca2+) to generate small clumps of cells. One million cells per condition were aliquoted into 
Eppendorf tubes and pelleted at 200g for 3min. Human stem cell nucleofection kit (Lonza) was used 
according to manufacturer instructions. Mastermixes, containing 100ul of solution I, I I and 10ug (total) 
of the plasmids, were prepared before ressuspending the cell pellets in the respective conditions. 
Nucleofections were completed using program B-016 on nucleofector 2b device (Lonza). Immediately 
post nucleofection, cells were ressuspended in 500µl of pre-warmed DMEM/F12 culture media 
supplemented with ROCK inhibitor and seeded onto the iMEFs monolayer. At 24hr post nucleofection, 
the wells were replenished with iPSC culture media and, 48hr post transfection, the antibiotic selection 
was started and carried out for 2 days (puromycin at 1ug/ml). Individual surviving clones were 
manually isolated and expanded in iPSC medium. 
2.2.10.5. T7 endonuclease assay 
This assay is designed to detect heteroduplex DNA that result from annealing DNA strands modified 
after CRISPR/Cas9 mediated cut, and this way, estimate success of sgRNA targeting. HEK293T cells 
were transfected with sgRNAs and Cas9 and cultured for 2 days before performing gDNA extraction. A 
PCR was performed with primers designed for the CRISPR/Cas9 targeted region. This step was followed 
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by a hybridisation step where 200ng of PCR products were diluted to 17 μl of water and 2 μl of NEB 
buffer2 and incubated at the following conditions (95 0C-5 min, 95-85°C at -2°C/s for 1 min, 85-25°C at 
-0.1°C/s for 1 min, 4°C ∞). This step was followed by a digestion with T7 endonuclease, where 10 μl  
of the previous reaction was digested with 0.5 μl  of T7 endonuclease (NEB M0302) for 15 min at 37 
0C. Mismatched nucleotides were digested in that reaction and resulting products were visualised in a 
1% agarose gel. 
2.2.11. Lentiviral infection 
HEK293T cells were used to produce lentivirus stocks. The cultures were seeded in 10cm dishes at 
4x106cells per plate. The infection packaging system, formed by 2 plasmids, was combined with 20µg 
of the vector of interest and 5.6µg of PEI in DMEM basal media and incubated at room temperature 
for 20min before being added to the HEK293T culture media. 24hr post infection, the media was 
removed and plates replenished with DMEM supplemented with 10% foetal bovine serum (FBS). That 
media was harvested 24hr later and filtered through a 45µm syringe filter before adding polybrene 
(8µg/ml). The filtered mixture containing virus was used to infect proliferating hiPSC and this in fection 
step was repeated later on the same day. Infected hiPSC were fed with DMEM/F12 supplemented with 
LAA (300ug/ml), FGF2 (5ug/ml) and Activin-A (10ug/ml) for 2 days before starting antibiotic selection. 
2.2.12. Romanowsky staining 
25x105 FoP-MKs were plated on a cytospin cassettes using a Shandon Cytospin 4 machine and stained 
with a Rapid Romanowsky stain (BioRad HS705). The stain process consists in submerging the slides 
into each solution (fixative, azure and eosin) for 40 sec. Slides were dried ove rnight and coverslips 
were applied.  
2.2.13. Western Blotting 
Cell pellets were washed with PBS (without Mg2+/Ca2+) before being snap-frozen and stored at -80˚C. 
Pellets were lysed in NP-40 lysis buffer and supernatant collected by centrifugation at 13,000rpm for 
15min at 4°C. The extracted protein concentration was determined by Bradford assay and whole-cell 
lysates were ran on a precast 4%-12% Bis-Tris polyacrylamide gel and transferred to PVDF membrane. 
Blocking was achieved using  5% milk in TBS-T (200nM Tris (pH 7.6), 1370mM NaCl, 1% Tween 20). 
Antibodies against protein of interest were used. Blots were imaged on the SRX-101A processor. 
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antibody dilution Antibody details 
rabbit anti-human BRD3 1:1000 Bethyl # A302-368A 
Rabbit anti-human BRD2 1:5000 Bethyl #A700-008 
mouse anti-human β-actin 1:10,000 AbCam # Ab6276 
mouse anti-rabbit HRP 1:10,000 AbCam # ab99702 
rabbit anti-mouse HRP 1:10,000 AbCam # ab6728 
Table 2.2.5 Antibodies used in western blots for confirmation of BET KOs. 
2.2.14. Crystal violet staining assay 
Cultures were washed with PBS and wells replenished with 2.5% glutaraldehyde for fixation at room 
temperature for 15 minutes. This method crosslinks all proteins and preserves morphological 
structure. Cell monolayers were washed twice with PBS and stained with 0.5% crystal violet solution 
for 10 minutes. Plates were immersed into a beaker to wash the stain and drained upside down. To 
solubilise the stain, the wells were washed with 1% SDS. Absorbance was read at 450nm.  
2.2.15. ATAC-seq 
The ATAC-seq protocol followed has been obtained from (Buenrostro et al. 2015). 
Open chromatin ATAC-seq libraries were generated from freshly prepared cells using a previously 
published protocol (Buenrostro et al. 2013). The cell samples were spun and washed with cold PBS. 
Lysis was performed with cold lysis buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl2 and 
0.1% IGEPAL CA-630) for 15min. Pellets were spun, before digestion (25 μL 2× TD buffer (20 mM Tris-
HCl, pH 8.00, 10 mM Magnesium Chloride), 2.5 μL transposase and 22.5 μL nuclease-free water) at 
37 0C for 30 min in the water bath. The samples were then purified using Zymo DNA purification kit 
before PCR to amplify and tag the fragments with Illumina-compatible adapters (table 2.2.6). PCR 
reaction (25 μL  of template, 12.5 μL  water, 10 μL  Phusion buffer, 1 μL dNTP, 0.5 μL  primer #1, 0.5 
μL  primer #2, 0.5 μL  Phusion). PCR conditions were as follows:  72 °C for 5 min; 98 °C for 30 s; and 
thermocycling at 98 °C for 10 s, 63 °C for 30 s and 72 °C for 1 min. For iPSC and MKs, 100K cells were 
used with 10 amplification cycles for PCR. Libraries cleaned up with Zymo DNA concentrator kit were 
quantified using a qPCR Library Quantification Kit (Kapa Biosystems), pooled and sequenced with a 
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50bp single-end protocol on an Illumina Hiseq 2500 (Cancer Research UK Cambridge Institute, 
Cambridge, UK).  
ID Adaptor Sequence  ID Adaptor Sequence 
Ad1 n/a  Ad2.13 GTCGTGAT 
Ad2.1 TAAGGCGA  Ad2.14 ACCACTGT 
Ad2.2 CGTACTAG  Ad2.15 TGGATCTG 
Ad2.3 AGGCAGAA  Ad2.16 CCGTTTGT 
Ad2.4 TCCTGAGC  Ad2.17 TGCTGGGT 
Ad2.5 GGACTCCT  Ad2.18 GAGGGGTT 
Ad2.6 TAGGCATG  Ad2.19 AGGTTGGG 
Ad2.7 CTCTCTAC  Ad2.20 GTGTGGTG 
Ad2.8 CAGAGAGG  Ad2.21 TGGGTTTC 
Ad2.9 GCTACGCT  Ad2.22 TGGTCACA 
Ad2.10 CGAGGCTG  Ad2.23 TTGACCCT 
Ad2.11 AAGAGGCA  Ad2.24 CCACTCCT 
Table 2.2.6. List of adapters used to tag ATAC-seq samples. Adapter #1 was used in all the samples 
with adapter #2 tagging individual samples. 
2.2.16. ChIP-seq 
ChIP-seq libraries were prepared using the BLUEPRINT consortium protocol.  
Samples for chromatin immunoprecipitation were fixed with 1% w/v formaldehyde for 10 minutes and 
quenched using 125mM Glycine before washing with PBS. Cells were centrifuged and lysed in ChIP 
lysis buffer (50 mM Hepes, pH 7.9, 140 mM NaCl, 1 mM EDTA, pH 8.0, 10% v/v Glycerol, 0.5% v/v NP-
40, 0.25% v/v Triton X-100 and protease inhibitors in water). Lysates were washed with ChIP washing 
buffer (10 mM Tris-HCl, pH 8.0, 200 mM NaCl, 1 mM EDTA, pH 8.0, 0.5 mM EGTA, pH 8.0 in water), 
before resuspending in shearing buffer 0.1% w/v SDS, 1mM EDTA, 10mM Tris-HCl, pH 8.0 and additional 
protease inhibitors in water. Lysates were sonicated using a Bioruptor (Diagenode), final SDS 
concentration of 0.1% w/v for 9 cycles of 30 seconds ‘on’ and 30 seconds ‘off’. Samples were 
immunoprecipitated in the IP-Star (Diagenode), using the following antibody H3K27ac (Diagenode 
C15410196). Chromatin was eluted in elution buffer (10mM Tris-HCl, pH 8, 0.3M NaCl, 5mM EDTA, 
0.5%SDS, and protease inhibitors) and reverse crosslinked (650 C/4hr), treated with RNase and 
proteinase K (650 C/30min). Libraries were prepared using the Diagenode MicroPlex Library 
preparation kit (C05010014), according to manufacturer’s instructions. Library quality was evaluated 
using Bioanalyser and quantified using qPCR library quantification kit (KAPA Biosystems), pooled and 
sequenced with 50bp single-end protocol on Illumina HiSeq 2500.  
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2.2.17. RNA-seq  
RNA-seq libraries were prepared using the BLUEPRINT consortium protocol.  
Cells were cultured as described in previous sections, washed with D-PBS before pelleting by 
centrifugation. Cell pellets ressuspended in 500µl Trizol reagent (cat. 15596026, Thermo Fisher 
Scientific) in a fume hood. Samples were kept at -80⁰C until further processing. RNA was manipulated 
in a fume hood, limiting environmental nuclease contamination with RNAaseZap (cat. AM9780, 
Thermo Fisher Scientific) by either myself or Ms Frances Burden, University of Cambridge. RNA was 
extracted from TRIzol preparations by phase-separation and precipitation. Libraries were synthesized 
from RNA using the KAPA Stranded RNA-Seq Kit with Riboerase (cat. 07962304001, Roche), using 
adapters included in the kit, and Agencourt AMPure XP beads (cat. A63880, Beckman Coulter) for 
purification. Libraries were quantified by RTqPCR using the KAPA Library Quantification Kit (cat. 
07960140001, Roche) and 1:6000 final dilution of sample. Sequencing was performed by the Welcome 
Trust Sanger Institute on the HiSeq2500 using 150bp read length paired-end sequencing.  
 
 
 
 
 
 
 
 
 
Table 2.2.7 Adapters used to prepare RNA-seq libraries. 
2.3. Bioinformatics analysis 
The bioinformatics analysis described in this section were performed by Dr. Denis Seyres, University 
of Cambridge. 
2.3.1 ATAC-seq and ChIP-seq analysis 
Sequence quality control was performed With FastQC from raw fastq files. FastQC runs different  
modules including: 
A001 ATCACG 
A002 CGATGT 
A003 TTAGGC 
A004 TGACCA 
A005 ACAGTG 
A006 GCCAAT 
A007 CAGATC 
A008 ACTTGA 
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- Per base sequence quality, shows an overview of the range of quality values across all bases at each 
position of the FastQ file. 
- Per sequence quality scores, allows to identify subsets of sequences with universally low quality 
values. 
- Per base sequence content, plots the proportion of each base position in a file for which one of the 
4 DNA bases has been called. 
- Per sequence GC content, measures the GC content across the whole length of each sequence, and 
compares with a modelled normal distribution of GC content. 
- Per base N content, plots the percentage of the base calls at each position in which an N has been 
called (sequencer unable to make a base call with sufficient confidence). 
- Sequence length distribution, generates a graphic distribution of fragment sizes in the file.  
- Sequence duplication level, calculates the duplication of each sequence.  
- Over-represented sequences and adapter contents, lists all sequences that make up more than 
0.1% of the total. It also shows a cumulative percentage count of the library proportion with adapter 
sequences at each position. 
Following QC, trimming was processed using Trim Galore to remove Illumina adapters and l ow quality 
bases. After trimming, reads under 36 bp length were discarded. Good quality reads were al igned to 
Human genome (hg38) with Burrows-Wheeler Aligner (recommended for read length shorter than 
70bp) with default parameters. Picard MarkDuplicates was used to remove duplicated reads. 
Duplicated reads, low mapping quality (mapping quality score, q<15) and multi-mapped reads were 
discarded using samtools. Read enriched regions (peaks) were called using MACS2 (Y. Zhang et al. 
2008) for ChIP H3K27ac and FSEQ [http://fureylab.web.unc.edu/software/fseq/] for ATAC samples. 
Input controls were down sized to ChIP library size prior to MACS2 analysis in matched cell types. 
No input control was used for the ATAC peak calling as FSEQ is designed to use read density 
variation in mapped reads to find biologically meaningful sites. A 5% false discovery rate (FDR) cut-
off was selected for filtering low confident peaks with MACS2 and a threshold of 6 was applied for 
FSEQ.  
Visualisation and analysis 
Bias in read distribution across the genome was analysed with deepTools plotFingerPrint tool. This 
tool counts the number of reads in each bin of the genome, rank them from low to high count and 
plot this rank against the cumulative sum of reads. Ideally, sample curves elbow occurs at  high x 
58 
 
values, good coverage is shown by low x intercept value and great enrichment by a large area 
between sample and input curves. Input usually follows the diagonal.   
 
Figure 2.2.1. PlotFingerPrint interpretation for quality analysis of ChIP and ATAC data sets. 
Differential analysis was performed by comparing WT and KO in both cell types. Sequencing 
batches were included as a potential batch effect. We performed differential analysis with two 
approaches: a peak based method and a binned based method. The peak-based approach, DiffBind 
(Stark and Brown 2018), starts to build a master set of peaks by making the union of overlapping 
peaks (at least 1bp) called initially by MACS2 or FSEQ peak caller from all samples. The idea is to 
assign a read uniquely to a peak and avoid confusion when a read overlap two peaks. We then used 
the wrapped method DESeq2 to perform differential analysis.  
We also tested for differential opened regions or differential acetylati on level with bin-based 
approach, csaw R package (Lun and Smyth 2016). We summarized read counts for each windows 
of genome. Reads are assigned to each window based on the 5’ end without any directional 
extension. Binned counts were normalised for trended biases with a Loess normalisation. We 
filtered out low confident region by global enrichment. Csaw computes a threshold based on the 
fold change over the level of non-specific enrichment (a fold change threshold of 3 was used here). 
The degree of background enrichment is estimated by counting reads into large bins across the 
genome (we set 2kb). Binning is necessary here to increase the size of the counts when examining 
low-density background regions. This ensures that precision is maintained when estimating the 
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background abundance. Using EdgeR package, a generalized linear mode (GLM) was fitted to the 
normalized counts for each window using the specified design, dispersions were estimated and p -
values are computed using the quasi-likelihood F-test. Putative differentially opened/acetylated 
bins were then merged to represent regions, a combined p-value was computed and false discovery 
rate was computed using combined p-values. 
2.3.2. Regulatory element detection using patterns of peaks 
Open chromatin peaks are called using fseq (Boyle et al. 2008). Additionally, an open chromatin 
coverage track is generated, which is normalised by dividing by the mean coverage genome -wide, 
and smoothed by binning consecutive segments of 40bp. Peaks are extended upstream and 
downstream symmetrically until their length is at least 3.2kb and overlapping segments are 
subsequently merged. These merged segments are considered separately.  
The covariance between the open chromatin track and the H3K27ac track is computed in an 800bp 
sliding window and subsequently smoothed by replacing each covariance value with the mean of 
the values in the surrounding 800bp. Local minima of the smoothed covariance are obtained as the 
positions for which the value is less than the values in the surrounding 160bp. Any local minima 
with a smoothed covariance less than -1 are recorded. 
For each local minimum, the stretch nearest to it and any other stretches within 100bp of it, for 
which locally normalised open chromatin coverage exceeds the locally normalised H3K27ac 
coverage are recorded and expanded to 400bp, where locally normalised coverage at a position is 
given by the coverage divided by the mean coverage in the surrounding 800bp region. These 
stretches are merged and recorded as the locations of regulatory elements.  
2.3.3. RNA-seq data analysis 
As for ATAC and ChIP-seq experiments, RNA-seq samples were first checked for sequence quality 
with FastQC. Then raw data were trimmed to remove Illumina sequencing adapters. Trimmed reads 
were pseudo-aligned to Ensembl human transcriptome (GRCh38.80) using Kallisto (Bray et al. 2016)  
with 100 rounds bootstrap in order get high accuracy in transcript abundance estimates. 
Transcripts abundance were summarized to gene level with tximport R Package  (Soneson et al. 
2015).  
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Transcript Per Million (TPM) values (log(TPM+1)) were used to assess sample to sample 
correlations. R package pheatmap was use to draw heatmap of correlations. Principal component 
analysis (PCA) analysis was carried out and first two components were plotted.  
Prior to differential analysis, genes with 0 count and no variance were filtered out from analysis. 
Sequencing batch was included into the design analysis to integrate effect of different library 
preparations. DESeq2 R package (Love et al. 2014) was then used to perform differential analysis. 
Both Wald and LRT tests were carried out, a FDR threshold of 5% was applied and the intersection 
of differentially expressed genes (DEG) identified by each test was retained as list of DEG for each 
comparison. Lists were split according to fold change directions and EnrichR web-server (E. Y. Chen 
et al. 2013b) was used to perform gene annotation enrichment. 
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3.1 Generation of an iPSC BRD3 KO model 
 
3.1.1 Introduction 
Platelets activity in thrombus formation is a determinant factor in myocardial infarction (Chu et al. 
2010; Klovaite et al. 2011b). This fact highlights the importance of studying the mechanisms that 
regulate platelet differentiation. As mentioned in chapter 1, Astle et al. have performed a large-scale 
GWAS on platelet traits, and identified BRD3 as a regulator of platelet volume (MPV) and volume 
distribution width (PDW) (Astle et al. 2016). GWAS are critical for the identification of novel genes in 
disease, but validation studies are required to understand the mechanistic pathways involved in the 
regulatory processes. Functional studies have revealed that BRD3 plays a role in formation of 
thrombocytes in zebrafish (Bielczyk-Maczyńska et al. 2014a), although its regulatory molecular 
mechanisms in haematopoiesis are largely unknown.  
 
The study of the biological role of proteins often relies on gene inactivation in model organisms. In 
particular, mouse knockout models became a common tool to study the role of proteins from a whole 
organism perspective (Vandamme 2014). In collaboration with the Wellcome Trust Sanger Institute, I 
tried to generate a BRD3 KO mouse model using Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR/Cas9) technology (W. Qin et al. 2016), but BRD3 KO mice were not viable.  Several 
chimeras (animals originating from the injection of KO ES cells in the WT Embryo) (Eckardt, McLaughlin, 
and Willenbring 2011) were obtained, however no offspring carried the BRD3 KO alleles, indicating 
that there was no germline contribution from these ES cells.  This is in agreement with reported 
attempts to generate other BET KO mouse models, where embryonic lethality was observed due to 
defects associated with low proliferation rates (Shang et al. 2009). The embryonic lethality of BRD3 KO 
mouse model motivated the search for an alternative BRD3 KO model. Upon evaluation of the models 
available for studying megakaryopoiesis, I have designed and generated an induced pluripotent stem 
cell (iPSC) model carrying a BRD3 KO mutation.  
 
iPSCs are broadly used in research due to stem cell -like characteristics such as self-renewal and 
differentiation capabilities (section 1.2.2.3). Self-renewal can be measured by proliferation assays, and 
the potential for differentiation is often characterised by high pluripotency levels and ability to form 
somatic-like cells. Alterations in these characteristics should be monitored when genetically 
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manipulating cells. This is particularly important when studying factors associated with cell cycle and 
regulatory function, such as BET proteins.    
 
Our understanding of regulatory mechanisms in gene transcription has benefited from advances in 
genetic engineering techniques. In recent years CRISPR/Cas9 became a ubiquitous method to 
genetically manipulate cell lines with applications ranging from basic biology research to clinical 
applications, as reviewed in (Z. Zhang et al. 2017). CRISPR/Cas9 system owes its success to its low cost, 
precision and simplicity. Although, this system presents disadvantages that need to be considered 
when selecting a technology to create genetic mutations. 1) The requirement for PAM sequences in 
the target sequence. 2) The possibility of off-targets occurrence, due to sequence homology with other 
genomic regions (Zhang et al. 2015). The current alternatives to CRISPR for generation of KO cell lines 
are Zinc Finger Nucleases (ZFNs) and TALENs, but both are less efficient and more laborious (Gaj et al. 
2013). Altogether, these techniques present valuable options to genetically manipulate disease 
models. CRISPR/Cas9 was the system I used to generate BRD3 KOs cell lines. 
 
In order to study the role of BRD3 in regulation of platelets formation, and due to the lack of reliable 
models for generation of in vitro platelets, the experiments in my thesis were conducted using a 
megakaryopoiesis forward programming (FoP) protocol. This protocol has already been used in the 
laboratory and it yields a high number of MK cells in a relatively short period of time (20 days). The 
choice of this system was further reinforced by the avai lability of in-house expertise in FoP (Dr Cedric 
Ghevaert’s lab). However, one of the drawbacks of this system is that the generated MKs are low 
ploidy (2N/4N), indicating low maturation when compared with bone marrow MKs. In fact, the 
polyploidisation levels, and high proliferative capability are phenotypic characteristics of fetal MKs (De 
Alarcon et al. 1996; Sola-Visner et al. 2007; Mattia et al. 2002). Despite the low ploidy level, the 
protocol has been reported to produce pro-platelet, but this is yet an unreliable, cell line-dependent 
process, hence why I studied BRD3 in MK formation only. Additionally, the protocol rely on the use of 
viruses containing transcription factors (TFs), including GATA-1. This could introduce artefactual 
results in my experiments as this TF is a direct BRD3 interactor. The alternative protocols for the 
generation of MKs have been described in more detail in section 1.2.2.4, but some of the 
disadvantages associated with these protocols include expensive complex cytokine cocktails, low MK 
yield and time consuming procedures for direct differentiation of cells. In the quest to avoid 
overexpression of GATA-1, the protocol developed by Feng et al. was tested (Q. Feng et al. 2014), but 
with no success in generating MKs, and therefore, this second protocol was abandoned.  
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MKs successful forward programming was evaluated by the expression of characteristic cell surface 
markers. In my experiments I monitored the expression of CD235a, CD41a and CD42b as these 
correspond to surface proteins found in MKs at different stages of differentiation. Anti-CD235a 
antibodies recognise glycophorin A, a sialoglycoprotein present in the cell membrane of erythroid-MK 
precursors and erythroid mature cells (Dahr et al. 1987; Tomita et al. 1978). CD41a antibodies detect 
integrin-αIIb surface membrane protein, found on megakaryocytes and platelets (Phillips et al. 1988). 
This protein is part of the glycoprotein IIb-IIIa receptor complex, which is activated upon triggering of 
the hemostatic cascade and binds to fibrinogen, vWF and vitronectin (Shattil et al. 1998). The co-
expression of CD41a and CD235a has previously been demonstrated on MK progenitor cells 
differentiated from human ESCs (Moreau et al. 2016). It has also been shown that CD235a+/CD41a+ 
progenitor cells are able to give rise to both erythroid and MK lineages (Klimchenko et al. 2009). Lastly, 
CD42b is a glycoprotein Ib (GPIb) which is a component of the GPIb-V-IX complex, expressed at late 
stage of MK differentiation (Du et al. 1987; Nishikii et al. 2015). The GPIb-V-IX complex is present on 
the surface of platelets and it functions as the receptor for vWF (A. K. Rao and Songdej 2017). In FoP 
of MKs, CD42b represents the last stage of MK maturity achieved with this protocol (Moreau et al. 
2016). 
In order to investigate whether BRD3 is essential in megakaryopoiesis, I initiated my studies with the 
generation and characterisation of two BRD3 KO iPSC lines, containing deletions in the BRD3 open 
reading frame. The transcripts expressed in MKs were identified and the gene targeted using 
CRISPR/Cas9. As BET proteins have been previously associated with cell cycle progression, I 
characterised BRD3 KO cells and compared with WT cells, based on proliferation and pluripotency 
assays. Ultimately, my aim for this section was to determine whether BRD3 was required for the 
differentiation of IPSC into MK  
 
3.1.2 Results 
3.1.2.1 Generation of BRD3 KO using CRISPR Cas9 nickase 
In order to generate BRD3 KO cell lines, I used the CRISPR/Cas9 technology with the Cas9 nickase 
(Cas9n) variant.  The Cas9n was directed to the target site by two sgRNAs complementary to opposite 
DNA strands. The double targeting strategy has a higher specificity than single sgRNA targeting, and it 
mitigates off-target activity up to 1,500 fold in cell lines (Mali et al. 2013; F. A. Ran, Hsu, Lin, et al. 
2013). This strategy relies on non-homologous end joining (NHEJ) to create mutations (insertions or 
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deletions) in the gene sequence. Gene knockout strategies often target the downstream region of the 
ATG (first translated codon) in order to completely disrupt protein synthesis or to create out-of-frame 
sequences. Otherwise, in frame deletions can produce a truncated protein with partial or complete 
functional activity.  
3.1.2.1.2 Target sequence identification 
I initiated this experiment with the identification of the CRISPR/Cas9 target site and the design of the 
sgRNAs at the BRD3 locus. The BRD3 sequence, and transcript details, were analysed using Ensembl 
genome browser. The transcripts present in MK cells were identified in the Blueprint database  
(https://blueprint.haem.cam.ac.uk/bloodatlas/). Conveniently, BRD3 has four protein-coding 
transcripts with the same start coding site, located on the second exon of the gene locus.  To maximise 
the chances of creating an out of frame mutation, the sgRNAs were designed to target a 200 bp region 
directly downstream of the ATG site (figure 3.1.1). Potential sgRNA sequences were designed using 
Wellcome Trust Sanger Institute CRISPR online tool (https://www.sanger.ac.uk/htgt/wge/) and only 
the 25% best matches (3 sgRNAs) were considered. Each sgRNA must be upstream of a Protospacer 
Adjacent Motif (PAM) sequence (NGG), although the PAM sequence was not included in the sgRNA.  
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Figure 3.1.1 BRD3 targeting strategy and sgRNA design for generation of BRD3 knockout using double 
Cas9 nickase. (a) Schematics of BRD3 target region. BRD3 coding sequence is located in the long arm of 
chromosome 9. The starting site (ATG) for all BRD3 protein-coding transcripts is found on exon 2. The 
target site was designed to include 200 bp downstream of the ATG codon. This strategy allows complete 
ablation of the protein by either disrupting the beginning of protein synthesis or creating a functionally 
inactive out-of-frame protein. (b) sgRNAs were designed using WTSI CRISPR online tool with the target 
sequence as input. Only the 25% best hits were selected (3 sgRNAs represented). The sgRNA sequences 
are required to be directly upstream of a protospacer adjacent motif (PAM) sequence (red squares). PAM 
sequences are recognised by Cas9 enzymes, but are not included in the sgRNAs sequences. Cas9 enzymes 
were expected to target 3 nucleotides upstream of the PAM (green arrows).  
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3.1.2.1.2 sgRNA targeting test 
 sgRNAs represented in figure 3.1.1 were cloned (section 2.2.10) into vector pSpCas9(BB)-2A-PURO 
(appendix 6.1.1.1). The validation of sgRNAs insertion was performed by restriction digestion, followed 
by Sanger sequencing (using U6 primer for sequencing) to ensure in-frame positioning of the sgRNAs 
inserts (appendix 6.2.1). Each validated plasmid was then expanded (section 2.2.10.2).  
T7 endonuclease assay was performed to verify sgRNAs targeting. gRNA-containing plasmids (sgRNA2, 
sgRNA 3, sgRNA8) were transfected into HEK293T cells along with Cas9(WT). HEK293T cells were 
chosen for sgRNA testing due to their high transfection efficiency at population level, leading to lower 
variability in the population, higher signal without the requirement for sub-cloning and expansion, 
resulting in a significantly decrease in test timescale. However, I am aware that using HEK293T, instead 
of the target iPSC, could become redundant if the target sequence was different in both lines. If the 
iPSC transfections had proven unsuccessful, I would have sequenced the target region in both cell lines 
to validate this hypothesis. After transfection, the HEK293T genomic DNA was extracted and a PCR of 
the target region was performed (figure 3.1.2.a). A hybridization step was carried out where PCR 
products were randomly hybridised to form duplex DNA fragments containing nucleotide mismatches 
(resulting from sgRNA successful targeting). The assay was completed by digestion of the hybridised 
PCR products with T7 endonuclease, which recognises and digests DNA mismatches (section 2.2.10.5). 
The T7 endonuclease assay is expected to reveal smaller product bands, indicating the digestion by T7 
endonuclease at mismatched nucleotides near the disrupted region (figure 3.1.2).   
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Figure 3.1.2 PCR for confirmation of sgRNA targeting efficiency at BRD3 locus. (a) Schematics of PCR 
to confirm sgRNAs targeting. Three sgRNAs (2, 3 and 8, green boxes) located downstream of the ATG 
site (blue) were tested in the assay. PCR primers (red) were designed outside of the targeted region 
(845 bp). (b) Gel showing T7 endonuclease assay results. HEK293T cells were transfected with sgRNAs 
2, 3 and 8 targeting BRD3 locus and Cas9. gDNA extracted and PCR performed, before T7 endonuclease 
assay was complete. Results for individual sgRNAs transfections are shown in lanes 3 (sgRNA2), 5 
(sgRNA3) and 7 (sgRNA8). All of these sgRNAs successfully created indels at the BRD3 locus. WT and 
Cas9 only, as well as non-T7 digested transfected conditions were loaded on a gel as controls.  
 
Figure 3.1.2.b shows that sgRNAs 2, 3 and 8 successfully create mismatches in the targeted region. 
Both 2+8 and 3+8 sgRNA pairs could have been selected to generate BRD3 KO in iPSC lines. Although 
sgRNA pair 3+8 was selected, due to the spacing between the two sgRNAs.  
3.1.2.1.3 Generation of BRD3 KO iPSC 
After testing the sgRNAs targeting efficiency, I generated BRD3 KO in two distinct iPSC lines, S4-SF5 
and A1ATD1-c. These KOs were generated at different stages, and the targeting strategy was similar, 
using the same sgRNAs, yet different plasmids and selection method were used. The sgRNAs targeting 
test was not repeated as the homology between sgRNAs and target region remaining unaltered.  
S4-SF5 cell line- BRD3 KO generated using vector pSpCas9n(BB)-2A-PURO 
To target BRD3 gene in iPSC S4-SF5, the sgRNAs were cloned into vector pSpCas9 (BB)-2A-PURO 
containing a puromycin gene which confers puromycin resistance to successful nucleofected cells. This 
vector also contains a Cas9n cassette. This allows the expression of the Cas9n enzyme with the ability 
to create single strand cuts (nicks) in the targeted DNA.  
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S4-SF5 cells were nucleofected (section 2.2.10.4) with vectors pSpCas9 (BB)-2A-PURO containing 
sgRNA3 and sgRNA8.  The experiment included two control conditions: cells nucleofected without 
plasmids to monitor the effect of nucleofection on cells; and non-nucleofected cells to monitor cell 
death after puromycin treatment. Puromycin treatment was initiated 2 days post-nucleofection. The 
treatment lasted until control cells (not nucleofected) were no longer observed (2 days). Twelve 
puromycin-resistant colonies were observed (from 1x106 nucleofected cells). These were fed 6 times 
per week and each individual colony passaged separately when large enough to handle and establish 
robust clonal lines. This method eventually required culture sub-cloning into single cells to ensure 
culture homogeneity.  
 
A1ATD1-c cell line- BRD3 KO generated using vector pSpCas9n(BB)-2A-GFP and pSpCas9n(BB)-2A-
tomato 
To target BRD3 gene in iPSC A1ATD1-c, sgRNAs 3 and 8 were cloned into vectors pSpCas9n(BB)-2A-
GFP and pSpCas9n(BB)-2A-tomato, respectively. The plasmid containing tomato fluorescent marker 
was derived from the plasmid containing GFP by removing the GFP gene and replacing it with tomato 
gene (work done by Dr Annette Muller, Dr Cedric Ghevaert’s lab, University of Cambridge). The 
plasmids also contain the ORF for Cas9 nickase. Plasmids were nucleofected into A1ATD1-c cells. This 
strategy allowed the sorting of cells containing both sgRNAs based on double labelling (GFP+/tomato+). 
The sorted clones were plated individually onto three 96 well plates pre-coated with vitronectin (288 
sorted single cells); fed 6 times per week, and passaged when large enough to handle. One hundred 
and nine (109) sorted cells formed colonies which were expanded. Only four clones were genotyped 
as a KO was promptly found. This method presents an improvement from the strategy previously used 
as it select cells successfully nucleofected based on double fluorescence labelling, increasing the 
probability of success; and it did not require culture subcloning because the clones formed were 
generated from sorted single cells. 
3.1.2.2 Confirmation of BRD3 KO clones 
The individual clones of both S4-SF5 and A1ATD1-c nucleofected cells were expanded, and genomic 
DNA extracted for genotyping by Sanger sequencing using primers BRD3.E2.REV and FWR (table 2.2.1). 
For clones containing deletions, PCR products were cloned into pGEM-T vector and sequenced to 
confirm the presence of disrupting mutations on both alleles (section 2.2.10.3). If the tested clone was 
heterozygous, the PCRs sequenced would present 2 different sequences, and PCRs from a homozygous 
clone would only present one sequence.  Primer T7F, with homology to promoter T7 present in pGEM-
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T was used to perform Sanger sequencing. Two successful BRD3 KO clones (S4-SF5 and A1ATD1-c) 
were confirmed as shown in figure 3.1.3.a.  
 
Protein knockout was confirmed by western blotting in S4-SF5 BRD3 KO and A1ATD1-c BRD3 KO. 
Western blot membrane was stained with BRD3 antibody and β-actin as a loading control (figure 
3.1.3.b).  
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Figure 3.1.3 Confirmation of BRD3 KOs in S4-SF5 and A1ATD1-c iPSc. (a) Sequence alignment of BRD3 
KOs to reference WT. PCR products from clonal cultures (generated from single cells) were inserted 
into PGEM-T and sequenced to confirm present deletions. S4-SF5 BRD3 KO shown is a heterozygous 
clone for 2 deletions (70 bp and 55 bp) and A1ATD1-c BRD3 KO is homozygous for a 58 bp deletion (b) 
Western blot analysis of BRD3 in WT and KO generated clones. Purified protein extracts from both S4-
SF5 BRD3 KO and A1ATD1-c BRD3 KO, as well as WT cells, were collected and fractionated using SDS-
PAGE conditions. Subsequently, the protein level of BRD3 and β-actin were analysed using polyclonal 
antibodies rabbit anti-human BRD3 and mouse anti-human β-actin. BRD3 was not detected in neither 
S4-SF5 BRD3 KO nor A1ATD1-c BRD3 KO proving complete knockout of BRD3 protein in both clones. 
(c) Transmitted light images of live cultures show no morphological differences between KOs and 
respective WT. Scale bars, 250 µm. 
 
Figure 3.1.3 shows the confirmation of S4-SF5 BRD3 KO and A1ATD1-c BRD3 KO.  Sequencing results 
of PCR products cloned into pGEM-T confirmed that S4-SF5 BRD3 KO is heterozygous with 2 deletions 
(70 bp and 55 bp) and A1ATD1-c BRD3 KO is homozygous for a 58 bp deletion (figure 3.1.3.a). To 
confirm that these deletions generated an out-of-frame protein, a western blot was performed on 
purified protein extracts from both clones. The membranes were stained with primary BRD3 and β-
actin antibodies. Figure 3.1.3.b shows that BRD3 KOs clones did not express BRD3 protein. 
Morphological observations confirm similarity between KOs and the corresponding WT cells (figure 
3.1.3.c).  
 
3.1.2.3 Characterisation of BRD3 KOs  
3.1.2.3.1  Proliferation assay 
As BET proteins have been associated with proliferation and cell cycle, I investigated whether BRD3 
knockout affects proliferation of iPSCs. There are several methods to study cell proliferation, such as 
DNA synthesis labelling, biomarker concentration measurements or cell staining followed by 
colorimetric measurement. One of the well-established staining methods used to compare 
proliferation between cell lines is the crystal violet assay. This assay relies on staining of the DNA and 
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proteins present in the cells (Sanford et al. 1951; Feoktistova, Geserick, and Leverkus 2016). This 
method does not distinguish between cell division stages nor does it take into account cells with 
different protein cargo. However, as crystal violet staining was to be used at iPSC stage only, the 
method was chosen as it is simple to set up, and it can also be used for cell morphology 
characterisation (section 2.2.14). In this experiment, iPSC WT and BRD3 KOs were seeded at 
incremental densities. Cells were fixed at days 4 and 6 post-seeding with glutaraldehyde to cross-link 
all proteins and preserve morphological structure. Crystal violet assay was performed. Figure 3.1.4 
shows results of this proliferation experiment. 
 
 
Figure 3.1.4 Proliferation analysis of BRD3 KO on iPSC. WT and KO cells were seeded at incremental 
densities and fixed at days 4 and 6 post-seeding. Crystal violet staining was performed and dye 
absorbance measured at 450 nm. a) Proliferation assay with S4-SF5 clones. Left panel shows the image 
of crystal violet stained S4-SF5 cultures at days 4 and 6. The absorbance measurements are plotted on 
the right panel. Mean absorbance ± standard deviation (SD), n=3, *p<0.05 two-tail t-test against WT 
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in similar condition. b) Proliferation assay for A1ATD1-c clones. Left image shows the stained cultures 
at days 4 and 6. The absorbance measurements are plotted on the right panel. Same proliferation 
trend was followed by A1ATD1-c WT and A1ATD1-c BRD3 KO (n=1). c) Images of stained WT and BRD3 
KO cultures. Scale bars, 250 µm. 
 
 
The proliferative activity of WT and BRD3 KO cells was determined after 4 and 6 days in culture, using 
crystal violet assay (figure 3.1.4). In both cell lines, the staining between the WT and BRD3 KO cells for 
the same condition (time points and densities) were very similar indicating that these cells had a very 
similar proliferation rate. This result was reflected on the absorbance readings, as BRD3 KO cells 
generally showed similar readings to the WT cells at the same time point and densities. Two exceptions 
were noted for S4-SF5 cells at day 4 (figure 3.1.4, top right panel) where statistical significant 
differences were found between WT and BRD3 KO. These differences were probably due to differences 
in seeding density and were not confirmed at day 6. Morphological similarities between WT and BRD3 
KO were confirmed with crystal violet staining (figure 3.1.4.c). Together, this data shows  similar 
proliferation rates between BRD3 KO cells and the corresponding WT cells suggests that BRD3 does 
not play a role in proliferation of iPSCs.  
 
3.1.2.3.2 iPSc pluripotency test 
Members of the BET family have been shown to regulate pluripotency by binding to regulatory regions 
of pluripotency genes; as well as regulating the exit of pluripotency states and driving differentiation 
networks (Wu et al. 2015; Roberts et al. 2017). To study whether absence of BRD3 affects pluripotency, 
I compared pluripotency levels between WT and BRD3 KOs. Cells were stained with antibodies against 
pluripotency surface markers SSEA4 (Stage-specific embryonic antigen 4) and Tra-1-60, and analysed 
by flow cytometry. Human SSEA4 is a glycolipid expressed in early embryonic development, and it is 
widely used in the identification of pluripotent cells (Kannagi et al. 1983).  Equally, Tra-1-60 is present 
in human embryonic stem and germ cells (Zhao et al. 2012).   
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Figure 3.1.5 BRD3 KO does not affect pluripotency of iPSC cultures. Undifferentiated iPSC cells were 
dissociated and stained with Tra-1-60 and SSEA4 antibodies. These surface markers are commonly 
found on the surface of undifferentiated and pluripotent cells. Staining intensity was analysed by flow 
cytometry. (a) Gating strategy for identification of pluripotent cells (Tra-1-60+/SSEA4+) using density 
plots. FS vs SS identifies population of interest. Plot shown with a threshold (discriminator) of 150 
applied to reduce the debris visualised. SSEA4 vs Tra-1-60 plot identifies pluripotent cells. (b) 
Comparison of pluripotency levels between cell lines A1ATD1-c and S4-SF5 (WT and KOs). The bar plot 
shows that all clones tested (WTs and KOs) expressed high levels of Tra-1-60+/SSEA4+ cells, indicating 
high pluripotency (n=1). 
 
Flow cytometry analysis shows that surface markers Tra-160 and SSEA4 are expressed at high levels, 
indicating pluripotency of all clones analysed. All clones showed a percentage of double positive cells 
(Tra-1-60+/SSEA4+) equal or over 75%. This experiment was run at different times for both cell lines 
(due to KOs being generated at different times). The similarity in pluripotency levels between the WT 
and KOs clones for both cell lines, suggests that BRD3 does not regulate mechanisms of pluripotency 
maintenance. The full characterisation of the pluripotency capabilities would only be achieved by 
differentiation into the 3 germ layers. Although, expression of pluripotency markers is a good 
indication of the differentiation potential. It was important to verify that pluripotency levels were not 
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disrupted in BRD3 KO cells, as I aimed to forward programme these cells into MKs and the protocol 
used is sensitive to the pluripotency levels in the initial population.  
 
3.1.2.4 Forward programming of BRD3 KO into megakaryocytes 
(MKs) 
As confirmed in the section above, BRD3 KO cell lines are viable and phenotypi cally similar to the 
corresponding WT. In order to investigate whether BRD3 is essential in megakaryopoiesis, I 
differentiated iPSC WTs and BRD3 KOs lines into MKs. The differentiation protocol used was the MK 
forward programming (FoP) protocol, developed by Moreau et al. (section 2.1.5). This protocol relies 
on the overexpression of three transcription factors, critically important in megakaryopoiesis 
differentiation: TAL1, FLI-1 and GATA-1 (figure 3.1.6). Briefly, the cells are single-cell seeded and 
infected with the viruses containing the three TFs. For the first 2 days, the differentiating cells are 
cultured in media containing BMP4 to drive differentiation towards mesoderm. In the following stage, 
cultures are supplemented with thrombopoietin (TPO) for differentiation towards the megakaryocytic 
lineage, and stem cell factor (SCF) for supporting cell division. Cell dissociation is performed at day 10 
to help selection of suspension MK progenitors based on culture conditions, as adherent cells will not 
survive suspension culturing. 
 
 
Figure 3.1.6 Schematic representation of FoP protocol. Viral transduction of TAL-1, FLI-1 and GATA-1 
along with mesoderm induction initiates the differentiation into mesoderm lineages. This initial stage 
is followed by culture into MK induction medium (TPO+SCF). Cell dissociation is performed at day 10 
and cultures are kept in suspension conditions. 
 
The progression of cells through the differentiation process was tracked by flow cytometry analysis of 
surface markers. The identification of the differentiating cells was done using a Forward Scatter (FS) 
versus Side Scatter (SS) plot. FS light is more sensitive to the cell size and SS light is more sensitive to 
cell homogeneity, therefore the differentiating cells are easily identified using these parameters 
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(Latimer 1982). The population identified in FS vs SS includes cells at different stages of differentiation, 
although this analysis gives a good indication to whether the culture is differentiating.  
 
A cell-specific variability in MK generation is characteristic of the FoP protocol. This variability has been 
observed in several laboratories and it is not currently understood. To investigate whether S4-SF5 and 
A1ATD1-c iPSC lines are capable to differentiate into MKs using FoP, I initiated 3 different experiments 
with both lines. In my experiments, S4-SF5 was not able to generate MKs robustly. This cell line only 
started differentiation in one of the experiments (figure 3.1.7.a), and all of the remaining attempts to 
form MKs from S4-SF5 cells were unsuccessful. A comparison of the generated MK populations 
between S4-SF5 clones (WT and BRD3 KO) and A1ATD1-c clones (WT and BRD3 KO) is shown in figure 
3.1.7. The data shown is based on FS vs SS analysis (differentiating population). 
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Figure 3.1.7 A1ATD1-c clones (WT and BRD3 KO) generate differentiating populations. Three 
attempts were made at generating MKs from both S4-SF5 and A1ATD1-c lines using the FoP protocol. 
Plots show percentage of identified MK populations (FS vs SS, y-axis) along differentiation timeline (x-
axis).  a) S4-SF5 clones (WT and BRD3 KO) do not survive the FoP differentiation. The plotted data 
represents the only experiment with S4-SF5 where some initial differentiation was observed. The WT 
(in yellow) and BRD3 KO (in green) followed the same pattern, but eventually the experiment did not 
succeed at generating MKs. b) A1ATD1-c clones (WT and BRD3) are successful at generating MKs. 
A1ATD1-c BRD3 KO follows the same differentiation pattern as A1ATD1-c WT. Mean of differentiating 
cells ± SD (n=3). 
 
A1ATD1-c BRD3 KO were capable to generate MKs by forward programming. Figure 3.1.7.b shows the 
identified MK populations generated from 3 experiments with A1ATD1-c iPSC using FoP protocol 
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(populations identified by FS vs SS, and include MK progenitors, immature and mature MKs). The data 
shows that A1ATD1-c BRD3 KO generates MK populations of similar yield to A1ATD1-c WT. This was 
the model used to study BRD3 requirements in megakaryopoiesis in the rest of my studies. Neither S4-
SF5 WT nor S4-SF5 BRD3 KO generated MKs, therefore no further work was carried out on these cells.    
 
The progression of cells through the differentiation process was followed by flow cytometry analysis 
of cell surface markers. In order to understand whether A1ATD1-c BRD3 KO follow the same 
differentiation trajectory as A1ATD1-c WT, I analysed the progression of FoP MKs (immature and 
mature populations) based on cell-surface markers CD235a, CD41a and CD42b. As described above, 
CD235a identifies glycophorin A, CD41a identifies integrin-αIIb and CD42b identifies glycoprotein Ib 
(GPIb). The following definitions were used to classify cell populations during forward programming 
differentiation; CD235a+/CD41a+ refers to MK progenitors; CD41a+/CD235a- are lineage committed, 
immature MK cells; and CD41a+/CD42b+ are mature MKs. Cultures were analysed by flow cytometry 
at day 10 (dissociation day), day 15 and day 20 when generally mature MKs are observed. Cell 
suspension samples were also cytospinned onto slides, and cells stained using Romanowsky staining 
to evaluate morphology (section 2.2.12). The gating strategy for population identification and 
representative images of populations are shown in figure 3.1.8. 
 
 
 
 
 
 
 
 
79 
 
 
 
Figure 3.1.8 BRD3 KO generates MKs with similar cell-surface pattern to WT. BRD3 KO and WT iPSCs 
were differentiated into MKs by FoP. Samples were stained with antibodies against surface markers 
CD235a, CD41a and CD42b at days 10, 15 and 20. Flow cytometry analysis was performed. a) Gating 
strategy for analysis of MK differentiation. Differentiating populations identified based on forward and 
side light scatter (FS vs SS). CD235a+/CD41a+ gates MK progenitors, CD41a+/CD235a- gates immature 
MK cells; and CD41a+/CD42b+ identify mature MKs. b) MK progenitors (CD235a+/CD41a+) development 
during FoP process for A1ATD1-c WT and A1ATD1-c BRD3 KO. c) Immature MKs (CD41a+/CD235a-) 
development. d) Mature MKs development (CD41a+/CD42b+). For a), b) and c) mean of gated 
population ± SD (n=3). e) Representative images of FoP cells at days 10 and 20. Cell suspensions were 
cytospinned onto slides and stained using Romanowsky staining protocol. Day 10 cultures (left panel) 
present expanded nucleus and frequent dividing cells (red arrows), indicating a very proliferative, but 
not highly differentiated culture. Day 20 cultures (right panel) show cells with smaller nucleus and 2N 
MKs (red arrows), indicating a differentiated MK mature population. Scale bars, 25 µm. 
 
80 
 
Flow cytometry analysis of cell-surface markers shows that A1ATD1-c BRD3 KO generate MK 
populations similarly to A1ATD1-c WT. During FoP, cultures generally acquire a MK progenitor cell-
surface signature (CD235a+/CD41a+) prior to day 10 when cultures are still in a high proliferative state 
(figure 3.1.8.e). MK progenitor cell differentiation was similar to both WT and BRD3 KO cells with 25-
30% of differentiating cells identified within the MK progenitor population (CD235a+/CD41a+) at day 
10 (figure 3.1.8.b). Although, the standard deviation between the three experiments (figure 3.1.8.b) is 
high for the progenitor population, the progression of progenitor cells in culture is very similar 
between WT and BRD3 KO. MK progenitors gradually lost CD235a and became committed to MK 
lineage (figure 3.1.8.c), a trend that is expected when using this protocol (Moreau et al. 2016). The 
differentiation profile for MK committed cells (CD41a+/CD235a-) was similar between WT and BRD3 
KO (figure 3.1.8.c). The loss of CD235a was followed by gain of CD42b (figure 3.1.8.d). This indicates 
differentiation towards MK maturity where ploidy cells are observed (figure 3.1.8.e).  Together this 
data shows that BRD3 KO did not affect MK differentiation profiles during MK-FoP. 
3.1.3 Discussion  
BRD3 was previously identified as a regulator of MPV and PDW in a GWAS study, and the attempts to 
generate a mouse knockout model failed maybe due to lethality at embryonic stage or failure to make 
gametes, indicating that BRD3 plays critical roles during embryo development. The first section of my 
thesis describes the generation of an iPSC BRD3 KO model, and the differentiation of these cells into 
MKs to investigate BRD3 requirements during megakaryopoiesis. These experiments show, for the first 
time, that BRD3 is not essential for MK differentiation. 
 
The results in this chapter show that BRD3 is not essential for maintenance of undifferentiated cell 
state. The deletions generated at the BRD3 locus, in both S4-SF5 and A1ATD1-c iPSC cells (figure 
3.1.3a), did ablate BRD3 protein production (figure 3.1.3.b). The BRD3 KO clones in both cell lines were 
viable and phenotypically similar to the corresponding WT cells. This indicates that BRD3 is not 
essential for iPSC survival. Morphologically, there were no differences observed between WT and KO 
lines (figure 3.1.3c). The same level of similarity was confirmed in proliferation assays, evaluated by 
crystal violet absorbance measurements (figure 3.1.4). Figures 3.1.4.a and 3.1.4.b show a proliferation 
comparison between WT and BRD3 KOs for S4-SF5 and A1ATD1-c, respectively. The results show 
minimal proliferation difference between the WT and KOs and these differences are maintained for 
the duration of the study (6 days). Possibly, this reflects a difference in initial cell seeding density rather 
than in proliferative potential. Overall, both WT and KOs for each line proliferated very similarly. As 
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well as regulating proliferation, BET proteins have been reported to play a role in pluripotency (Wu et 
al. 2015; Roberts et al. 2017). For this reason, I investigated the effects of BRD3 on expression of 
pluripotency markers. Comparison of pluripotency between WT and BRD3 KOs, evaluated by the 
expression levels of Tra-1-60 and SSEA4 (Figure 3.1.5.b), shows that pluripotency levels were not 
affected by the absence of BRD3. Together, these results show that BRD3 is not essential for 
pluripotency maintenance nor proliferation of iPSCs. Considering the failed attempt to generate a 
BRD3 KO mouse, my results suggest that BRD3 might be essential for regulation of other embryonic 
differentiation processes, rather than embryonic stem cell maintenance. If the BRD3 KO iPSC clones 
were not viable I would have designed an inducible knockdown strategy using CRISPR interference 
(CRISPRi) or shRNA. The inducible knockdowns would not only allow to investigate whether BRD3 is 
essential during the MK differentiation process, but also to identify the timing when the protein is 
active, as inducible systems have the convenience to be induced at different stages. With BRD3 KO 
iPSCs being viable and phenotypically similar to the WT, I investigated whether these cells were able 
to differentiate into MKs. 
 
BRD3 KO iPSCs were able to generate MKs using a forward programming system. In order to study 
BRD3 requirements during megakaryopoiesis, I differentiated iPSCs (BRD3 KOs and WTs of both S4-
SF5 and A1ATD1-c cell lines) using FoP. The cell lines studied have different MK generation capability. 
S4-SF5 clones (both WT and BRD3 KO) did not survive the differentiation process, and as a 
consequence no further work was carried out on S4-SF5 clones (figure 3.1.7.a). The cell line-specific 
variability in MK generation, using FoP, has been observed by other laboratories, but is currently 
unexplained. One hypothesis is that different iPSC lines need different amount of lentiviruses for 
successful infection, and therefore, their outcome in a protocol based on viral infection could be cell-
specific. The remaining experiments were conducted in A1ATD1-c clones. A1ATD1-c BRD3 KO clone 
followed the same differentiation pattern as the corresponding WT for all the MK populations studied 
(progenitors, immature and mature MKs) (figure 3.1.8). The differentiation of MKs was evaluated by 
the level of expression of surface markers (CD235a, CD41a and CD42b). The first differentiation stage 
identified during FOP is MK progenitors (CD235a+/CD41a+) at day 10. Both WT and BRD3 KO presented 
cultures with similar levels of MK progenitor cells (figure 3.1.8.b), indicating that BRD3 is not required  
for early stages of differentiation.  The loss of CD235a, and maintenance of CD41a, indicates MK 
lineage commitment, and the similarities between WT and BRD3 KO (figure 3.1.8.c) suggest that BRD3 
is not required during MK lineage commitment. BRD3 KO also differentiated into mature MKs, verified 
by acquisition of CD42b surface antigen, similarly to the WT. These results indicate that BRD3 is not 
essential for the establishment of mature MKs.  
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The results presented in this section were unexpected, particularly following BRD3 identification as a 
regulator of platelet traits in a GWAS, and the failure in the generation of a mouse BRD3 KO model. As 
an epigenetic reader, if BRD3 regulated the factors influencing platelet traits, I expected to capture 
these events at megakaryocyte stage (platelet precursor). However, it is important to remember that 
GWAS capture very small effects. The absence of BRD3 could cause minimal disruption in MK 
differentiation that characterisation based on surface markers would not capture. Additionally, the 
results of my experiments need to be interpreted with caution, due to flaws that could explain the 
successful generating of MKs from BRD3 KO iPSCs. Firstly, the initial overexpression of GATA-1 in FoP 
could compensate for the absence of BRD3. GATA-1 and BRD3 are direct interactors, and it has been 
shown that GATA-1 recruits BRD3 to both active and repressed GATA-1 target genes during erythroid 
maturation (Janine M Lamonica et al. 2011). In the same study, this association happened 
independently of histone acetylation, indicating that BRD3 recognises acetylated GATA-1 regardless 
of chromatin acetylation signatures. If a similar mechanism happened in megakaryopoiesis, the role 
of BRD3 could become redundant following GATA-1 overexpression. GATA-1 expression levels, as well 
as the other TFs overexpressed in FoP, have been shown to eventually fall to the normal expression 
levels found in cord blood (Moreau et al. 2016). However, if BRD3-GATA-1 binding was required for 
the initial regulatory mechanisms of megakaryopoiesis, this mechanism could have been overcome 
while GATA-1 was still being overexpressed. A different study looking at the interaction between BET 
proteins and GATA-1 in erythropoiesis, showed that BRD3 co-occupies a high number of GATA-1-
binding sites, but depletion of BRD3 does not affect erythroid transcription (Stonestrom et al. 2015). 
Together, the above mentioned studies indicate  that BRD3 interacts with GATA-1, but is not required 
for GATA-1-specific gene regulation in erythropoiesis. A similar regulation mechanism could act in 
megakaryopoiesis, where BRD3 is present at GATA-1 occupied sites, but not actively contributing to 
GATA-1-mediated transcription. This hypothesis could be tested by comparing chromatin occupancy 
profiles for BRD3 and GATA-1 during megakaryopoiesis, using a MK differentiation protocol that does 
not rely on the overexpression of GATA-1. To investigate chromatin co-occupancy between GATA-1 
and BRD3, a chromatin immunoprecipitation (ChIP) experiment could be performed using antibodies 
against GATA-1 and BRD3 on WT MKs. Additionally, a GATA-1-ChIP experiment could be performed on 
BRD3 KO cells to identify the BRD3 requirement on recruitment of GATA-1. The integration of both 
experiments would allow to investigate BRD3 requirements on GATA-1-mediated regulation of 
megakaryopoiesis.  
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The second reason that could explain the results in this section is that BRD3 might be compensated by 
a structurally similar protein. The sequence homology between BET proteins has been well studied, 
and the compensation of BRD3 by BRD2 has been suggested for erythropoiesis (Stonestrom et al. 
2015), a process that is evolutionary very close to megakaryopoiesis (Svoboda et al. 2015). One 
possible experiment to test whether one of the other BET proteins compensates the absence of BRD3 
is to generate combinatorial BET KOs on iPSCs, and differentiate these KOs into MKs. A comparison 
between BRD3 KO and the combinatorial BET KOs would give an indication on potential protein 
redundancy mechanisms. For example, if BRD2 compensates absence of BRD3, a BRD2+3 KO should 
form defective MKs or not be able to differentiate into the MK lineage all together.  
 
Finally, BRD3 was identified as a regulator of MPV and PDW, and although megakaryopoiesis is a valid 
model to study regulation of early platelet formation, conclusions should not be extrapolated lightly. 
Additionally, the MKs generated by FoP, although comparable to in vivo MKs, are still an immature 
and low ploidy MK cell (Moreau et al. 2016), and the role of BRD3 might be negligible at this stage. If 
BRD3 is active at a later stage of MK differentiation, or platelet release, that differentiation window 
might have been missed in my experiments. In order to study BRD3 effects at later stages of MK 
differentiation, a different protocol would have to be tested; however current in vitro differentiated 
cells do not yet match fully differentiated adult cells.   
 
Importantly, the results presented in this chapter were based only on cell surface markers. Although 
important in cell characterisation, surface expression signatures do not reveal the molecular 
mechanisms of differentiation. In order to study the regulatory role of BRD3 in megakaryopoiesis, I 
have performed further experiments, looking at genome-wide data, which I describe in the section 
3.2. 
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3.2 BRD3 regulation in Megakaryopoiesis  
 
3.2.1 Introduction  
Previously, I described the generation of BRD3 KO IPSC lines and their differentiation into MKs. The 
BRD3 depletion did not affect MK differentiation, evaluated by the expression of well-characterised 
MK surface markers. Although, these results do not reveal details about the regulatory mechanisms 
of BRD3 during megakaryopoiesis.  
 
Transcriptional regulation is a well-orchestrated mechanism involving a complex signalling network 
between chromatin, TFs and cofactors. Transcription machinery locates at active regions characterised 
by specific features, such as accessible chromatin structure and particular posttranslational chromatin 
marks (Harrow et al. 2012; Calo and Wysocka 2013). Histone acetylation is a mark present on active 
promoters and enhancers where cell-specific transcription factors and co-factors bind. Lysine 
acetylation recruits BET proteins involved in haematopoietic transcription networks, as reviewed in 
(Stonestrom et al. 2016). However, the role of BRD3 on establishment of acetylation signatures, and 
consequently on transcriptional regulation during megakaryopoiesis is largely unknown.  In this 
section, I describe the experiments to investigate the regulatory mechanisms of BRD3 during FoP of 
MKs. 
 
 Regulatory elements, such as promoters or enhancers, are often accessible and active in a cell -specific 
manner (Heintzman et al. 2007a; Thurman et al. 2012; Noh et al. 2015). In order to identify changes in 
chromatin accessibility resulting from BRD3 absence, I performed assay for transposase-accessible 
chromatin with sequencing (ATAC-seq) on WT and BRD3 KO cells. ATAC-seq is a simple method that 
uses efficient enzymatic fragmentation for identification of increased-accessibility regions (Buenrostro 
et al. 2013). Other methods for assaying chromatin accessibility include DNase-seq (Boyle, Davis, et al. 
2008) and formaldehyde assisted isolation of regulatory elements with sequencing (FAIRE-seq) (Giresi 
et al. 2007), although these alternative methods include laborious protocols and require higher 
amount of starting material than ATAC-seq. However, ATAC-seq data alone does not provide sufficient 
high resolution to identify regulatory elements. 
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 A subset of accessible regulatory elements is active in a cell -specific manner, and therefore marked 
with activation marks, such as H3K27ac (Creyghton et al. 2010). To identify the regions where 
activation marks change due to BRD3 absence, I performed chromatin immunoprecipitation followed 
by genome-wide parallel sequencing (ChIP-seq), using antibodies against H3k27ac and BRD3. ChIP-seq 
is used for genome-wide identification of histone marks and protein-DNA interactions, owing its 
success to the decreasing cost of next-generation sequencing. ChIP-seq offers advantages such as high 
resolution, and greater coverage than the predecessor array-based ChIP-chip (Lee et al. 2006; Buck et 
al. 2004). However, ChIP-seq restricts the identification of regulatory elements to regions that are 
targeted by specific antibodies, and it is heavily dependent on antibody specificity. The integration of 
ATAC-seq and ChIP-seq data sets improves the detection of those regions which are both accessible 
and active. By analysing the differences between WT and BRD3 KO, I aimed at identifying regions 
directly regulated by BRD3. Therefore, an effect of BRD3 absence would be observed in BRD3 KO cells 
with possible changes in chromatin activity and/or accessibility.  
Changes in regulatory elements generally affect expression of the genes regulated by those elements. 
In order to evaluate the consequential effects of BRD3 KO, I generated RNA-seq data from WT and 
BRD3 KO. These datasets were generated to confirm transcription variation as a result of alterations 
at regulatory regions. Investigation of the changes in chromatin structure and/or active marks 
(H3K27ac) in regulatory regions, as a result of BRD3 absence, and the study of the transcriptional 
consequences in MKs would progress our understanding of the BRD3 role in megakaryopoiesis.  
3.2.2 Results  
In order to study BRD3 regulatory mechanisms during megakaryopoiesis, samples for ATAC-seq, ChIP-
seq and RNA-seq were collected from iPSC (WT and BRD3 KO) and MKs (WT and BRD3 KO) cultures. 
MKs were generated using the FoP protocol in triplicates, and iPSCs samples were collected at the 
beginning of each FoP experiment. Cells were differentiated for 20 days before sorting based on 
CD42b+ cells (MKs) (section 2.2.9). Other selection methods were tested, such as CD42+-bead 
selection, but high cell loss was observed. Ficoll separation of cell populations is also routinely 
performed, although the populations selected are more heterogeneous than sorted populations. 
Sorted cells were split into 3 aliquots for ChIP-seq, ATAC-seq and RNA-seq, and processed according 
to respective protocols. Libraries were prepared for all samples. Data analysis was performed by Dr 
Denis Seyres, University of Cambridge. 
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3.2.2.1 Changes in accessible chromatin induced by BRD3 KO 
To investigate differences in open chromatin between WT and BRD3 KO, I generated ATAC-seq data 
sets from iPSC and MK samples (WT and KO). ATAC-seq is a method to map chromatin accessibility 
genome-wide. The method relies on hyperactive T5n transposase to digest the chromatin at accessible 
regions and insert sequencing adapters compatible with sequencing technologies (Adey et al. 2010). I 
prepared ATAC-seq libraries from samples containing 100K cells (section 2.2.15). Single-end Illumina 
sequencing was performed, therefore each fragment was only read by the sequencer in one direction; 
in contrast to paired-end reading where the sequencer reads each fragment from both ends.  
 
A comparison between the WT and BRD3 KO in iPSC and MK samples was performed. Prior to 
differential analysis, we assessed quality of ATAC-seq samples by evaluating bias in read distribution 
over the genome using deepTools plotFingerPrint tool (figure 3.2.1.a). This tool ranks the bins in the 
genome based on number of reads, and plots this ranking against the cumulative sum of reads. This 
method is used to evaluate sample enrichment over input. Samples with low enrichment were not 
considered for analysis. We performed differential analysis with two approaches: a window -based 
approach (csaw R package) and a peak-based method (diffbind R Package). The former approach does 
not rely on peak called by another program. The second merges pre-called peaks in order to create a 
master set of peaks in which reads are counted. None of the methods return differentially opened 
regions between KO and WT conditions, in both iPSCs and MK at a 5% FDR.  
 
We also analysed the correlation, in terms of read number per peak (log(RPKM+1)), between ATAC-
seq replicates in the same cell type. Figure 3.2.1.b shows correlation heatmap for iPSCs (WT and BRD3 
KO), and 3.2.1.c shows correlations for MK replicates.  
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Figure 3.2.1 Quality assessment of ATAC-seq samples. ATAC-seq samples were collected from WT and 
BRD3 KO cells for both iPSC and MK followed by sequencing. a) Enrichment plots of ATAC-seq samples 
over input for iPSC (left) and MK (right). Enrichment calculated using deepTools plotFingerPrint tool. 
b) Heatmap representing correlation between iPSC replicates (WT and BRD3 KO). c) Heatmap 
representing correlation between MK replicates (WT and BRD3 KO).  The corre lation values in b) and 
c) were computed on normalised read count (log(RPKM+1)) over diffbind master set of peaks. d) IGV 
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representation of ATAC-seq peaks called for iPSC and MK over G3BP2 gene promoter. High similarity 
was observed between WT and BRD3 KO replicates. 
 
All samples presented sufficient enrichment over input. Although, in general MK samples had higher 
enrichment than iPSC (figure 3.2.1.a). In this analysis, good genome coverage is shown by low X 
intercept value, and good enrichment by a large area between sample and input curves (diagonal). 
Heatmaps of sample correlation show no separation by condition (WT and BRD3 KO) (figure 3.2.1.b/c). 
We noticed a smaller overall correlation in iPSCs (0.55-0.7) compared to MK (0.80-0.85). This 
difference can be due to a more spread signal in iPSCs. We visually inspected the replicates, using IGV, 
and confirmed the high similarity of accessible chromatin patterns between WT and BRD3 KO (figure 
3.2.1.c). 
3.2.2.2 Changes in H3K27ac chromatin signatures due to BRD3 KO  
To explore how BRD3 regulates the active chromatin landscape, I performed a ChIP-seq experiment 
using H3K27ac and BRD3 antibodies in WT and BRD3 KO cells. The ChIP protocol followed is described 
in section 2.2.16. Essentially, the ChIP-seq protocol relies on the immunoprecipitation step where an 
antibody is used to enrich the DNA bound to the epitope of interest (in here, H3K27ac and BRD3). 
Libraries are prepared from the enriched DNA and next-generation sequencing performed to generate 
ChIP-seq data sets. In my experiments, H3K27ac and BRD3 data sets were generated to analyse any 
loss of H3K27ac mark in BRD3 KO, and consequently to confirm whether those changes were due to 
BRD3 absence. To exclude false positives, the ChIP on BRD3 was also done on BRD3 KO cells. 
Unfortunately, the enrichment above input for BRD3 ChIP-seq on WT data sets was very low and peak 
calling was not performed (data not shown). 
Two of the MK WT samples did not pass quality assessment as the enrichment and signal -to-noise 
ratio were very low. Therefore, only one MK WT replicate remained, and we were not able to 
performed differential analysis for MK. For iPSC, and similarly to ATAC, we used diffbind and csaw 
approaches to identify differences in chromatin acetylation resulting f rom BRD3 KO. Differentially 
acetylated regions were not found with a FDR threshold of 5%.  
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Figure 3.2.1 Quality assessment of ChIP-seq samples. ChIP-seq libraries were prepared from WT and 
BRD3 KO cells for both iPSC and MKs. a) Enrichment plots of ChIP-seq samples over input for iPSC (left) 
and MK (right). Enrichment calculated using deepTools plotFingerPrint tool. b) Heatmap representing 
correlation between iPSC replicates (WT and BRD3 KO). c) Heatmap representing correlation between 
MK replicates (WT and BRD3 KO).  The correlation values in b) and c) were computed on normalised 
read count (log(RPKM+1)) over diffbind master set of peaks . d) IGV representation of ChIP-seq peaks 
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called for iPSC and MK over G3BP2 gene promoter. High similarity was observed between WT and 
BRD3 KO replicates. 
 
Enrichment analysis shows good enrichment for all ChIP-seq samples (figure 3.2.2.a). Correlation 
between WT and BRD3 KO replicates, for the same cell type, was confirmed to be high (figures 
3.2.2.b/c) (MK: 0.77-0.9 ; iPSCs: 0.9-0.96). Differential analysis on MK was not possible due to the 
availability of only one WT replicate. However, we manually analysed the ChIP-seq tracks on IGV, and 
found that WT and BRD3 KO are very similar. As an example, in figure 3.2.2.d, we show ChIP-seq tracks 
for both iPSC and MK cells (WT vs BRD3 KO). The gene promoter shown is associated to this active 
histone mark in both cell lines and presents a typical pattern of acetylation with two ChIP-seq H3K27ac 
peaks (figure 3.2.2.d) and one broader peak for ATAC-seq (figure 3.2.1.d). This combination of patterns 
can be integrated for the detection of regulatory regions. In here, we used it to evaluate differences 
in patterns between WT and BRD3 KO. 
3.2.2.3 Integration of accessible and active chromatin using 
patterns of peaks (RedPop)  
Due to the striking similarity between WT and BRD3 KO data sets analysed in this section, we 
investigate whether any differences could be identified in patterns of ATAC-seq and ChIP-seq data 
integration. Open chromatin around binding sites typically results in a broad, low-resolution peak of 
elevated ATAC-seq coverage (Ernst et al. 2011; Consortium 2012). The surrounding nucleosomes of a 
regulatory element are typically acetylated, leaving two peaks in H3K27ac coverage, spaced a few 
hundred base-pairs apart. By combining the genomic coverage tracks of an open chromatin and an 
H3K27ac assay, regulatory elements can be detected with high precision. Dr Ernest Turro, University 
of Cambridge, developed an algorithm for regulatory element detection using patterns of peaks 
(RedPop) that utilises these patterns. This method for mapping chromatin landscape has not been 
published yet and it is briefly described in section 2.3.2. Figure 3.2.3 shows results of ATAC-seq and 
ChIP-seq data integration for iPSCs and MKs, respectively. No differences in patterns was identified 
between WT and BRD3 KO in both iPSC and MKs.  
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Figure 3.2.3 Humpy pattern search on ATAC-seq and ChIP-seq data sets shows no difference between 
WT and BRD3 KO. a) Covariance analysis principle. Local minimum is identified in regions with high 
covariance value. These regions reflect a depletion in H3K27ac signal and an enrichment of ATAC 
signal. b) computeMatrix and plotProfile tools from deepTools were used to plot profile over identified 
humpy regions. All regions were scaled to the same size (‘humpy start’ and ‘humpy end’ on x -axis) and 
an additional region of 1kb were added for plotting upstream and downstream of the scaled regions. 
The y-axis represents the number of reads normalized to get a 1x depth of coverage (RPGC). 
Sequencing depth is defined as: (total number of mapped reads * fragment length) / effective genome 
size. 
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3.2.2.4 RNA-seq data sets  
To explore the transcriptional regulation function of BRD3, and verify the consequences of the results 
obtained with ATAC-seq and ChIP-seq, I used RNA-seq to study transcriptome expression of WT and 
KO samples at iPSC and MK stages. For all samples, three replicates were collected, and libraries 
prepared according to method described in section 2.2.17. Transcripts abundance were estimated 
with Kallisto [PMID:27043002] and summarized to gene-level with tximport R package [PMID: 
26925227].  
 
 
Figure 3.2.4 RNA-seq correlation heatmap shows no differences between WT and KO. Correlation 
heatmap using log(TPM+1) was computed for RNA-seq experiments. It shows a clear split between cell 
types but no separation by condition (WT and KO). Within each cell types, overall spearman correlation 
is very high. 
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Differential expression analysis between WT and BRD3 KO was performed for iPSC and MK data sets 
using Deseq2. Results are shown in figure 3.2.5. 
 
Figure 3.2.5 Volcano plots show differentially expressed genes between WT and BRD3 KO. RNA-seq 
libraries were prepared from WT and BRD3 KO cells (iPSC and MKs) for pair-end Illumina sequencing. 
Volcano plots representation of differential gene expression analysis in WT vs BRD3 KO for a) iPSC and 
b) MKs. Blue and red dots mark the genes with significantly decreased or increased expression in BRD3 
KO compared to WT samples (FDR>0.05). The x-axis shows log2fold-changes in expression and the y-
axis –log10 (p-value). Horizontal dashed lines show the log10 of the maximum p-value observed at 
FDR 5%.  A low number of differentially expressed genes between BRD3 KO and WT were identified in 
both iPSC and MKs. 
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Differential expression analysis in iPSC and MKs reveals transcriptional differences between BRD3 KO 
and WT. Only 95 genes in BRD3 KO iPSC and 89 genes in BRD3 KO MKs were differentially expressed 
when compared to the respective WTs (supplementary tables 1 and 2 for lists of genes). Gene ontology 
(GO) enrichment analysis was performed using EnrichR (Kuleshov et al. 2016; Chen et al. 2013), but 
gene enrichment associations were low, e.g. only 4/95 dysregulated genes in iPSC were associated 
with mineral absorption mechanisms and 2/89 differentially expressed genes in MKs were associated 
with cAMP metabolic processes. The comparison between differentially expressed genes in iPSC and 
MKs revealed 8 common genes (DYNLT3, CXCL11, ZNF555, S100A6, ZNF560, HIST1H3C, GRID2 and 
CYP2E1). GO enrichment analysis did not revealed a particular biological function for this set of 
common genes. 
In order to determine if any correlation between the set of differentially expressed genes in BRD3 KO 
MKs and transcriptional functions exist, I performed a transcriptional enrichment analysis using 
EnrichR with ENCODE (Consortium 2012) and CHEA (Lachmann et al. 2010) databases. Transcriptional 
enrichment identifies TF binding sites at gene promoters, and it is used to infer associations between 
those genes and the TFs. This analysis can be used to discover the biological function of TFs.  Eight 
genes were identified as being associated with GATA-1 transcription regulation (figure 3.2.6.a).  
To explore whether any of the differentially expressed genes in BRD3 KO MKs had been previously 
associated with MKs or platelet traits, I compared this list with genes previously identified in GWAS 
and metadata analysis on blood traits (Astle et al. 2016; Gieger et al. 2011; J. Li et al. 2013; Vasquez et 
al. 2016). Interestingly, only gene ZFPM2 was common between my data and the list of genes 
previously associated with platelet traits in al l of the references above. Figure 3.2.6.b shows the 
expression levels of this gene in my iPSC and MKs. ZFPM2 encodes for a zinc finger protein known as 
FOG2. ZFPM2 protein product  interacts with elements of the GATA family with important functions in 
cell fate determination (Chlon and Crispino 2012). This gene is highly expressed in platelets, as shown 
in Blueprint data (figure 3.2.6.c). 
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Figure 3.2.6. BRD3 KO disrupts expression of genes previously associated with GATA-1 transcription 
and platelet traits. a) Transcription enrichment analysis (EnrichR) revealed association of differentially 
expressed genes in BRD3 KO MKs (y-axis) and GATA-1 (x-axis for enriched terms), including ZFPM2 
previously associated with platelet traits b) Expression of gene ZFPM2 in my iPSC and MK samples (WT 
and BRD3 KO). Expression levels represented as log(FPKM). c) Expression of gene ZFPM2 in blood cells 
was analysed in Blueprint data (blueprint.haem.cam.ac.uk/bloodatlas). Axis represent blood cell type 
(x-axis) and expression levels as log2fpkm (y-axis).  
 
Following the low number of differentially expressed genes in BRD3 KO cells (both iPSC and MKs), and 
to determine whether a possible compensatory mechanism exists at transcriptional level in 
megakaryopoiesis, I compared the BRD2 and BRD4 transcript levels between WT and BRD3 KO iPSCs 
and MKs (figure 3.2.7). 
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Figure 3.2.7 BRD2 and BRD4 are similarly expressed in WT and BRD3 KO cells. RNA-seq data from 
iPSC and MKs was analysed for comparison of BRD2 and BRD4 transcripts between WT and BRD3 KO 
cells. The x-axis shows genes analysed (BRD2 on left, BRD4 on right) and the y-axis shows gene 
expression levels as log (FPKM). 
 
Comparison of gene transcription levels revealed that BRD2 and BRD4 are similarly expressed between 
WT and BRD3 KO cells (figure 3.2.7). This similarity was confirmed in both iPSC and MK cells. No major 
effect was observed on BRD2 and BRD4 transcription associated with BRD3 depletion.  
 
3.2.3 Discussion  
Despite being identified in a GWAS study as a regulator of platelet traits, BRD3 is not essential for 
generation of megakaryocytes (the platelet progenitor cell). Although, the translational mechanisms 
regulated by BRD3 during megakaryopoiesis remain unknown. In this section, I described experiments 
that aimed at understanding the BRD3 role at regulatory elements during megakaryopoiesis. In order 
to achieve this goal, I investigated differences in accessible and active chromatin induced by the 
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absence of BRD3, and investigated the gene transcriptional differences between WT and BRD3 KO 
model at two stages of megakaryopoiesis.  
I have found that genome-wide chromatin accessibility and H3K27ac marks do not change in absence 
of BRD3 during FoP of MKs. Comparison of ATAC-seq and ChIP-seq on H3K27ac datasets between WT 
and BRD3 KO revealed that both chromatin accessibility and H3K27 acetylation levels are very similar 
(figures 3.2.1 and 3.2.2). This result was confirmed at both iPSC and MK stage of differentiation, and 
reinforces my results in section 3.1 where BRD3 KO did not fail to generate MKs. However, these 
results also augment the concerns around the potential artefactual contribution of overexpression of 
GATA-1 in the FoP protocol. Interestingly, a study looking at the regulation of acetylation on erythroid-
specific chromatin domains found that GATA-1 establishes erythroid-specific acetylation signatures on 
histones H3 and H4 through recruitment of CREB-binding protein (CBP) (Letting et al. 2003). Therefore, 
it is acceptable to hypothesise that GATA-1 overexpression in FoP could induce MK-specific H3K27ac 
signatures similarly in WT and BRD3 KO. This would explain why chromatin activation marks were 
identical in WT and BRD3 KO MKs. To avoid this downfall, a new protocol for generation of MKs should 
be used to perform these experiments. If differences in accessible and active chromatin between WT 
and BRD3 KO were identified, it would be interesting to fully characterise these (promoters, 
enhancers, etc) to investigate BRD3 transcription targets. This data would help understand whether 
BRD3 regulates gene transcription via enhancer-mediated regulation, or at promoters via recruitment 
of transcriptional machinery.  
A second explanation for the similarity between WT and BRD3 KO acetylation signatures in MKs is that 
the establishment of H3K27ac could be BRD3-independent. As an epigenetic reader, BRD3 is capable 
of recognising acetyl lysines and regulate transcription, but the protein might not have an active role 
in the deposition of the histone mark. In this case, the absence of BRD3 would not be expected to alter 
chromatin acetylation, and the genome-wide H3K27ac landscape would be equivalent to WT. 
Interestingly, a study on the role of BRD4 at enhancer regions during differentiation, demonstrates 
that this BET protein does not regulate H3K27ac enrichment at enhancer regions (Lee et al. 2017). 
Additionally, the study shows that BRD4 recruitment to acetylation-activated enhancers is facilitated 
by the cooperation between TFs and CREB-binding protein (CBP). A similar mechanism could regulate 
the recruitment of BRD3 to active regulatory elements in megakaryopoiesis. As mentioned above, 
GATA-1 establishes acetylation via interaction with CBP in erythropoiesis, therefore we can 
hypothesise that if a similar cooperation mechanism regulates BRD3 recruitment in megakaryopoiesis, 
acetylation signatures would not change in the absence of BRD3. In order to investigate whether MK-
specific TFs and HATs recruit BRD3 to regulatory elements during MK formation, a ChIP -seq 
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experiment against BRD3 and histone marks could be performed on directed differentiated MKs 
derived from MK-specific TFs-KO cells and HATs-KO cells. This experiment would allow to identify the 
elements where a particular TF and/or HAT are required for the recruitment of BRD3. The ChIP-seq 
experiment on histone marks would allow to characterise those regulatory elements, e.g. 
H3K4me1+/H3K27ac+ for active enhancers. 
A third hypothesis that could explain the ChIP-seq results of my experiments is that BRD3 might not 
interact directly with H3K27ac regions. A study on histone recognition by bromodomain modules 
reported that BRD3 interacts preferentially with H2K36ac and H2K85ac (Filippakopoulos et al. 2012). 
In this study, the researchers developed a peptide-based array harbouring acetyl lysine sites of N-
terminal tails of histones H3 and H4, to screen for interactions with bromodomains. The lack of 
interaction between H3K27ac on histone tails and BRD3 could explain why H3K27ac signalling is similar 
between WT and BRD3 KO, despite the differences in gene transcription, as BRD3 could regulate those 
genes through binding to a different histone mark. 
My experiments revealed transcriptional differences between WT and BRD3 KO in both iPSCs and MKs 
(figure 3.2.5). The differentially expressed genes in BRD3 KO MKs could be regulated in a GATA-1 
independent manner, explaining the discrepancy between genome-wide acetylation signatures and 
gene expression. A study exploring GATA-1 and BET interaction mechanisms in erythropoiesis revealed 
that, despite the high chromatin co-occupancy between BRD3 and GATA-1, BRD3 KO cells expressed 
all GATA-1 target genes at normal levels upon GATA-1 induction (Stonestrom et al. 2015). Therefore, 
in my experiments, GATA-1 could be controlling acetylation levels and transcription of all its related 
genes, but not transcription of the differentially expressed genes identified. 
 
Although the number of genes differentially expressed was low, the BRD3 role on transcription of 
those genes could explain the GWAS identification of BRD3 as a regulator of platelet traits. BRD3 could 
be part of the transcriptional machinery at the gene promoters, or could regulate gene transcription 
via enhancer occupancy. Interestingly, ZFPM2, was the only differentially expressed gene in BRD3 KO 
MKs that has been previously identified in several GWAS as being associated with platelet traits (Astle 
et al. 2016; Gieger et al. 2011; J. Li et al. 2013; Vasquez et al. 2016). ZFPM2 encodes for FOG2, an 
interactor with members of the GATA family (Chlon and Crispino 2012). If BRD3 regulates ZFPM2, the 
effects of the gene dysregulation in MK generation could have been overcome by the overexpression 
of TFs. Alternatively, as expression of ZFPM2 is higher in platelets than in MKs (figure 3.2.6.b), the 
effects of the gene dysregulation in BRD3 KO cells may only affect platelet formation and not MKs.  
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The transcriptional differences between WT and BRD3 KO cells could also be an indirect effect of the 
BRD3 absence in transcriptional complexes regulating those genes. BRD3 is part of transcriptional 
complexes, including BET proteins and other important proteins (Dawson et al. 2011). The absence of 
one of the protein elements from the complex is probably compensated, at least partially, by other 
proteins in the same complex, but it could stil l have a knockdown effect on transcription. To identify 
BRD3-interactors, a BRD3-pull down experiment could be performed during MK differentiation. 
Knocking out those proteins in iPSC and differentiating into MKs would reveal whether the effects on 
transcriptional were similar to those observed in BRD3 KO, and therefore, whether the results of my 
experiments were an indirect result of BRD3 KO. 
BET proteins are elements of transcriptional complexes, and in order to investigate whether one of 
the other BET proteins compensated the absence of BRD3, I compared BRD2 and BRD4 RNA expression 
levels between WT and BRD3 KO cells (figure 3.2.7). Differences in BRD2 and BRD4 expression were 
not identified, although this does not confirm the absence of a BET compensatory mechanism, as the 
proteins levels were not investigated. A study on the role of BRD3 and BRD4 in myogenesis has 
reported that BET protein expressions varied throughout the time course of the experiments without 
change in mRNA expression (Roberts et al. 2017). In order to further investigate the interactions 
between BET proteins during megakaryopoiesis, I performed the BET inhibition experiments described 
in section 3.3. 
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3.3 BET inhibition in Megakaryopoiesis 
 
3.3.1 Introduction  
In the previous chapters I showed that, using a forward programming model for megakaryopoiesis, 
BRD3 is not essential for MK differentiation. BRD3 KO cells are viable, capable of differentiating into 
MKs, and no effects on chromatin accessibility nor H3K27ac levels or position were observed when 
compared with WT cells. Despite these similarities in chromatin architecture, BRD3 KO cells presented 
a set of differentially expressed genes, probably as the result of BRD3 dysregulation on transcription 
of those genes.  
 
BRD3 protein has been shown to be present in BET protein-containing complexes with important 
transcriptional functions (Dawson et al. 2011). In order to identify nuclear complexes associated with 
BET proteins in leukemia cells, Dawson et al. applied a multiple approach including identification of 
protein complexes that bind to a BET-inhibitor; immunoprecipitation of BET-bound chromatin; and 
identification of protein complexes bound to chromatin marks previously associated with BET 
proteins. This complementary approach enabled the identification of the inhibitor targets (BETs) and 
the proteins associated with those targets. Interestingly, this study revealed that BET proteins 
associate with transcriptionally relevant complexes PAFc and SEC, and may function to recruit these 
complexes to chromatin. BET inhibition affected recruitment of BET-containing transcriptional 
complexes to chromatin, resulting in disruption of gene transcription.  
 
BET inhibitors bind with high affinity to the binding pockets in BETs proteins, thereby resulting in 
displacement of BET proteins from chromatin. The therapeutic potential of these antagonist molecules 
has been explored for treatment of various malignancies, but also to dissect the mechanisms of BET 
regulation in a variety of systems (Junwei Shi and Vakoc 2014). Interestingly, BET inhibition targets 
gene transcription in a selective and cell-dependent manner which could be caused by BET proteins 
occupancy at enhancer elements (Lovén et al. 2013a). As an example, BRD4 has been found to bind 
chromatin at promoters and active enhancers, and its occupancy pattern correlates with that of active 
histone marks, such as H3K27ac (Lovén et al. 2013a). The ablation of BRD4 from such regulatory 
elements, by inhibition treatment, leads to dysregulation of nearby genes (Delmore et al. 2011a). 
However, association of enhancers and genes based on genomic distance is a poor predictor of direct 
regulation. As enhancer activation is a dynamic process during cell cycle and differentiation, it is 
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reasonable to speculate that BET inhibition effect is cell stage-dependent as well as cell type-
dependent.   
 
BET inhibition targets all BET proteins, and therefore disrupts BET complexes that regulate cell 
differentiation. My previous results show that iPSCs are capable of differentiating into MKs in the 
absence of BRD3. Although, the requirements of other BET proteins during megakaryopoiesis, and the 
timing of their function, are unknown. Additionally, BET proteins present in the complexes could 
potentially compensate for the absence of BRD3. Therefore, I used BET inhibition to investigate the 
effects of disrupting BET complexes at different stages of differentiation. The results of these 
experiments could also help unveil the possible role of BRD3 in BET-containing transcriptional 
complexes during megakaryopoiesis, by comparison with BRD3 KO experiments previously described. 
Due to the structure similarities between BETs, protein-specific inhibitors have not yet been developed 
and all BET inhibitors target BET proteins indiscriminately, although with different affinities. In my 
experiments I used BET inhibitor PFI-1, a molecule that binds preferentially to BRD2 and BRD4 (Picaud 
et al. 2013). That study showed that, in a leukemic cell line model, this inhibitor causes G1 cell -cycle 
arrest and induces apoptosis by displacing BRD4 from the chromatin.  
 
 My inhibition experiments were initiated by identifying the maximum inhibitor concentration 
tolerated by iPSCs. By using a concentration at which iPSC survive, I was able to discriminate between 
the outcomes of inhibition during FoP and the possible side effects on cell  proliferation. This 
experiment was followed by a series of experiments to evaluate the impact of BET inhibition on MK 
generation. Finally, I inhibited different stages of MK differentiation and evaluated outcomes based 
on cell surface stage-specific markers. Thus, blood-committed cells were identified based on 
expression of transmembrane glycoprotein CD34 (Sidney et al. 2014) and transmembrane leukosialin 
CD43 (Kessel et al. 2017); MK progenitors and immature MKs were identified based on CD41a and 
CD235a as described previously in section 3.1. 
 
3.3.2 Results  
3.3.2.1 BET inhibition on iPSC proliferation 
BET proteins have been shown to play important roles in stem cell cycle and proliferation, and it was 
important to identify concentrations that would not affect cell proliferation to isolate the real effect 
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on differentiation from a collateral effect on proliferation. This way, any adverse effects observed 
during MK differentiation would be due to the BET biological inhibition during differentiation rather 
than an effect on initial iPSC proliferation. The rationale for this experiment was that the highest 
concentration with no effect on iPSC would be used in the MK forward programming.  
 
The first experiment to test the effect of BET inhibition on iPSC proliferation was performed at 
concentrations ranging from 1nM to 0.2μM. These concentrations were based on literature where the 
same BET inhibitor was used (Picaud et al. 2013). The experiment was initiated by seeding iPSC cells 
(A1ATD1-c WT) at 2e4 cells/well in 24 well plates pre-coated with vitronectin. BET inhibition was 
initiated 24 hr post-seeding. The inhibitor was reconstituted in DMSO and further dilutions were 
completed in media by sequential dilution. Control wells were fed with either regular iPSC media with 
no DMSO (-DMSO), as a control for normal cell proliferation; or media supplemented with DMSO (+ 
DMSO), as a control for DMSO effects on proliferation.  The concentration of DMSO used in the control 
was equivalent to the concentration of DMSO present in the highest concentration of inhibitor. 
Triplicates for each condition were set in each plate and 3 plates were set up to allow timeline analysis. 
Cultures were fed daily for 5 days. At days 1 (D1), 3 (D3) and 5 (D5) a plate was fixed to perform crystal 
violet assay (2.2.14). The results of this experiment are shown in figure 3.3.1. 
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Figure 3.3.1 BET inhibition at 1nM - 0.2μM does not affect iPSC proliferation. iPSC WT were seeded 
on vitronectin coated 24 well plates. 24hr later, inhibition treatment was initiated with media 
containing BET inhibitor in concentrations ranging from 1nM to 0.2μM. Control conditions included 
iPSC routine media (-DMSO) to monitor against iPSC normal growing conditions, and media with DMSO 
(+DMSO) as DMSO was used to reconstitute the inhibitor. (a) Images of cultures stained with crystal 
violet. Cultures were fixed at 3 time points (D1, D3 and D5) and crystal violet proliferation assay 
performed. At each time point, the staining was very similar among all the conditions tested.  (b) 
Normalised absorbance readings. Readings were recorded at 450nm and normalised to the highest 
absorbance reading of DMSO control on D5. All concentrations tested (including the highest = 0.2μM, 
in green) showed similar absorbance readings to control conditions (+DMSO in red), pair end t-test vs 
DMSO at each time point, n=3. 
 
BET inhibition at concentrations between 1nM and 0.2μM did not affect iPSC proliferation.  For each 
time point, crystal violet staining was homogenous throughout the plates, indicating no difference in 
proliferation among all conditions (figure 3.3.1.a). The staining was more intense for older cultures 
indicating that cultures were proliferating along the timeline of the experiment. Both control 
conditions (- DMSO and + DMSO) stained similarly, suggesting that DMSO did not affect cell 
proliferation. Similarly, none of the inhibitor concentrations tested decrease proliferation. This result 
was confirmed by absorbance readings, as all the conditions tested were similar to the controls at the 
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same time point. Absorbance readings were normalised to the +DMSO control condition at D5. Figure 
3.3.1.b clearly shows the increase in absorbance as a result of increased cell numbers , and 
independent of culture condition. The tested inhibitor concentrations did not cause an effect on 
proliferation, as even the highest concentration tested (0.2μM) showed similar absorbance to both 
control conditions. Therefore, I hypothesised that the tested concentrations might have been too low, 
and the experiment described below was performed to test a higher range of inhibitor concentrations.  
 
In the second experiment, in addition to identify the inhibitor concentration that affects iPSC 
proliferation, I also wanted to investigate whether BRD3 KO cells respond differently to BET inhibition 
than WT cells. Therefore, the experiment was performed with WT and KO cells. The experiment was 
performed with inhibitor concentrations ranging from 0.2μM to 10μM. The lowest concentration 
(0.2μM) was the highest concentration tested in the previous experiment. The experiment was 
initiated by seeding iPSC cells (A1ATD1-c WT and BRD3 KO) at 2e4 cells/well in 24 well plates.  The 
inhibition initiation and culturing conditions were similar to the previous experiment. The same set of 
controls as in the previous experiment were used. Triplicates for each condition were set up and 
cultures were maintained for 4 days (3 inhibition days). The cultures were stopped earlier than on the 
previous experiment, as severe differences were observed and some of the cultures did not survive 
for longer than 4 days. Results are shown in figure 3.3.2. 
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Figure 3.3.2 Morphological analysis show effect of BET inhibition on iPSC proliferation. WT and BRD3 
KO cells were seeded at 2e4 cells/well and treated with concentrations of BET inhibitor ranging from 
0.2μM-10μM. Control conditions included media-only (-DMSO) and media supplemented with the 
highest DMSO concentration used to reconstitute the inhibitor (+DMSO). Representative images show 
that the effect of BET inhibition on iPSC proliferation is concentration-dependent. Scale bars, 250 µm. 
 
Representative microscopy pictures show a concentration-dependent effect of BET inhibition on iPSC 
proliferation (figure 3.3.2).  For both WT (figure 3.3.2.a) and BRD3 KO (figure 3.3.2.b), the control 
conditions, and the lower concentration of inhibitor (0.2 μM), presented a high cell monolayer 
coverage as a result of high proliferation. These cells formed large colonies with defined edges, 
characteristic of iPSC. Morphological changes were observed at concentrations higher than 0.2 μM 
with colonies presenting a fibroblastic appearance (spindle appearance). The severity of this 
phenotype was directly associated with inhibitor concentration (figure 3.3.2.a and b). A decrease in 
cell numbers (based on visual observation) was also directly correlated with increase in inhibitor 
concentration. Complete cell death was observed at 5μM and 10μM (figure 3.3.2.a and b, bottom 
right). The effect of BET inhibition on iPSC proliferation was similar between WT and BRD3 KO cells.  
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In order to quantify the inhibitor effects observed on iPSC proliferation, I performed a crystal violet 
proliferation assay. At day 4, the cultures were fixed and stained with crystal violet. The dye was 
dissolved and absorbance readings of the solubilised dye were recorded (section 2.2.14). Darker 
staining, and consequently higher absorbance values, are directly associated with higher cell numbers. 
The results of this proliferation assay are represented in figure 3.3.3.  
 
 
Figure 3.3.3 Crystal violet assay confirms BET inhibition effects on iPSC proliferation for inhibitor 
concentrations higher than 0.2μM. Cultures pictured in figure 3.3.2 were fixed with glutaraldehyde 
and stained with crystal violet. (a) Images of culture plates stained with crystal violet solution. WT and 
KO cells present similar levels of stain for similar conditions. Controls and lower inhibitor 
concentrations resulted in darker staining, confirming higher cell proliferation. A decrease in colour 
intensity was observed with the increase in inhibitor concentration.  (b) Normalised absorbance 
reading of crystal violet. The crystal violet dye was extracted from the cells monolayer and the solution 
collected for reading absorbance at 450nm wavelength. Mean of normalised values to DMSO ± SD, 
n=3, *p<0.05 two-tail t-test against DMSO. 
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Crystal violet stained cultures (WT and BRD3 KO) confirmed the concentration-dependent effect of 
inhibition on iPSC proliferation. Image 3.3.3.a shows the culture plates stained with crystal violet. Each 
plate contains triplicates of all experimental conditions. Staining confirmed the inhibitor concentration 
effect observed with microscopy for both WT and BRD3 KO cells. Control conditions show intense 
staining similarly to conditions with lower inhibitor concentrations. For conditions with high de nsity of 
cells, some of the cell monolayer lifted during the assay processing, hence some missing staining is 
seen in figure 3.3.3.a. Higher concentrations (5 μM and 10 μM) presented clear wells, as a result of 
cell death.  
 
Figure 3.3.3.b shows the absorbance readings for both WT and BRD3KO. The values were normalised 
to +DMSO condition for two reasons: firstly, as in the previous experiment, this condition represents 
a more accurate control as it contains the DMSO present in the inhibitor conditions , which could 
potentially have an effect on proliferation independently from the inhibitor effect; secondly, the 
stained cell monolayer in the -DMSO control condition was significantly affected by processing, 
particularly in the WT plate, introducing an error in the absorbance readings. Absorbance readings 
confirmed the BET inhibitor concentration effect on iPSC proliferation. Lower concentration tested 
(0.2 μM in green) showed significantly similar readings to control (+DMSO in red) as in the previous 
experiment (figure 3.3.1) where this was the highest concentration tested. Absorbance readings 
between WT and KO were very similar for each condition. Statistically significant differences in 
absorbance were recorded for concentrations higher than 0.2 μM (for WT) and 0.5 μM (for BRD3 KO). 
For both clones, the normalised readings steadily decrease with the increase of inhibitor 
concentration. This correlation suggests a direct association between proliferation of cells and the BET 
proteins function.  
 
 
3.3.2.2 BET inhibition on MK FoP – inhibitor concentration test 
The results shown above demonstrate that BET inhibition severely affected iPSC proliferation at 
concentrations higher than 0.2μM. That experiment also showed that low concentrations of BET 
inhibitor used (< 0.2 μM) are tolerable by iPSCs. Following these results, I interrogated whether BET 
inhibition affects MK formation. In order to study BET inhibition on MK generation, 3 concentrations 
were tested: 2nM, 20nM, 200nM. These concentrations are within the concentration range that did 
not affect iPSC proliferation (lower and equal to 0.2μM). These concentrations were chosen in order 
to separate the inhibitor effects on proliferation from the effects on differentiation.  
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BET inhibition was administered from day 1 (1i) during the forward programming protocol (figure 
3.3.4). The choice of inhibition starting day was based on the FoP timeline (figure 3.3.4.a). On day 0, 
cells were infected with viruses containing the TFs, and in order to keep this step undisrupted, 
inhibition was initiated on day 1 (day after infection). A +DMSO control condition was included as this 
was the vehicle used to dissolve the inhibitor. DMSO was used at the equivalent amount present in 
the highest inhibitor concentration (200nM). Cells were cultured as an adherent monolayer, and fed 
with media supplemented with inhibitors until day 10. At day 10, cultures were dissociated and stained 
with surface markers CD235a and CD41a. Population analysis was performed by flow cytometry. Day 
10 cultures normally present a major population of CD235a+ cells, and a secondary population of 
CD235a+/CD41a+ cells, indicating the presence of MK progenitors.  
 
 
Figure 3.3.4 BET inhibition at Fop-day 1 (1i) affects MK progenitor differentiation. (a) Schematics of 
the experiment. Single-cell culture seeded for infection with virus containing 3 MK-specific TFs. 
Cultures were fed according to the FoP MK protocol. Inhibition was started at day 1 (1i) with BET 
inhibitor supplemented in the media at 2nM, 20nM and 200nM. +DMSO control condition was 
included. Cultures were kept adherent until day 10 before dissociation and analysis. (b) Day 10 
dissociated cells were stained with CD235a and CD41a antibodies and analysed by flow cytometry. FS 
109 
 
vs SS plots show gated differentiating population. CD235a vs CD41a plots show the stained populations 
within the differentiating population. BET inhibition severely affects formation of MK progenitors at 
concentrations equal and higher than 20nM. 
 
 
Results in figure 3.3.4 show that BET inhibition affects MK progenitor formation when initiated at day 
1. Flow cytometry analysis of cultures at day 10 are shown in figure 3.3.4.b. The number of events 
identified in the differentiating population (in 3.3.3.b, top panel) was significantly affected at 
concentrations equal and higher than 20nM. The inhibition at the highest concentration tested 
(200nM) resulted in complete cell death. This inhibition effect was also observed in the generation of 
bi-potent (erythroid-MK) progenitor cells (CD235a+) where concentrations ≥ 20nM severely reduced 
progenitor numbers (figure 3.3.4.b, bottom panel).  
 
3.3.2.3 BET inhibition in MK FOP - day 1 vs day 10 inhibition (1i vs 
10i) 
The inhibition experiments described above show that BET inhibition at concentrations ≥ 20nM affects 
generation of MK progenitors (figure 3.3.4), but not iPSC proliferation (figure 3.3.1). The results on 
generation of MK progenitor were observed with inhibition initiated at an early stage of 
differentiation. However, the experiments described do not explore the effect on BET inhibition at 
later stages of MK differentiation. In order to study BET requirement at later stage of MK 
differentiation, the following experiment was designed with inhibition initiated when cells are already 
committed to the MK lineage (CD235a+/CD41a+). The MK-lineage committed population is generally 
observed at day 10 of the FoP MK protocol, hence this was the time point selected to start inhibition 
at later stage (10i). In addition, early inhibition (1i) was also included in this experiment to confirm the 
results obtained in the previous experiment. The same concentrations of inhibitor were tested (2nM, 
20nM and 200nM). 
 
The experiment was initiated by setting up a FoP MK run. Three replicates were subjected to BET 
inhibition on day 1 (1i) at three different concentrations: 2nM, 20nM and 200nM. Controls included 
+DMSO (DMSO 1) and –DMSO (figure 3.3.5). Cultures were kept adherent until day 10, when all cells 
were dissociated and stained with CD235a and CD41a antibodies for flow cytometry analysis. From 
day 10 onwards, three replicates cultures were subjected to BET inhibition (10i) at the same 
concentrations as 1i, and three +DMSO controls were included (DMSO 10). Cultures were kept in 
suspension until day 20 with regular feeds, following the FoP MK feeding schedule. Flow cytometry 
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analysis for CD235a, CD41a and CD42b was performed at days 10 and 20 for 1i and 10i cultures. Day 
10 results (for 1i cultures) were similar to the previous experiment (Appendix 6.2). Figure 3.3.5.b shows 
results for this experiment at day 20 (1i and 10i, respectively).  
 
 
 
Figure 3.3.5 BET inhibition affects early stage of MK differentiation (1i), but not late differentiation 
(10i). (a) Experiment schematics. iPSC WT were single-cell seeded and infected with viruses containing 
the ORF for 3 TFs. BET inhibition was initiated either at day 1 (1i in green) or day 10 (10i in red). Three 
concentrations were used: 2nM, 20nM and 200nM. DMSO control included at equivalent amount used 
to resuspend the highest concentration of inhibitor (200nM). Samples were stained with antibodies 
against CD235a, CD41a and CD42b and analysed by flow cytometry at day 10 and day 20 (yellow time 
points).  
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(b) Flow cytometry results at day 20 for 1i cultures (same cultures as in (b)) and 10i cultures. Cells 
stained with antibodies against CD235a, CD41a and CD42b to analyse MK progenitor population 
(CD3235+/CD41a+) and mature MK population (CD41a+/CD42b+).  
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d)  Comparison of differentiating population (FS vs SS) and MK mature population (CD41a+/CD42b+) at 
day 20 for all inhibition conditions (n=1). MK generation was observed in all conditions, except in 1i at 
concentrations 20nM and 200nM. 
 
BET inhibition affects early stages of MK differentiation. Flow cytometry results demonstrate that early 
BET inhibition (1i) affects megakaryopoiesis prior to MK progenitors (CD235+/CD41a+) differentiation 
(figure 3.3.5.b). At day 10, differentiating population (identified in FS vs SS plot) was not observed for 
inhibitor concentrations higher than 2nM (i.e. 20nM and 200nM). At the lowest concentration used 
(2nM), a lower number of events was observed, but the differentiation pattern of the progenitors was 
similar to DMSO control. The affected cultures (20 nM, 200nM) did not recover from the effects of 
early inhibition (figure 3.3.5.c). Day 20 analysis of these cultures (20nM and 200nM) show an absence 
of differentiated population. Cultures inhibited with 2nM recovered after day 10, and the population 
profile was similar to DMSO control with progenitors loosing CD235a (CD41a+/CD235a-) and gaining 
CD42b (CD41a+/CD42b+) indicating MK maturation (figure 3.3.3.c, top panel). 
 
BET inhibition from day 10 did not affect megakaryopoiesis. At day 10, when 10i cultures were treated 
with the inhibitor, MK progenitors (CD235a+/CD41a+) represented 50% of the live population of cells 
(fig 3.3.5.b). These cultures were not affected by inhibition, at any of the tested concentrations, as day 
20 results show mature MKs in culture (figure 3.3.5.c, 10i). Interestingly, the 10i cultures at the highest 
concentration, 200nM, show a slight delay in MK maturation in comparison with the other conditions. 
Flow cytometry analysis of this culture (10i at 200nM) at day 20 shows that 15% of the differentiating 
population did not acquire CD41a, remaining only CD235a+. This differentiation delay could be the 
result of inhibition on cells that at day 10 were at an early differentiation stage than rest of the 
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population. Altogether, the results of this experiment show that early megakaryopoiesis stages, but 
not late stages, are affected by BET inhibition at concentrations that do not cause an effect on iPSC 
proliferation (≥ 20nM) (figure 3.3.5.d). 
 
3.3.2.4 Defining the megakaryopoiesis stage affected by BET 
inhibition 
The effect of BET inhibition on early megakaryopoiesis was confirmed in the experiments described 
above. However, the mechanism by which BET proteins regulate early megakaryopoiesis has not been 
previously studied. The experiment described below aimed at identifying the megakaryopoiesis stage 
affected by BET inhibition. To do so, samples from inhibited cultures (and corresponding DMSO 
controls) were characterised at different time points, based on surface markers characteristic of early 
MK differentiation stages: haemogenic endothelium (CD144 and CD309), blood-lineage commitment 
(CD43+/CD34+), MK progenitors (CD41a+/CD235a+) and immature MKs (CD41+/CD235-). Inhibition was 
initiated at days 1, 5 or 10 (1i, 5i and 10i) and samples were stained with antibodies for flow cytometry 
analysis at days 5, 10, 15 and 20. Haemogenic endothelium staining is not shown as at day 5 cultures 
were no longer staining positive, either because the timeframe for expression of these markers had 
been missed, or this stage is non-existent in FoP cells. Figure 3.3.6 shows the results for 2 experiments 
performed: experiment 1 only included one replicate, and experiment 2 was performed in triplicate.  
 
 
Figure 3.3.6 BET inhibition affects early differentiation and MK-lineage commitment. iPSC cells were 
differentiated into MKs using FoP. BET inhibition was initiated at days 1, 5 and 10 (i1 (green), 5i (blue) 
and 10i (red)) and samples analysed at days 5, 10, 15 and 18/20 (yellow). Results of flow cytometry 
analysis for blood-commitment (CD34+/CD43+) and MK lineage commitment (CD41a+/CD235a+)  
overtime are shown in b) c) and d). Photos of cultures at day 10 are shown on e).   
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b) Development of blood-committed cells in BET inhibited cultures over time. Samples were stained 
with antibodies against CD34 and CD43 markers. Control cultures shown in black. Inhibition conditions 
(1i, 5i and 10i are shown in dark colours) and corresponding DMSO controls (DMSO 1, DMSO 5 and 
DMSO 10) are shown in light colours. Top plot shows results for experiment 1 (n=1) and bottom plot 
shows results for experiment 2 as mean percentage of (CD34+/CD43+) cells ± SD (n=3). Blood-
commitment was impaired with BET inhibition from day 1, and significantly affected with BET 
inhibition from day 5. 
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c) Development of MK progenitor (CD235a+/CD41a+) cells in BET inhibited cultures over time. 
Differentiation of MK progenitors was impaired with BET inhibition from day 1 (dark green) in both 
experiments. In experiment 2 (bottom) 5i also impaired MK progenitor generation and 10i was 
significantly affected. Top plot shows experiment 1 (n=1) and bottom plot shows results for 
experiment 2 as mean percentage of (CD235a+/CD41a+) cells ± SD (n=3). 
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d) Development of MK-lineage committed cells in BET inhibited cultures over time. Samples stained 
with antibodies against CD235a and CD41a. Populations shown have lost CD235a and retained CD41, 
prior to expression of CD42b. In both experiments, 1i cultures did not form immature MKs. In 
experiment 2, 5i also failed to generate MKs and 10i cultures were significant affected with a 
decreased percentage of immature MK in culture. Top plot shows experiment 1 (n=1) and bottom plot 
shows results for experiment 2 as mean percentage of (CD41a+/CD235a+) cells ± SD (n=3). 
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e) Light transmission images of cultures at day 10 prior to dissociation (experiment 2). All control 
conditions presented cell clumps in suspension, characteristic of differentiating FoP cells (generally 
CD235a+/CD41a+). Inhibited cultures at day 1 (1i) and day 5 (5i) presented undifferentiated single-cells 
in suspension. Scale bars, 250 µm. 
 
BET inhibition impaired MK differentiation prior to blood-commitment as well as MK progenitor 
commitment. In experiments shown in figure 3.3.6, condition 1i did not differentiate and eventually 
died. In both experiments, generation of blood-committed cells (CD34+/CD43+) was severely impaired 
in 5i cultures (figure 3.3.6.b, dark blue). When inhibition was initiated (day 5), control cultures were 
equally around 10%-20% CD34+/CD43+ in both experiments. The development of these cells over time 
was very similar in both experiments. Interestingly, the development of MK progenitor cells 
(CD235a+/CD41a+) was very different for 5i conditions in both experiments (figure 3.3.6.c dark blue). 
In experiment 1, 5i cells developed MK progenitors to a similar level to the control conditions, whilst 
in experiment 2 the cells in 5i condition did not survive. The same result was observed at the next 
stage of differentiation (CD41+/CD235a- immature MKs) with 5i cells in experiment 1 forming immature 
MKs and 5i cells in experiment 2 not surviving. This difference in results is probably due to the disparity 
in differentiation pattern observed in both experiments. At day 10, control cultures in experiment 1 
were 50% CD235a+/CD41a+  while in experiment 2 cultures were only 20% CD235a+/CD41a+  (figure 
3.3.6.c, black). Differentiation of 10i cells was not affected in experiment 1, but differentiation was 
severely impaired in experiment 2.  This suggests that BET proteins are required prior to MK progenitor 
generation.  
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3.3.3 Discussion  
BET proteins have been shown to be part of multiprotein  complexes playing important roles in 
transcription (Dawson et al. 2011). The role of these complexes, and individual BET proteins, in 
megakaryopoiesis has never been investigated. In this chapter, I described a series of experiments 
designed to study the effects of inhibiting BET proteins (BRD2, BRD3 and BRD4) during MK 
differentiation, in order to understand the requirements of these proteins during FoP of MKs. BET 
inhibitors have a high affinity to the BET family, and therefore are an important tool to study the roles 
of BET proteins in cell biology. Several BET inhibitors are currently being tested for the treatment of 
haematopoietic cancers and inflammatory diseases (Prinjha, Witherington, and Lee 2012). 
Understanding the functions of BET proteins in megakaryopoiesis will allow a better prediction of BET 
inhibition effects on MKs and platelets in patients undertaking the treatments.  
 
BET proteins are required for iPSC maintenance as BET inhibition affects proliferation. The FoP 
protocol is established on iPSC, therefore this study was initiated with the determination of the 
inhibitor concentration range tolerated by iPSC. This allowed the uncoupling of the inhibition effects 
on cell proliferation from the effects on cell differentiation during FoP. Using proliferation assays, I 
determined that iPSC are resistant to the inhibitor used (PFI-1) at concentrations below 200nM (fig. 
3.3.1, 3.3.2 and 3.3.3). In agreement with these results, the inhibitor has been shown to have a high 
affinity to all BET proteins at IC50 values ranging from 98nM-220nM for BRD4 (BD1, BD2) and 111nM 
for BRD2 (Picaud et al. 2013). In the same study, PFI-1 inhibitor was shown to affect cell survival of 
sensitive cells at concentrations higher than 100nM, and resistant cells did not respond to inhibition 
concentrations below 5-10μM. In my experiments, if the tested concentrations had no effect on iPSC 
proliferation, I would have further increased the inhibitor concentrations. If the iPSCs were insensitive 
to the inhibitor, this would suggest that BET proteins have no function on iPSC proliferation. However, 
the role of BET proteins on cell cycle progression has been extensively reported in human cell line 
models (LeRoy, Rickards, and Flint 2008a; Maruyama et al. 2002; Dey et al. 2000). In particular, BRD4 
has been shown to stimulate G2/M transition (Dey et al. 2000) and regulate cell cycle progression (Dey 
et al. 2003). Therefore, my results on BET inhibition of iPSCs are aligned with previous reports. After 
determining the inhibitor concentration at which iPSCs were insensitive, I designed inhibition 
experiments to evaluate effects of BET proteins ablation on MK differentiation.  
 
BET inhibition impaired early (1i), but not late (10i), MK differentiation, suggesting that BET proteins 
have a stage-dependent function in early megakaryopoiesis. At day 1 of FoP, cells are still very 
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immature and are cultured in mesoderm media (BMP4 supplementation), whilst at day 10 the 
presence of MK progenitors (CD235a+/CD41a+) is normally observed. In my experiments, a significant 
difference was observed in differentiation of progenitors and mature MKs following inhibition at 
different stages of FoP. Using flow cytometry analysis of cell surface markers, I observed that BET 
inhibition severely impaired megakaryopoiesis prior to MK progenitor stage (figure 3.3.6.b, c and d). 
These results suggest that BET proteins regulate early haematopoietic differentiation, but are 
dispensable after the generation of MK progenitors. If no significant differences had been found upon 
inhibition at neither stage, this would suggest that BET proteins do not regulate megakaryopoiesis. On 
the other hand, if inhibition affected several stages, it would suggest that BET proteins were essential 
throughout megakaryopoiesis.  
These findings are consistent with earlier research on the effects of BET inhibition in early 
haematopoietic differentiation. It has been reported that BRD4 interacts with haematopoietic TFs, and 
BET inhibition suppresses the functional outcome of the haematopoietic TFs (Roe et al. 2015). 
Furthermore, BRD4 has been shown to interact with TWIST, a TF that controls mesodermal 
development, and this interaction is disrupted by BET inhibition (Jian Shi et al. 2014). In a different 
study, BRD4 knockdown affected mesodermal gene expression, indicating a BRD4 regulatory role in 
mesodermal differentiation (Rodriguez et al. 2014a). Thus, it can be hypothesised that the disruption 
of BRD4-TFs interactions could have affected mesoderm differentiation in 1i cultures. Interestingly, a 
study exploring the effects of BRD4 at different stages of thymocytes differentiation found that BRD4 
deletion results in reduced proliferation rates and impaired early cell development (Gegonne et al. 
2018). That study also showed that BRD4 deletion did not affect late stage of thymocytes 
differentiation, despite the protein normally being expressed at that stage. That report is in agreement 
with the hypothesis that BET proteins are required for the recruitment of cell -specific TFs and 
transcriptional regulatory complexes to chromatin during gene activation (Bhagwat et al. 2016b), but 
have a seemingly redundant function after cell-identity acquisition. In order to study which BET protein 
regulates early megakaryopoiesis, a ChIP experiment on BET proteins (especially BRD4 and BRD2) 
could be performed to investigate these proteins occupancy at genes whose transcription is affected 
by BET inhibition. Thus, if a gene promoter or enhancer was occupied by a BET protein, and its 
expression changed following BET inhibition, we could infer that the BET protein identified had an 
active role in regulation of those genes. 
One significant flaw in my experiments, as mentioned in earlier sections, is the overexpression of TFs 
in the chosen differentiation model. In the context of BET inhibition, Lamonica et al. showed that BET 
inhibition displaces both BRD3 and GATA-1 from chromatin with inhibitory consequences in erythroid-
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specific gene expression (Lamonica et al. 2011). However, this study only focused on the interactions 
between BRD3 and GATA-1, neglecting the possible contribution of other BET proteins in the 
regulation of GATA-1 target genes. In fact, a different study in erythropoiesis, showed that depletion 
of BRD2 fails to promote expression of GATA-1 target genes, similarly to the effect of BET inhibition 
(Stonestrom et al. 2015). Together, these studies show that BET inhibition affects GATA-1-dependent 
gene signatures in erythropoiesis, as BETs are required for stabilisation of GATA-1 under normal 
conditions. In my experiments, the failed differentiation of 1i cultures could be explained if BET 
proteins were required for GATA-1 recruitment only at early stages.  
 
The discrepancy between the BRD3 KO results (section 3.1) and the inhibition results (section 3.3) on 
MK generation suggests distinct roles for BET proteins in megakaryopoiesis. Firstly, the BRD3 
deficiency could be compensated by one of the other BET proteins. This, at least partially, 
compensation of protein functions has been previously suggested within the BET family as BRD2 
compensates BRD3 during erythropoiesis (Stonestrom et al. 2015). This compensation would have 
been prevented in the inhibition experiments, explaining the discrepancy in results between BRD3 KO 
and inhibition experiments. Secondly, BET proteins BRD4 and/or BRD2 might be critical for MK 
differentiation either individually or as part of transcriptional complexes that are disrupted by BET 
inhibition. In order to clarify these hypothesis, I designed an experiment where BET proteins were 
ablated in iPSCs and differentiated into MKs. The BET KOs were designed either individually or in 
combination (e.g. BRD2 KO, BRD2+3 KO, etc) to understand individual, as well as compensatory 
functions between BET proteins during megakaryopoiesis. This experiment is described in section 3.4. 
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3.4 BET regulation in Megakaryopoiesis 
 
3.4.1 Introduction  
The results shown above led to the hypothesis that either BRD3 is not essential in megakaryopoiesis 
or its functions are compensated by one of the other BET proteins. If the compensation hypothesis 
was correct, it would explain the discrepancy between the inhibition and the BRD3 KO results, as the 
surrogate BET protein would be inactivated by inhibition. On the other hand, if BRD3 KO results are 
due to BRD3 simply being redundant, the inhibition experiments revealed the critical role of other BET 
proteins. Therefore, this section describes the experiments designed to investigate the role of 
individual BET proteins, and understand the possible compensatory effects among BET proteins during 
MK differentiation. 
 
To investigate whether BET proteins compensate BRD3 absence, and/or which BET protein is essential 
for megakaryopoiesis, a knockdown experiment was initially designed. CRISPRi or RNAi are commonly 
used systems to generate selective knockdowns, and these methods differ mainly on their targets, as 
CRISPRi targets DNA while RNAi targets mRNA. CRISPRi offers lower off-target effects, and a cleaner 
depletion of the target gene than RNAi (Stojic et al. 2018). To perform the experiments in this section, 
I initially designed a system comprising stably expressed dCAS9 fused to a transcription repressor 
domain KRAB. Being an rTetR (reverse tetracycline repressor) inducible system, it would be induced in 
the presence of tetracycline, and this feature could be exploited at different stages of differentiation. 
This is an important feature, as it would be interesting not only to identify the essential BET(s) 
protein(s) in megakaryopoiesis, but also the timing when the protein is acti ve.  The system also 
contained sgRNAs targeting individual BET proteins promoters that, upon induction, lead the dCas9-
KRAB to the target sequence. The plasmids containing dCas9-KRAB and BET-targeted sgRNA inserts 
were stably integrated into iPSCs by viral infection (plasmid maps in appendix 6.1.3). Unfortunately, 
the system failed to induce dCas9 once it had been induced once. This presented a challenge as upon 
the induction to verify integration, the system became unusable. Due to time constraints, the dCas9-
KRAB system was not optimised, and this study plan was replaced by the generation of individual and 
combinations of BET KOs using CRISPR/Cas9n. 
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The aim of this experiment was to generate iPSCs deficient in individual or combinations of BET 
proteins (BET KOs), and differentiate these cells into MKs. The BET KOs included individual (BRD2 KO, 
BRD3 KO and BRD4 KO) and a combination of KOs (BRD2+3, BRD2+4, BRD3+4 and BRD2+3+4). This 
approach allows to evaluate the effects of each individual BET protein, as well as the possible 
redundancy in BET protein function, during the differentiation of MKs. Thus, for example if BRD2 
compensates the absence of BRD3 in megakaryopoiesis as it does in erythropoiesis, the BRD2+3 KO 
would not be able to generate MKs, while the BRD2 KO could or not be successful. Equally, this 
experiment would help to reveal if one of the BET proteins was absolutely essential for MK 
differentiation, as all of the lines with a KO of the protein would not generate MKs.  
 
3.4.2 Results  
3.4.2.1 Design and synthesis of CRISPR/Cas9 system to target BRD2 
and BRD4 
The aim of this work was to generate BET KO cell lines using CRISPR technology. The  strategy used was 
similar to the generation of BRD3 KO (section 3.1) with 2 sgRNAs and Cas9 nickase directed at the 
target region. The target regions for BRD2 and BRD4 were identified by evaluation of the protein-
coding transcripts using Ensembl, followed by the selection of the transcripts significantly expressed 
in MKs using Blueprint data (transcripts with FPKM ≥1). The BRD2 and BRD4 targeted transcripts are 
listed in table 3.4.1. 
 
PROTEIN TRANSCRIPT LOG2 FPKM IN MKS 
BRD2 ENST00000374825 1.726150138 
 ENST00000607833 3.567799186 
 ENST00000449085 2.71428508 
BRD4 ENST00000263377 1.681969935 
 ENST00000371835 1.919117427 
Table 3.4.1 Targeted transcripts for BRD2 and BRD4 KO generation. Transcripts significantly 
expressed in MKs, according to Blueprint data. Transcript information extracted from Ensembl.  
 
The target sites were established based on the first common exon between the transcripts for each 
gene (figures 3.4.1 for BRD2 and 3.4.2 for BRD4). sgRNA sequences were designed using Wellcome 
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Trust Sanger Institute CRISPR online tool (https://www.sanger.ac.uk/htgt/wge/) with selection of the 
25% best targets, based on sequence homology prediction (off -targets prediction).  
 
3.4.2.1.1 BRD2 targeting 
 
 
Figure 3.4.1 Schematics of BRD2 targeted transcripts. BRD2 transcripts expressed in MKs were 
identified from Blueprint data. First common exon (4) was selected to knockout all the protein 
variations in MKs. Within exon 4, sgRNA sequences were determined and sequence homology verified 
(BLAST) in order to minimize off-target effects. sgRNA sequences (purple) and PAM sequences (red 
boxes) shown.   
 
 
Exon 4 of the BRD2 longer transcript is the first common exon among the BRD2 transcripts expressed 
in MKs, and therefore it was selected as the target region. Despite being a small exon (138 bp), four 
sgRNAs were identified with low sequence homology to other regions in the genome (verified by 
BLAST). 
 
3.4.2.1.2 BRD4 targeting 
The first common exon in both BRD4 transcripts expressed in MKs corresponds to exon 10 of the longer 
transcript, and therefore the BRD4 was targeted in 2 regions to avoid partial expression of transcript 
ENST00000263377 that could lead to a partially or completely active protein. Exons 10 and 11 were 
not targeted, despite being common exons between both transcripts, because the sgRNA sequences 
found in that region presented high homology with distant genomic regions (off -targets).   
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Figure 3.4.2 Schematics of BRD4 targeted transcripts. Two BRD4 transcripts expressed in MKs were 
identified from Blueprint data. Due to the transcripts significant length difference, two regions were 
targeted. sgRNA sequences were identified and sequence homology verified (BLAST) in order to 
minimize off-target effects. Exons 10 and 11 were not targeted due to high sequence homology with 
other regions that can lead to off-target effects. Exons 12, 13 and 14 are short exons, and therefore 
were all targeted to maximize success. sgRNA sequences (purple) and PAM sequences (red boxes) 
shown.   
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The selected sgRNAs were cloned into vectors pSpCas9n(BB)-2A-GFP (for BRD2 sgRNAs) and 
pSpCas9n(BB)-2A-tomato (for BRD4 sgRNAs) (section 2.2.10.2). The cloning success was confirmed by 
restriction digestion and Sanger sequencing (appendix 6.2.2 and 6.2.3), before the plasmids were 
expanded. T7 endonuclease (section 2.2.10.5) was performed to test target efficiency of the sgRNAs 
(figure 3.4.3). Primer sequences are listed in table 2.2.1. 
  
 
Figure 3.4.3 T7 endonuclease assay confirms BRD2 sgRNAs target efficiency. PCR strategy for T7 
endonuclease for a) BRD2 and b) BRD4. c) BRD2 sgRNAs (10, 11, 12 and 13) located on exon 4 were 
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tested in the T7 assay. Gel showing T7 endonuclease assay results. HEK293T cells were transfected 
with sgRNAs targeting BRD2 locus and Cas9. gDNA extracted and PCR performed, before T7 
endonuclease assay was complete. Results for individual sgRNAs transfections are shown in lanes 5 
(sgRNA10), 7 (sgRNA11), 9 (sgRNA12) and 11 (sgRNA13). All of these sgRNAs successfully created indels 
at the BRD2 locus. WT (lane 1) and Cas9 only (lane 3), as well as non-T7 digested transfected conditions 
(lanes 2, 4, 6, 8, 10, 12) were loaded on a gel as controls for the T7 digestion.   
 
 
All selected sgRNAs were successful as smaller bands than the WT band were observed. This indicates 
T7 endonuclease digestion at mismatches near the disrupted region. sgRNAs targeting BRD4 were not 
tested by T7 endonuclease as primers for the region had not been optimised. Although, the 
nucleofection for generation of the BET KOs was performed with BRD2 and BRD4 targeting sgRNAs.  
3.4.2.2 Generation and confirmation of BET KO clones 
 Plasmids containing sgRNAs were nucleofected either into WT cells (for all BRD2 and BRD4 KO 
combinations) or into BRD3 KO cells (for all the combinations including BRD3 KO)  (section 2.2.10.4). 
Combinations of sgRNAs nucleofected are listed in table 3.4.2.  
 
TARGET KO SGRNAS NUCLEOFECTED IPSC LINE 
BRD2 sgRNA.BRD2.KO_10,11,12,13 A1ATD1-c WT 
BRD4 sgRNA.BRD4.KO_1,2,8,9,10,11,12,13 A1ATD1-c WT 
BRD2+BRD4 sgRNA.BRD2.KO_10,11,12,13 
sgRNA.BRD4.KO_1,2,8,9,10,11,12,13 
A1ATD1-c WT 
BRD2+BRD3 sgRNA.BRD2.KO_10,11,12,13 A1ATD1-c BRD3 KO 
BRD4+BRD3 sgRNA.BRD4.KO_1,2,8,9,10,11,12,13 A1ATD1-c BRD3 KO 
BRD2+BRD3+BRD4 sgRNA.BRD2.KO_10,11,12,13 
sgRNA.BRD4.KO_1,2,8,9,10,11,12,13 
A1ATD1-c BRD3 KO 
Table 3.4.2 sgRNAs nucleofected into iPSC for generation of BET KOs. 
Nucleofected cells were individually sorted into 96 well plates coated with vitronectin. Using a 
different fluorescent protein per gene facilitated sorting of clones containing sgRNAs targeting 
different genes (GFP for BRD2, and tomato for BRD4). Individual clones (36 in total) were expanded 
until stable lines were obtained. gDNA was extracted from each clone for PCR amplification across the 
target region (same primers as represented in figure 3.4.3.a and b). The PCR products sizes were 
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compared with WT PCR product. Clones with smaller product sizes, indicating deletions in the target 
sequence, were selected for Sanger sequencing. From a total of 36 unconfirmed KO clones, the 
following were sequenced: 8 BRD2 KOs, 6 BRD2+3 KOs, 9 BRD4 KOs, 8 BRD3+4 KOs, 4 BRD2+4 KOs and 
only 1 was a BRD2+3+4 KO. PCR products from BRD2+3 revealed WT for BRD2. Similarly, sequencing 
of BRD4 exon 2, in unconfirmed BRD4 KOs, revealed that none of the clones was a BRD4 KO and PCRs 
of exons 12, 13 and 14 were not successful despite several attempts. Due to the limited amount of 
time left, the study of BRD4 KOs was abandoned for the scope of this thesis, including BRD4 KO, 
BRD2+4 KO, BRD3+4 KO and BRD2+3+4 KO. Therefore, work was carried out on BRD2.  
 
PCR products from one promising BRD2 KO clone (following sequencing) were inserted into pGEM-T 
easy vector to confirm the deletions. pGEM-T was transformed into E.coli and blue-white 
recombination screening performed by using X-gal in the agar plate (section 2.2.10.3). Six white 
colonies from each clone were expanded and mini preps sent for sequencing.  Figure 3.4.4 shows 
confirmation of the BRD2 KO. 
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Figure 3.4.4 Confirmation of BRD2 KO clone. (a) Alignment of sequenced PCR products from the 
successful BRD2 KO to the BRD2 gene sequence. (b) Western blot confirmation of BRD2 protein KO. 
(c) Morphological comparison between WT, BRD2 KO and BRD3 KO (studied in sections 3.1 and 3.2). 
Scale bars, 250 µm. 
 
Sanger sequencing revealed deletions in exon 4 of BRD2, and the absence of protein was confirmed 
by western blotting. Morphological assessment of BRD2 KO reveals differences to the WT and BRD3 
KO. Transmitted light images (figure 3.4.4.c) show that BRD2 KO presents an uncharacteristic iPSC 
morphology, as colonies have less defined edges than both WT and BRD3 KO. Also, the cell morphology 
of BRD2 KO is more stretched than the typical iPSCs round cell morphology.  
 
3.4.2.3 Characterisation of BRD2 KO - proliferation and pluripotency  
A proliferation assay was performed motivated by an observed difference in growth between WT and 
BRD2 KO cells. iPSCs (WT and BRD2 KO) were dissociated into single cell suspensions and seeded onto 
vitronectin coated 48 well plates. Cells were cultured with standard iPSC media for 6 days. Crystal 
violet assay was performed at days 4 and 6 (section 2.2.14). The results of the proliferation assay are 
shown in figure 3.4.5. 
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Figure 3.4.5 Proliferation assay reveals decreased growth phenotype for BRD2 KO. Single cell cultures 
were seeded at 2e4 and 4e4 cells/well in 48 well plates, and cultured for 6 days. Cultures were fixed 
with glutaraldehyde at days 4 and 6 and crystal violet assay performed. Experiment included triplicates 
for each condition. (a) Microscopic images (40x) of crystal violet stained cultures show atypical cell 
morphology of BRD2 KO in comparison with WT. Scale bars, 250 µm. (b) Absorbance readings at 450 
nm. Dye was dissolved and absorbance read at 450 nm. Represented are the mean absorbance ± SD, 
n=3, *p<0.05, **p<0.001 two-tail t-test against WT in similar condition. 
 
Proliferation assay confirms growth and morphology phenotypes observed for BRD2 KO. Crystal violet 
staining revealed differences in colony growth with the BRD2 KO clone staining more sparingly than 
WT. Microscopic images confirm the spindle morphology of BRD2 KO (figure 3.4.5.a). These cultures 
present a differentiated morphology that is completely atypical of iPSCs. Absorbance readings 
revealed that BRD2 KO proliferates significantly slower than WT.  
 
The morphological phenotype observed in BRD2 KO motivated a pluripotency test to analyse whether 
this is a real phenotype, or whether these cells were differentiated. The flow cytometry antibodies for 
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pluripotency markers (Tra-1-60 and SSEA4) used for characterisation of BRD3 KO (section 3.1) were 
used in this test. Cells from WT and BRD2 KO iPSC cultures were dissociated and stained with 
antibodies against Tra-1-60 and SSEA4 (section 2.2.8). Results of the BRD2 KO pluripotency test are 
shown in (figure 3.4.6).  
 
 
Figure 3.4.6 Pluripotency analysis reveals BRD2 KO population heterogeneity. Single cells were 
stained with antibodies against SSEA4 and Tra-1-60. Unstained single cells were used as negative 
control. BRD2 KO cells analysed (right) presented heterogeneously expressed SSEA4 and Tra-1-60. The 
WT cells (left) presented high levels of expression for both markers tested.  
 
 
Flow cytometry analysis revealed heterogeneity in expression of pluripotency markers on the surface 
of BRD2 KO cells (figure 3.4.6). These cultures contained cel ls with a range of SSEA4 and Tra-1-60 
expression, including a small percentage of cells not expressing SSEA4 ( right panel). This could reflect 
BRD2 functions in cell cycle. However, the majority of the BRD2 KO population sustained a high level 
of pluripotency, indicating that BRD2 is not essential for pluripotency maintenance. WT cells presented 
a homogeneous population with high expression of both SSEA4 and Tra-1-60 (figure 3.4.6, middle). 
 
3.4.2.4 Forward programming of BET KOs into MKs 
In order to investigate whether BRD2 is essential in megakaryopoiesis, I differentiated BRD2 KO into 
MKs using the FoP protocol. WT and BRD3 KO were also included to compare differentiation efficiency 
in the same FoP experiment. Triplicates experiments were performed for each clone. The FoP protocol 
was followed as described previously and at day 10 (dissociation day), samples were stained with 
antibodies against CD34, CD43, CD235a and CD41a for identification of blood-commitment and MK 
progenitors differentiation potential, expected at day 10. Results are shown in figure 3.4.7. 
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Figure 3.4.7 BRD2 KO differentiates into MK lineage. BRD2 KO was differentiated into MKs in a FoP 
experiment, alongside with WT and BRD3 KO. At days 10 and 15, cultures were stained with surface 
marker antibodies to study the cultures differentiation potential. a) Microscopy images of WT, BRD2 
KO and BRD3 KO cultures in suspension at day 10. The clumps observed are characteristic of day 10 
cultures and represent MK progenitor cells. Scale bars, 250 µm. b) Percentage of differentiating cells 
in culture, identified by flow cytometry using FS vs SS gating strategy. c) Percentage of blood-
committed cells (CD34+/CD43+) in culture. d) Percentages of MK progenitors (CD235a+/CD41a+)  
present in culture. Mean % of positive stained populations ± SD, n=3, *p<0.05 two-tail t-test against 
WT in the same condition (b,c and d). 
 
 
BRD2 KO are capable of differentiating into MK lineage cells. At day 10 of FoP differentiation, BRD2 KO 
cells were morphologically similar to both WT and BRD3 KO with agglomerates of cells in suspension, 
typical of day 10 differentiating cultures (figure 3.4.7.a). Flow cytometry analysis confirmed the 
differential potential of BRD2 KO, as over 40% of cells in culture were differentiating at day 10 and 
30% at day 15 (figure 3.4.7.b). This population is identified through FS vs SS gating. Comparatively, the 
amount of differentiating cells in WT and BRD3 KO cultures was slightly higher at day 10 (60%), but 
similar to BRD2 KO at day 15 (figure 3.4.7.b). Surface markers staining at day 10 shows that 15-20% of 
differentiating cells in the 3 cultures were similarly expressing CD34 and CD43 (figure 3.4.7.c), and 
around 25% of differentiating cells were MK progenitors (CD235+/CD41a+) (figure 3.4.7.d). This 
indicates that the potential to differentiate into blood-committed and MK-committed lineage is not 
disrupted by the absence of neither BRD2 nor BRD3. The same result was observed at day 15 with 
BRD2 KO differentiating similarly to BRD3 KO and WT (figures 3.4.7.c and 3.4.7.d).  
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3.4.3. Discussion 
The previous results described in my thesis raised the hypothesis that BRD3 could be compensated by 
another BET protein. Additionally, I reported that a BET antagonist inhibits the differentiation of early 
stages of MK generation. This second result suggests that one of the BET proteins, or a combination 
of them, is essential for the formation of MKs. However, it remains unknown which BET protein plays 
a critical role in megakaryopoiesis. The identification of the critical BET protein, and their function in 
megakaryopoiesis, would allow further understanding of the process regulating MKs and platelets 
differentiation. This would lead to better prediction of the consequences on MKs and platelets 
resulting from BET inhibitor treatments. 
 
In order to investigate which BET protein is required for differentiation of MKs, I designed a set of 
experiments to KO BET proteins individually and in combination. These experiments would allow to 
study individual BET protein requirements for the process of MK formation, but also to investigate any 
potential redundancies in protein functions. Due to time constraints, I was only able to generate and 
characterise the BRD2 KO. The morphology of BRD2 KO iPSCs is dissimilar to that of WT and BRD3 KO, 
suggesting that BRD2 could have a role in regulation of genes important for the determination of the 
cytoskeleton structure. Despite this difference in morphology, BRD2 KO cells are pluripotent and are 
capable of generating MK progenitors. The results of my experiments show that BRD2 is not required 
for the differentiation of blood-committed cells (figure 3.4.7.c) nor for the formation of MK 
progenitors (figure 3.4.7.d). Together the differentiation of BRD2 KO experiment shows that BRD2 is 
not essential for the differentiation of pluripotent cells into the MK-lineage, using the FoP system.  
 
However, the redundancy hypothesis among BET proteins could also apply to the BRD2 KO. If BRD2 is 
being compensated by other BETs, the generation and differentiation of combinatorial KOs would 
allow to identify which of the BET proteins has compensatory functions. Once identified the 
redundancy, and in order to confirm it, an overexpression experiment could be performed, where both 
proteins would be singularly overexpressed in the combinatorial KO. For example, if BRD3 
compensates BRD2 during megakaryopoiesis, BRD2+3 KO would not generate MKs, and the 
overexpression of BRD3 or BRD2 in BRD2+3 KO would potentially recover the MK formation ability 
observed in BRD2 KO and BRD3 KO. 
 
In my experiments, both BRD2 KO and BRD3 KO were capable of forming MK progenitors, suggesting 
that individually BRD3 and BRD2 are not essential during early stages of megakaryopoiesis. 
133 
 
Considering that BET inhibition impaired differentiation of MKs, I hypothesise that BRD4 might play a 
major role in early MK differentiation. The differentiation of BRD4 KO into MKs would answer this 
question, because if BRD4 was essential, BRD4 KO would not form MKs. This hypothesis is supported 
by previous studies where BRD4 was reported to coactivate lineage-specific TF TWIST during normal 
mesoderm differentiation (Shi et al. 2014). Mesoderm is the first stage in FoP MK differentiation, and 
the inhibition of BRD4 could be the cause for the impairment of early MK differentiation. Together the 
results reported in this section show that BRD2 is not essential for generation of MK progenitors using 
the FoP protocol. 
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Chapter 4 
Conclusion and future work 
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The association of BRD3 as a regulator of PMV and PDW in a GWAS for platelet traits (Astle et al. 2016), 
and the current testing of BET inhibitors in clinical trials for haematological cancers (Abedin et al. 2016; 
Doroshow et al. 2017) are driving motives to understand the role of BRD3 in platelet differentiation. 
The aim of my project was to study the role of BRD3 in megakaryopoiesis, the process that generates 
platelet progenitors. In order to do so, I conducted my experiments using a megakaryopoiesis model, 
forward programming (FoP), developed by Dr Thomas Moreau (Moreau et al. 2016). 
 
Despite being a GATA-1 direct interactor, BRD3 is dispensable for MK differentiation using the MK-FoP 
protocol. The generation of a BRD3 KO iPSC model proved that BRD3 is not required for the 
maintenance of pluripotent cells (figures 3.1.3.c and 3.1.5). BRD3 KO cells are also capable of 
differentiating into MKs, indicating that BRD3 is not essential during megakaryopoiesis (figure 3.1.8). 
In fact, my experiments show that BRD3 does not play a role in regulating chromatin architecture 
(figure 3.2.1) nor H3K27 acetylation signatures (figure 3.2.2) in megakaryopoiesis. These results align 
with previously reported studies showing that BRD3 is dispensable for GATA-1-induced transcription, 
despite the direct BRD3-GATA-1 interaction (Stonestrom et al. 2015). I suggest three possible 
hypothesis for the lack of detectable phenotype upon BRD3 ablation.  Firstly, BRD3 could simply be 
redundant, or have little regulatory functions in the differentiation of MKs. Secondly, GATA -1 
overexpression in FoP could overcome the role of BRD3 in TFs recruitment and MK -specific gene 
activation. Lastly, BRD3 absence could be compensated by other BET protein. A BET protein 
compensation mechanism has been shown in erythropoiesis (Stonestrom et al. 2015). The high gene 
expression correlation between erythroblasts and MKs has been reported (Watkins et al. 2009), and 
this could be reflected on protein function to a certain extent. Therefore, it is acceptable to speculate 
that one of the other BETs could replace BRD3. Interestingly, in this thesis I show that BRD2 is also 
dispensable in megakaryopoiesis, using a FoP system.  The differentiation of BRD2+3 KO is required to 
verify whether there is compensation between BRD2 and BRD3 in megakaryopoiesis.  
 
BET inhibition impairs MK progenitor generation, but not late megakaryopoiesis. Inhibition of BET 
proteins at early stages of megakaryopoiesis severely impaired the differentiation of iPSCs into MK 
progenitors, indicating that BET proteins are required for early differentiation (figure 3.3.6). This result 
is supported by previous studies showing that BET proteins regulate cell -specific TF recruitment 
(Stonestrom et al. 2015), and BET inhibition dysregulates TF-regulated gene signatures (Roe et al. 
2015), impeding differentiation. Moreover, given that BRD2 KO and BRD3 KO were successful at 
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generating MK progenitors, it is acceptable to hypothesise that BRD4 could be the essential BET 
protein in early megakaryopoiesis. The BRD4 depletion in the inhibition experiments would explain 
why the iPSCs did not differentiate into MKs. Previous studies demonstrated that BRD4 is a major 
regulator of mesoderm differentiation, the first differentiation stage in megakaryopoiesis (Rodriguez 
et al. 2014b; Jian Shi et al. 2014). Also, BET inhibition has an effect on lineage-specific networks due to 
the disruption of BRD4 from cell-specific enhancers (J.-E. Lee et al. 2017; Chapuy et al. 2013). My 
inhibition experiments were subjected to the same study flaws that I identified in my other 
experiments: the overexpression of GATA-1, and the possibility for a BET compensatory effects. 
However, if GATA-1 overexpression overcame the BRD3 requirement for MK differentiation; the same 
artefactual influence could not overcome the absence of all the BET proteins. Additionally, if there was 
a BET compensatory mechanism, it would have been impaired with inhibition, hence why 
differentiation failed at early stages, probably when BRD4 is essential. This hypothesis will require 
further validation with experiments suggested below.  
 
In order to overcome some of the possible flaws in my experiments and progress the study of BET 
proteins regulation in megakaryopoiesis, I suggest the following experiments. Firstly, the TFs 
overexpression in the MK-FoP presents an impediment to explore the transcriptional mechanisms 
regulated by BET proteins, as these are direct TFs interactors. To perform future experiments, an 
alternative directed differentiation protocol for generation of MKs could be tested. Secondly, in order 
to dissect whether there is a BET compensation in megakaryopoiesis, the BET KOs experiment 
described in section 3.4 would require completion. To get insights into the transcriptional pathways 
regulated by BET proteins, a transcriptome analysis of the BET KO combinations at MK stage would be 
performed. If one of the BET proteins is essential (BETe) in megakaryopoiesis, it is expected that the 
BETe KO clones will not generate MKs. In that case, a knockdown of BETe could be generated and 
differentiated into MKs.  To identify the transcriptional pathways regulated by the BETe, RNA -seq data 
from WT and BETe KD would allow the analysis of differentially expressed genes and the assessment 
of pathway enrichment. It would be interesting to compare BETe KD transcriptome with RNA -seq data 
from BET inhibition of MKs to verify whether the affected pathways are similar. Lastly, to characterise 
the BETe regulatory mechanisms in megakaryopoiesis, a MK ChIP-seq experiment, using BETe and MK-
specific TFs antibodies on MKs, would allow to identify genome -wide regions co-occupied by both 
BETe and TFs in WT and BETe KD. Additionally, in order to establ ish the chromatin landscape for 
differentiated MKs, the same ChIP-seq experiment would include antibodies against H3K4me3 (for 
promoter identification) and H3K27ac (for active promoter and enhancer identification).  The 
correlation between co-binding of BETe and TFs at identified regulatory regions (promoters and 
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enhancers) and the pathways affected by BETe KD (and/or inhibition) would provide insights on the 
BET regulation in megakaryopoiesis.   
 
This thesis presents the first reported experiments to study the role of BRD3 in chromatin architecture 
and H3K27ac signature during megakaryopoiesis. Additionally, BET regulatory mechanisms in 
generation of MKs have never been explored. Here, I show that BRD3 ablation does not significantly 
affect MK generation, as opposed to BET inhibition that impairs early megakaryopoiesis. Therefore, 
my studies progress the available knowledge on regulatory circuits in megakaryopoiesis, and 
consequently, platelets generation. These, and suggested future studies, will help inform the 
mechanisms behind the occurrence of side effects, such as thrombocytopenia, in current clinical trials 
testing BET inhibitors, and guide the development and application of future BET antagonist drugs.  
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6.1. Plasmids  
6.1.1 Plasmids used for generation of Knockouts 
 
 
 
 
Figure 6.1.1.1 pSpCas9n(BB)-2A-PURO (PX462, Addgene). This vector contains two expression 
cassettes, Cas9n and the gRNA scaffold. The vector also contain a puromycin sequence for selection 
based on puromycin treatment. The vector was digested using BbsI enzyme for insertion of the 
annealed oligos into the sgRNA scaffold. PvuI enzyme was used to check sgRNA insertion before 
sequencing. Plasmid used for generation of BRD3 KO in S4-SF5 cells. 
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Figure 6.1.1.2 pSpCas9n(BB)-2A-GFP (PX461, Addgene). This vector contains two expression 
cassettes, Cas9n and the gRNA scaffold. The vector also contain a green fluorescence protein (GFP) 
sequence for visualisation. The vector was digested using BbsI enzyme for insertion of the annealed 
oligos into the sgRNA scaffold. PvuI enzyme was used to check sgRNA insertion before sequencing. 
Plasmid used for generation of BRD3 KO and BRD2 KO in A1ATD1-c cells. 
 
 
173 
 
 
 
 
 
 
 
 
 
Figure 6.1.1.3 pSpCas9n(BB)-2A-tomato. This vector contains two expression cassettes, Cas9n and the 
gRNA scaffold. The vector also contain a tomato sequence for visualisation. The vector was digested 
using BbsI enzyme for insertion of the annealed oligos into the sgRNA scaffold. PvuI enzyme was used 
to check sgRNA insertion before sequencing. Plasmid used for generation of BRD4 KO in A1ATD1-c 
cells. 
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6.1.2 Plasmids used for generation viral particles 
containing TFs for FoP protocol 
 
 
 
 
 
 
 
 
Figure 6.1.2.1 pWPT-FLI-1. Plasmid containing ORF for FLI-1. This plasmid was used to produced 
viruses used in FoP for differentiation of MKs. 
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Figure 6.1.2.2 pWPT-GATA1. Plasmid containing ORF for GATA-1. This plasmid was used to produced 
viruses used in FoP for differentiation of MKs. 
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Figure 6.1.2.3 pTRIP-TAL1. Plasmid containing ORF for GATA-1. This plasmid was used to produced 
viruses used in FoP for differentiation of MKs. 
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6.1.3 Plasmids used for generation of Knockdowns 
 
 
 
 
 
 
Figure 6.1.3.1 dCas9-KRAB plasmid (Addgene# 50917). Tet-inducible dCas9 lentiviral expression 
vector. The neomycin cassette confers resistance to the infected cells. This plasmid is TRE-promoter 
regulated, a 3rd generation plasmid. Therefore, infections with this plasmid also require a packaging 
plasmid, encoding for GAG, POL, TAT and REV genes, and an enve lope plasmid, containing the VSV-G 
gene. Plasmid-containing virus were produced and cells infected along with lentiGuide Puro (figure 
6.1.5). This plasmid was used for the attempts to generate BET knockdowns.  
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Figure 6.1.3.2 lentiGuide-PURO plasmid (Addgene # 52963). This lentiviral backbone expression 
vector contains a RNA scaffold element for insertion of customisable RNAs. The puromycin cassette 
confers resistance to the infected cells. Plasmid was cloned with respective sgRNAs duplexes by 
restriction digestion (BsmbI). Plasmid-containing virus were produced and cells infected along with 
dCas9-KRAB (figure 6.1.4). This plasmid was used for the attempts to generate BET knockdowns.  
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6.2 Alignment of Sanger sequences to confirm sgRNAs 
insertions 
 
 
Figure 6.2.1 Sequence alignment for confirmation of BRD3 sgRNAs insertion into pSpCas9n(BB)-2A-PURO 
(for generation of BRD3 KO in S4-SF5 cells). Sanger sequencing was performed using U6 forward primer 
(GGGCAGGAAGAGGGCCTAT). sgRNAs cloned: sgRNA.BRD3.KO.2 (AGTCGCCCCCGCGGGG), 
sgRNA.BRD3.KO.3 (TGTGAACCCACCCCCCCCGG) and sgRNA.BRD3.KO.8 (CCCCGCGGGGGCGACTGTCG). 
 
 
Figure 6.2.2 Sequence alignment for confirmation of BRD3 sgRNA 3 insertion into pSpCas9n(BB)-2A-GFP 
(generation of BRD3 KO in A1ATD1-c cells). Sanger sequencing was performed using U6 forward primer 
(GGGCAGGAAGAGGGCCTAT). sgRNAs cloned: sgRNA.BRD3.KO.3 (TGTGAACCCACCCCCCCCGG). 
 
 
Figure 6.2.3 Sequence alignment for confirmation of BRD3 sgRNA 3 insertion into pSpCas9n(BB)-2A-
tomato (generation of BRD3 KO in A1ATD1-c cells). Sanger sequencing was performed using U6 
forward primer (GGGCAGGAAGAGGGCCTAT). sgRNAs cloned: sgRNA.BRD3.KO.8 
(CCCCGCGGGGGCGACTGTCG). 
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Figure 6.2.4 Sequence alignment for confirmation of BRD2 sgRNAs insertion into pSpCas9n(BB)-2A-
GFP (for generation of BRD2 KO in A1ATD1-c cells). Sanger sequencing was performed using U6 
forward primer (GGGCAGGAAGAGGGCCTAT). sgRNAs cloned: sgRNA.BRD2.KO.10 
(TTAATAGTACCCATGTCCAT), sgRNA.BRD2.KO.11 (ACTTGAAAACAATTATTATT), 
sgRNA.BRD2.KO.12(AATGTAACAGTTGGTGAACA) and sgRNA.BRD2.KO.13 
(CAACTGTTACATTTACAACA). 
 
 
 
 
Figure 6.2.5 Sequence alignment for confirmation of BRD4 sgRNAs insertion into pSpCas9n(BB)-2A-
tomato (for generation of BRD4 KO in A1ATD1-c cells). Sanger sequencing was performed using U6 
forward primer (GGGCAGGAAGAGGGCCTAT). sgRNAs inserted: sgRNA.BRD4.KO.1 
(GATTTCTCAATCTCGTCCCA), sgRNA.BRD4.KO.2 (TTCCCAAATGTCTACAACAC), sgRNA.BRD4.KO.8 
(TGCCCCTTCTTTTTTGACTT), sgRNA.BRD4.KO.9 (CCCCGGGAGGGAGCAGAAGA), sgRNA.BRD4.KO.10 
(GGGGGCGAGGACTTCATCGC), sgRNA.BRD4.KO.11 (ACCCTTCATTGCCACCCAGG), sgRNA.BRD4.KO.12 
(CACTACCCCAGCAGCCATCA) and sgRNA.BRD4.KO.13 (CAGGGCAGCGGCTCGGTTGC). 
 
 
 
 
 
181 
 
6.2. Differentially expressed genes in BRD3 KO 
6.2.1 BRD3 KO iPSC 
Ensembl ID gene name log2FoldChange pvalue FDR 
ENSG00000005381 MPO 3.044 1.38E-03 3.35E-02 
ENSG00000007129 CEACAM21 -6.192 1.05E-07 3.35E-05 
ENSG00000015153 YAF2 -1.794 4.50E-04 1.65E-02 
ENSG00000018280 SLC11A1 1.983 2.29E-08 1.06E-05 
ENSG00000038295 TLL1 3.025 1.21E-03 3.08E-02 
ENSG00000075388 FGF4 3.115 9.85E-07 2.01E-04 
ENSG00000076356 PLXNA2 -1.906 3.70E-08 1.52E-05 
ENSG00000080031 PTPRH -1.921 9.41E-05 5.91E-03 
ENSG00000088882 CPXM1 -2.096 1.80E-08 8.47E-06 
ENSG00000094755 GABRP 1.101 9.12E-07 1.90E-04 
ENSG00000099284 H2AFY2 -1.978 4.52E-09 2.59E-06 
ENSG00000105880 DLX5 -3.956 1.00E-07 3.31E-05 
ENSG00000113361 CDH6 -2.301 1.90E-05 1.85E-03 
ENSG00000115138 POMC 2.711 1.42E-03 3.40E-02 
ENSG00000115325 DOK1 -1.848 1.95E-05 1.88E-03 
ENSG00000121351 IAPP 2.333 2.27E-04 1.05E-02 
ENSG00000124721 DNAH8 -1.902 1.57E-07 4.40E-05 
ENSG00000125144 MT1G 5.092 5.95E-30 1.40E-25 
ENSG00000125414 MYH2 3.043 2.21E-09 1.62E-06 
ENSG00000125848 FLRT3 -1.942 5.11E-12 7.51E-09 
ENSG00000126010 GRPR 1.119 1.37E-04 7.49E-03 
ENSG00000127124 HIVEP3 -3.624 6.85E-06 9.47E-04 
ENSG00000127399 LRRC61 -2.176 9.38E-10 7.14E-07 
ENSG00000130649 CYP2E1 -2.236 3.56E-06 5.76E-04 
ENSG00000134201 GSTM5 4.547 1.07E-07 3.35E-05 
ENSG00000134686 PHC2 -2.082 5.90E-11 7.70E-08 
ENSG00000135248 FAM71F1 -1.758 3.33E-09 2.18E-06 
ENSG00000142583 SLC2A5 -2.004 9.58E-11 1.07E-07 
ENSG00000143195 ILDR2 -2.087 1.71E-05 1.76E-03 
ENSG00000143369 ECM1 -2.288 1.05E-04 6.42E-03 
ENSG00000143669 LYST -1.961 1.52E-05 1.59E-03 
ENSG00000144152 FBLN7 -2.435 3.29E-05 2.84E-03 
ENSG00000144785 AC073896.1 -2.859 4.04E-04 1.53E-02 
ENSG00000144810 COL8A1 -2.499 1.36E-04 7.45E-03 
ENSG00000145247 OCIAD2 -2.600 2.65E-10 2.49E-07 
ENSG00000146648 EGFR -1.712 3.59E-05 3.04E-03 
ENSG00000148516 ZEB1 -2.929 1.88E-05 1.84E-03 
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ENSG00000148848 ADAM12 -2.581 7.76E-05 5.24E-03 
ENSG00000148948 LRRC4C 2.422 1.37E-03 3.35E-02 
ENSG00000149294 NCAM1 -1.503 1.02E-05 1.19E-03 
ENSG00000151376 ME3 -3.040 1.03E-07 3.35E-05 
ENSG00000152208 GRID2 1.163 5.34E-04 1.81E-02 
ENSG00000154146 NRGN -3.547 4.44E-06 6.69E-04 
ENSG00000154760 SLFN13 -1.354 2.91E-04 1.24E-02 
ENSG00000155622 XAGE2 5.059 7.16E-06 9.79E-04 
ENSG00000160097 FNDC5 -1.953 3.93E-05 3.22E-03 
ENSG00000162344 FGF19 2.332 2.84E-06 4.90E-04 
ENSG00000162909 CAPN2 -1.910 4.22E-05 3.37E-03 
ENSG00000163492 CCDC141 2.539 2.51E-04 1.13E-02 
ENSG00000165169 DYNLT3 4.395 2.34E-09 1.66E-06 
ENSG00000166741 NNMT -4.607 1.74E-05 1.76E-03 
ENSG00000167785 ZNF558 3.243 4.96E-04 1.74E-02 
ENSG00000168542 COL3A1 -6.832 6.75E-05 4.72E-03 
ENSG00000169085 VXN -2.719 2.36E-04 1.08E-02 
ENSG00000169248 CXCL11 2.479 1.39E-06 2.76E-04 
ENSG00000171004 HS6ST2 -1.592 1.53E-04 7.91E-03 
ENSG00000172339 ALG14 -1.392 3.15E-04 1.30E-02 
ENSG00000173809 TDRD12 2.449 4.61E-08 1.78E-05 
ENSG00000175868 CALCB 2.568 1.65E-03 3.69E-02 
ENSG00000182580 EPHB3 -2.031 9.42E-09 4.61E-06 
ENSG00000182870 GALNT9 -2.793 7.00E-04 2.14E-02 
ENSG00000186300 ZNF555 2.706 1.39E-05 1.48E-03 
ENSG00000186439 TRDN 3.001 1.63E-06 3.14E-04 
ENSG00000187105 HEATR4 1.737 1.73E-04 8.59E-03 
ENSG00000187193 MT1X 1.799 1.74E-12 3.40E-09 
ENSG00000188483 IER5L -2.666 1.45E-10 1.48E-07 
ENSG00000188707 ZBED6CL -2.072 3.64E-09 2.25E-06 
ENSG00000197415 VEPH1 1.342 7.03E-04 2.14E-02 
ENSG00000197956 S100A6 3.185 8.68E-07 1.84E-04 
ENSG00000198028 ZNF560 5.242 3.57E-12 5.60E-09 
ENSG00000198417 MT1F 4.910 3.53E-08 1.48E-05 
ENSG00000198732 SMOC1 -2.267 4.75E-06 6.97E-04 
ENSG00000203685 STUM 3.235 2.33E-03 4.46E-02 
ENSG00000213401 MAGEA12 -4.032 6.67E-20 7.84E-16 
ENSG00000215386 MIR99AHG -4.048 9.40E-04 2.57E-02 
ENSG00000240184 PCDHGC3 -1.531 7.96E-07 1.75E-04 
ENSG00000253230 LINC00599 1.777 1.80E-03 3.93E-02 
ENSG00000253507 AC104257.1 2.128 1.18E-05 1.31E-03 
ENSG00000255132 AC090138.1 4.569 5.36E-06 7.76E-04 
ENSG00000258947 TUBB3 -1.090 1.38E-06 2.76E-04 
ENSG00000258952 SALRNA1 -2.613 1.36E-13 3.99E-10 
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ENSG00000260362 AC007218.1 1.997 5.01E-05 3.85E-03 
ENSG00000260518 BMS1P8 -3.491 4.74E-06 6.97E-04 
ENSG00000261143 ADAMTS7P3 -4.857 1.64E-06 3.14E-04 
ENSG00000263020 AL662899.2 -1.804 3.11E-04 1.29E-02 
ENSG00000268119 AC010615.2 2.684 7.57E-11 8.89E-08 
ENSG00000268861 AC008878.3 -7.323 6.53E-08 2.36E-05 
144.3173154 HIST1H4F 0.471 1.22E-04 7.03E-03 
7127.822855 AL161431.1 0.247 1.55E-07 4.38E-05 
216.2395137 HIST1H2BB 0.321 1.69E-04 8.46E-03 
56.77799995 HYDIN2 0.563 3.32E-13 8.66E-10 
327.0661473 HIST1H3C 0.312 8.00E-06 1.05E-03 
152.7581079 AC007846.1 0.516 2.30E-07 6.00E-05 
17.12738923 AC000093.1 17.592 1.51E-04 7.88E-03 
16.93240146 AC007846.2 27.999 8.32E-07 1.79E-04 
6.2.1 Table of differentially expressed genes between WT and BRD3 KO in A1ATD1-c iPSC cells. 
Common differentially expressed genes between BRD3 KO iPSC and MKs highlighted in grey.  
 
6.2.1 BRD3 KO MKs 
Ensembl ID gene name log2FoldChange pvalue FDR 
ENSG00000019991 HGF 5.261 4.320E-05 2.503E-03 
ENSG00000064225 ST3GAL6 1.920 1.032E-03 2.829E-02 
ENSG00000066382 MPPED2 1.829 7.550E-05 3.881E-03 
ENSG00000081237 PTPRC 2.417 1.680E-06 1.889E-04 
ENSG00000082781 ITGB5 1.178 1.800E-05 1.257E-03 
ENSG00000085733 CTTN 1.508 1.808E-04 7.643E-03 
ENSG00000102245 CD40LG 2.272 1.220E-05 9.038E-04 
ENSG00000105767 CADM4 1.751 1.939E-04 8.074E-03 
ENSG00000109705 NKX3-2 3.765 3.201E-04 1.149E-02 
ENSG00000111186 WNT5B 2.752 8.430E-11 3.750E-08 
ENSG00000111554 MDM1 1.264 1.460E-05 1.060E-03 
ENSG00000116194 ANGPTL1 -1.636 5.820E-05 3.184E-03 
ENSG00000117586 TNFSF4 1.690 2.180E-07 3.450E-05 
ENSG00000118946 PCDH17 1.369 5.551E-04 1.759E-02 
ENSG00000119283 TRIM67 -2.352 2.970E-15 3.370E-12 
ENSG00000124406 ATP8A1 1.245 3.900E-06 3.795E-04 
ENSG00000130508 PXDN -1.049 7.350E-09 1.890E-06 
ENSG00000130649 CYP2E1 -2.359 1.725E-03 4.044E-02 
ENSG00000132932 ATP8A2 2.875 7.560E-06 6.378E-04 
ENSG00000134871 COL4A2 3.788 2.670E-05 1.751E-03 
ENSG00000136404 TM6SF1 1.378 7.439E-04 2.224E-02 
ENSG00000137959 IFI44L -1.394 1.930E-18 6.020E-15 
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ENSG00000139329 LUM 5.806 1.350E-07 2.340E-05 
ENSG00000143226 FCGR2A 1.280 1.860E-04 7.811E-03 
ENSG00000143333 RGS16 1.088 2.065E-04 8.345E-03 
ENSG00000143367 TUFT1 1.737 1.453E-04 6.449E-03 
ENSG00000144648 ACKR2 1.176 5.267E-04 1.680E-02 
ENSG00000146555 SDK1 2.386 4.700E-07 6.690E-05 
ENSG00000147804 SLC39A4 1.659 2.380E-06 2.560E-04 
ENSG00000148926 ADM -1.488 1.660E-07 2.750E-05 
ENSG00000151491 EPS8 -1.421 8.410E-05 4.229E-03 
ENSG00000151962 RBM46 4.910 8.920E-07 1.146E-04 
ENSG00000152208 GRID2 2.529 1.620E-03 3.867E-02 
ENSG00000152315 KCNK13 2.846 2.760E-08 5.880E-06 
ENSG00000154217 PITPNC1 2.125 3.530E-06 3.504E-04 
ENSG00000155158 TTC39B 1.576 1.120E-10 4.740E-08 
ENSG00000155926 SLA 1.200 1.650E-10 6.860E-08 
ENSG00000163898 LIPH 1.590 8.610E-06 6.928E-04 
ENSG00000164691 TAGAP 2.390 1.158E-03 3.037E-02 
ENSG00000165092 ALDH1A1 2.344 4.870E-09 1.290E-06 
ENSG00000165169 DYNLT3 1.911 3.060E-05 1.917E-03 
ENSG00000165949 IFI27 -1.849 1.870E-49 2.330E-45 
ENSG00000166035 LIPC 1.164 4.250E-10 1.580E-07 
ENSG00000169248 CXCL11 1.805 8.670E-05 4.300E-03 
ENSG00000169946 ZFPM2 1.629 6.440E-10 2.320E-07 
ENSG00000172819 RARG 1.489 8.220E-08 1.560E-05 
ENSG00000173083 HPSE 1.335 1.860E-05 1.277E-03 
ENSG00000173110 HSPA6 2.068 3.136E-04 1.127E-02 
ENSG00000173334 TRIB1 1.211 1.550E-05 1.113E-03 
ENSG00000174944 P2RY14 2.835 1.960E-05 1.335E-03 
ENSG00000175556 LONRF3 2.626 4.500E-05 2.594E-03 
ENSG00000179639 FCER1A 1.348 1.280E-08 2.960E-06 
ENSG00000180353 HCLS1 1.380 1.212E-03 3.137E-02 
ENSG00000182771 GRID1 1.975 5.046E-04 1.624E-02 
ENSG00000183632 TP53TG3 -5.102 5.100E-09 1.340E-06 
ENSG00000183785 TUBA8 1.549 5.880E-07 7.840E-05 
ENSG00000186190 BPIFB3 1.841 1.299E-03 3.296E-02 
ENSG00000186300 ZNF555 1.762 6.420E-07 8.430E-05 
ENSG00000188219 POTEE 1.374 8.140E-06 6.621E-04 
ENSG00000188959 C9orf152 2.595 1.098E-04 5.186E-03 
ENSG00000196611 MMP1 2.137 9.580E-18 2.170E-14 
ENSG00000197956 S100A6 3.657 1.626E-04 7.025E-03 
ENSG00000198028 ZNF560 5.021 5.410E-07 7.410E-05 
ENSG00000205609 EIF3CL 1.195 3.056E-04 1.109E-02 
ENSG00000217644 AL355864.1 1.287 3.035E-04 1.105E-02 
ENSG00000224400 AC010880.1 1.842 1.230E-06 1.454E-04 
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ENSG00000225255 AP000527.1 2.469 1.560E-07 2.630E-05 
ENSG00000227550 TRBV7-5 2.801 3.432E-04 1.207E-02 
ENSG00000229308 AC010737.1 1.982 1.711E-03 4.026E-02 
ENSG00000230450 NEK2P4 4.778 3.920E-05 2.325E-03 
ENSG00000231431 FAR2P4 1.716 1.110E-05 8.387E-04 
ENSG00000232533 AC093673.1 1.097 8.116E-04 2.378E-02 
ENSG00000234211 AL451067.1 3.527 2.636E-04 9.889E-03 
ENSG00000234350 AC007405.1 -1.972 6.020E-06 5.459E-04 
ENSG00000235288 AC099329.1 1.356 7.640E-05 3.922E-03 
ENSG00000236956 NF1P8 3.829 4.720E-07 6.690E-05 
ENSG00000244470 AC105918.1 1.788 6.250E-06 5.549E-04 
ENSG00000248796 MED15P8 4.405 9.370E-07 1.181E-04 
ENSG00000251301 LINC02384 1.919 4.860E-07 6.810E-05 
ENSG00000254319 AC246817.2 -2.696 3.680E-07 5.390E-05 
ENSG00000255446 AP003064.2 5.803 2.890E-06 3.018E-04 
ENSG00000256683 ZNF350 1.068 1.264E-04 5.790E-03 
ENSG00000260877 AP005233.2 2.347 5.801E-04 1.811E-02 
ENSG00000261127 AC133548.2 -4.407 3.820E-19 1.590E-15 
ENSG00000261466 AC136944.4 -2.827 1.330E-12 1.230E-09 
ENSG00000261796 ISY1-RAB43 1.261 7.390E-06 6.286E-04 
ENSG00000265799 AC090844.3 -2.039 1.010E-06 1.254E-04 
ENSG00000278272 HIST1H3C 0.948 2.240E-11 1.210E-08 
ENSG00000278996 FP671120.1 0.286 1.967E-04 8.150E-03 
6.2.1 Table of differentially expressed genes between WT and BRD3 KO in A1ATD1-c MK cells. 
Common differentially expressed genes between BRD3 KO iPSC and MKs highlighted in grey. ZFPM2 
(highlighted in red) has previously been associated with platelet traits in GWAS studies.  
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6.3. BET inhibition - appendix 
 
 
Figure 6.3.1. Flow cytometry results at day 10 for cultures inhibited at day 1 (1i),  related to figure 
3.3.5. FS vs SS plots (top panel) show gated differentiating cells. CD235a vs CD41a (bottom panel) show 
MK progenitor cells. BET inhibition at day 1 prevents the formation of MK progenitor population 
expected at day 10.  
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